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ABSTRACT 
Histopathology induced by a medicinal plant indigenous to South Africa that has shown anti-
microbial activity against both drug-sensitive and drug-resistant strains of Mycobcterium 
tuberculosis. Mycobacterium tuberculosis is the causative agent of pulmonary tuberculosis 
(TB). It is responsible for more deaths annually than any other pathogen globally. (Kathleen 
et al., 1993).  
Pulmonary tuberculosis is a global burden with new cases being reported annually. There are 
challenges that compromise the conventional treatment of this disease such as drug resistance 
among TB patients. The ethno-botanical discovery of medicinal plants extracts is bringing a 
new hope in the fight against the drug resistant strains of Mycobacterium tuberculosis. Some 
researchers in South Africa have ethno-botanically identified some plants which are being 
used by traditional healers to cure ailments related to tuberculosis. However, there is a threat 
of toxicity associated with compounds isolated from these medicinal plants (Lall and Meyer, 
1999). 
The aim of this study was to investigate the histopathology that may be induced by the plant 
extract that has shown in-vitro inhibition against both drug- resistant and drug-sensitive 
strains of Mycobacterium tuberculosis. The objectives of the study: carry out a 7 day pilot 
repeated oral toxicity study on albino Swiss mice to: Establish the dosages to be administered 
in the 28 day study and standardise methodologies for assessing animal weight, feed 
consumption, clinical observations and histopathology. To carry out a 28 day repeated oral 
toxicity study using the dosages obtained from the 7 day study on Swiss albino mice. 
In the two studies no dose dependent lesions were observed. All lesions observed are 
spontaneous,  age related to laboratory animals. Therefore the NOAL/NOAEL/MTD for this 
study is 500mg/kg.b.wt. 
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CHAPTER 1  
LITERATURE REVIEW AND STUDY OBJECTIVES 
 
1.1 INTRODUCTION 
Tuberculosis (TB) still remains a health problem globally with over a million new infections 
and a mortality rate of 1.5 million individuals annually (Hawn et al., 2014). The emerging 
multi-drug resistant (MDR) strains that accompany human immune deficiency virus (HIV) 
infection in high-incidence populations contribute significantly to the health burden of TB 
(Areeshi et al., 2014). The standard treatment that is advocated by the World Health 
Organization (WHO) for active tuberculosis includes long-term therapy that incorporates the 
use of isoniazid, rifampicin, pyrazinimide and ethambutol as front line drugs (WHO, 2013).  
Drug resistance against established treatment options for TB makes research into new forms 
of therapy an imperative in health care (Ntulela et al., 2009). 
 
South Africa is currently witnessing a high number of cases of drug-resistant TB. In some 
parts of the country, one in ten cases of TB is resistant to treatment. It is therefore essential to 
have new anti-tuberculosis agents, which can be readily and simply produced from some 
local source (Warner et al., 2014). A logical starting point for this research of new agents 
would be the herbal medicines which have been used for centuries in rural areas by local 
healers. Western developed countries have harvested ethno botanical knowledge and have 
produced drug therapies for conventional medicines for other ailments. The activity of 
extracts of the active plants and their properties still require study in animal models in order 
to assess their future as new anti-tuberculosis agents (Lall and Meyer, 1999). 
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Researchers are working together in the investigation of new TB agents that can be available 
to patients suffering from TB. Several works have been published recording the ethno 
botanical use of plants in South Africa, Uganda and Mexico. In the same published papers, it 
is clearly stipulated that many African and Mexican plants have ethno-botanical use for the 
treatment of tuberculosis and related symptoms such as coughing, respiratory ailments and 
fever (Lall and Meyer, 1999; Camacho- Corona et al., 2008; McGaw et al., 2009;  
Ntulela et al., 2009; Tabuti et al., 2010).  
 
Natural products continue to play the most significant role in the drug discovery and 
development process and plants are recognized as useful sources of highly active anti- 
microbial metabolites (Balunas and Kinghorn, 2005). Screening programmes of plant 
remedies are emphasized so as to validate the traditional use of herbal treatments, and for 
providing leads in the discovery of new active principles. Such screening programmes have 
to be supported by toxicity studies (McGaw et al., 2009).  
 
This study focuses on qualitative and quantitative experimental findings after the 
administration of a medicinal plant extract to animals. This will include daily observation of 
animals, recording of feed consumption, recording of animal weights, macroscopic 
examination of animals at necropsy, tissue harvesting, histological procedures and 
microscopy. 
 
There was no available data on dosages producing toxicity for the experimental plant. The 
Organisation for Economic Co-operation and Development (OECD) well documents guides 
on testing and assessing of chemicals employing acute, sub-acute oral toxicity tests, as well 
as dose range finding studies. Dose range Finding Studies (also known as a 7 or 14 day sub-
3 
 
acute toxicity studies) are normally carried out prior to a 28 day oral toxicity study in an 
attempt to establish the upper limit of the dose sequence. This sub-acute toxicity study begins 
with a three dose regime (e.g 1000mg/kg, 500mg/kg, 250mg/kg body weight) per day per 
group per sex repeatedly for 7 days. On the other hand acute toxicity testing involves a once 
off administration (e.g. 1000mg/kg.b.wt) of the chemical, which is then followed by animal 
observation for a period of 14 days. In the event whereby there is evidence of toxicity, the 
dose in which toxicity has occurred is used as the upper limit for the dosing sequence in the 
main study. If there is no such toxicity, the dose will be used as the starting dose for the main 
study (OECD, 2008). 
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1.2 PULMONARY TUBERCULOSIS PANDEMIC  
Pulmonary tuberculosis is a contagious airborne disease of the lower respiratory tract. The 
causative agent is Mycobacterium tuberculosis. This disease is responsible for more deaths 
annually than any other disease globally. Although it was thought that TB was controlled 
especially in the developing countries, the disease is undergoing a dramatic resurgence 
throughout the world. The emergence of MDR- TB strains further complicates the treatment 
and control of the bacteria, influencing the need to develop new strategies for prevention and 
treatment beyond the current available therapies (Verrall et al., 2014).   
 
Tuberculosis (TB) is a global health burden with over a million new infections and a 
mortality rate of 1.5 million individuals annually (Hawn et al., 2014). The emerging MDR 
strains of the Mycobacterium that is accompanied by Human Immune Deficiency Virus 
(HIV) in high incidence populations contribute significantly to sustaining the problem. The 
conventional TB treatment that is advocated by the World Health Organization (WHO) for 
active tuberculosis includes a long-term therapy (six months) that incorporates the use of 
Isoniazid, Rifampicin, Pyrazinimide and Ethambutol as front line drugs (Ntulela et al., 2009).  
The causative agent of PTB (Mycobacterium tuberculosis) was first isolated by Robert Koch 
in 1882. The M. tuberculosis is a slender, straight gram positive rod with rounded ends. It is a 
non-motile, non-sporing organism that stains well with Ziehl-Neelsen stain. The title of the 
study   strictly focuses on PTB since the preliminary studies carried out on ethno-botanically 
selected plants exhibited promising results when tested against the causative agent of PTB 
(Lall and Meyer, 1999). 
 
Pulmonary tuberculosis is regarded as the disease which killed the ancient Egyptians and the 
Iron Age British Settlers (Mokrousov, 2008). Literature concerning scientific knowledge and   
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the treatment of TB in the past talks about the conventional and internationally accepted first 
line treatment regime as outlined by the World Health Organization (WHO). The 
conventional treatment includes the initial treatment with Izoniazid, Rifampicin, 
Pyrazinamide and Ethambutol for two months, followed by four months continuation phase 
of further treatment with Izoniazid and Rifampicin. The six months regime has been very 
successful until recently when the Human Immuno- Deficiency Syndrome came into 
existence (O’Mahony and McCarthy, 2010). 
 
Multidrug resistant TB (MDR- TB) is one form of TB which is characterized by the 
resistance of Mycobacterium tuberculosis to at least Isoniazid and Rifampicin, the most 
effective anti-TB drugs. MDR-TB results from either primary infection with the resistant 
strain or may develop in the course of treatment (Mishra et al., 2014). 
 
Extensively drug-resistant TB (XDR-TB) is the second resistant form of TB that is also 
caused by the Mycobacterium tuberculosis that is resistant to Isoniazid and Rifampicin as 
well as any flouroquinolones and any of the second-line anti-TB injectable drugs (Amycacin, 
Kanamycin, or Capreomycin). These forms of TB do not respond to the standard six months 
treatment with first-line anti-TB drugs. Treatment can take up to two years or more with 
drugs that are less potent and much more expensive (WHO, 2008).        
 
Recently, there have been reports of an increase in the numbers of drug resistant forms of TB. 
The WHO surveillance conducted in 2008 estimated 440 000 cases of MDR-TB and 963 
cases XDR-TB globally (WHO, 2010). The surveillance documented the potential 
demographic risk factors as well as clinical risk factors that have contributed to increase in 
drug resistance. These are: 
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 Prior exposure to anti-TB drugs 
 The association between sex and MDR-TB 
 The association between HIV status and MDR-TB 
 
Previously treated TB patients who fail to complete the prescribed conventional therapy 
(relapses) are likely to develop drug resistance to one or more treatment regimes. This is a 
major challenge and it impacts badly on the issue of drug resistance (Mishra et al., 2014). 
In most countries the majority of TB patients who have developed the MDR-TB happen to be 
males. Furthermore, the WHO which reported outbreaks of drug resistance among people 
affected with HIV states that currently there is limited information available about the 
association of HIV and drug resistance TB at a population level. However, the preliminary 
studies conducted in Mozambique in 2007 have been found to have a significant association. 
Drug resistant TB maybe associated with HIV for the fact that people affected by HIV have 
weakened immune system; as a result they are more vulnerable to TB infection (WHO, 
2010). Table 1.1 shows recent numbers of tuberculosis incidences, TB patients with HIV + 
status, MDR-TB in the high burden countries, South Africa inclusive. 
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Table 1.1 Recent Developments in the Nature of the Disease Globally 
 
 
AFGSTN BNGDSH BRZL CABODIA CHINA DRC ETHIOP INDIA SA INDO KENYA 
POP in 
Million 32 150 197 14 1 348 68 85 1 241 50 242 42 
Tot new  case 26.8 148.2 71.3 38.6 865.1 106.4 154.5 1211.4 325.3 313.6 93.9 
Tot 
Retreatment 1.3 7.4 10 1.5 46.8 7.9 4.6 304.4 45.9 7.7 10.1 
TB Hiv + 6.4 1.9 49.1 32.5 208.6 30.6 65.1 688.5 323.4 3.5 97.1 
MDR 700 1.7 560 330 49.1 2.6 1.7 21 5 5.7 2.4 
                        
 NOTE: 
NUMBERS 
ARE IN 
THOUSANDS                       
 
MZBQ MYANMAR NIGERIA PAKISTAN PHILLS 
RUSSIAN 
FED 
THAILAND UGANDA 
U.R 
TANZ 
V.NAM ZIM 
POP in 
Million 24 24 162 177 95 143 70 35 46 89 13 
Tot new  case 43.2 13.2 84.2 255.1 188.4 104.3 63.9 45 58.2 91.5 36.9 
Tot 
Retreatment 4.3 11 8.8 11.4 136.6 55.2 37.7 4 2.9 8.6 4.3 
TB Hiv + 41.8 4.5 7.6 8.3 3.9 79.5 49.8 39.4 53.5 59.1 35.3 
MDR 1.3 4.4 2.5 7.1 7.5 7.5 890 560 480 2 610 
(Source: Adapted from WHO Global TB Report 2010) 
 
South Africa in particular is witnessing an explosion in the number of new cases of drug 
resistant tuberculosis (Klopper et al., 2013). It is therefore essential to have new anti-
tuberculosis agents that can be produced from local sources. Herbal medicines have been 
dispensed by traditional healers for especially the rural population to cure a wide range of 
ailments including PTB (Lall and Meyer, 1999). South Africa has a record of the ethno-
botanical use of medicinal plants in the country including the publications by Ntulela, Tabuti, 
Lall and Meyer. Furthermore, Lall and Meyer specifically emphasize running of the 
screening programmes of these medicinal plants. These medicinal plants can provide leads in 
the discovery and development of new active drugs (McGaw et al., 2008). Table 1.2 shows 
the latest TB rates as per province in South Africa.   
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Table 1.2 Latest TB rates as per Province in South Africa (2001- 2005) 
 
Province TB rate / 100,000 
2001 
TB rate/10,000   
2005 
% Increase 
E Cape 510 662 23 
Free State 460 789 42 
Gauteng 320 496 36 
KZN 206 911 77 
Limpopo 91 287 68 
Mpumalanga 222 445 50 
North West 383 627 39 
N Cape 561 922 39 
W Cape 841 1031 18 
South Africa overall 424 669 37 
(Source: Edginton and Naidoo, 2007)       
 
1.2.1 THE WHO RESPONSE ON TB TREATMENT AND CONTROL IN SA 
In response to treatment challenges the WHO conducted a study in which an article was 
published in 2008 under the heading ‘Community involvement in tuberculosis care and 
prevention’. The main focus of the study was to involve the community in the 
implementation of the prevention strategies of the disease. As stated earlier, the major 
treatment challenge seemed to occur because TB patients do not complete the six months 
conventional treatment. The WHO brought up some strategies in their study conducted in 
South Africa at Gugulethu and Hlabisa areas. In a nutshell the main objective was to evaluate 
the cost-effectiveness of community-based initiatives compared with conventional 
approaches, involving community health workers as well as people with TB. The outcome of 
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the study indicated that the community-based TB care, prevention, and supervision were 
more cost-effective and acceptable to the patients. (WHO bulletin, 2008). In Hlabisa area the 
main objective was to assess the acceptability and effectiveness of traditional healers as 
supervisors of the conventional TB treatment over the clinics supervision. According to 
WHO report TB patients were satisfied with the services rendered by traditional healers, and 
for this reason the community-based programme was effective than the hospital care. In view 
of the above, it is therefore necessary to involve the traditional healers in TB treatment 
programmes and they can play an important role in the care and control of TB (Klopper et al., 
2013).  
 
1.2.2 TRADITIONAL MEDICINE AND RESEARCH IN SOUTH AFRICA   
World Health Organization defines traditional medicine as the sum of the knowledge, skills 
and practices based on the theories, beliefs and experience of indigenous different cultures 
that are used to maintain health as well as to prevent, diagnose, improve or treat physical and 
mental illness (WHO, 2010). Herbal medicines include herbs, herbal material, herbal 
preparations and finished herbal products that contain parts of plants or other plant material 
as active ingredients. Herbal treatments are considered most popular form of traditional 
medicine. WHO and the member states are co-operating together in promoting the 
engagement of traditional medicines for health care. The core aim is to: 
 Support and integrate traditional medicine into national health systems in 
combination with national policies and regulation for products, practices 
and providers to ensure safety and quality. 
 Ensure the use of safe, effective and quality products and practices, based 
on available evidence. 
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 Acknowledge traditional medicine as part of primary health care, to 
increase access to care and preserve knowledge and resources. 
 Ensure patient safety by upgrading the skills and knowledge of traditional 
medicine providers (WHO, 2010). 
 
As much as WHO acknowledges traditional medicine, it is still calling for patient safety 
when traditional medicine is used.   Researchers at the University of Pretoria in South Africa, 
in the department of Botany have conducted several studies on the promising medicinal plant 
in the fight against both the drug-sensitive (H37Rv) and drug-resistant strains of 
Mycobacterium tuberculosis (CCKO28469v). Lall and Meyer published a paper in 1999 
titled ‘In-vitro inhibition of drug-resistant and drug-sensitive strains of Mycobacterium 
tuberculosis by ethno-botanically selected South African plants’. Twenty medicinal plants 
which are used by traditional healers to cure pulmonary related diseases were tested. Plants 
extracts of both water and acetone were used. In this study it is reported that Euclea 
natalensis yielded best results in both water and acetone preparations and low toxicity when 
compared with the rest of the plants tested. Sensitivity testing was carried on two techniques, 
the traditional plate method and the radiometric method.. In both the methods Euclea 
natalensis showed best results (Lall and Meyer, 1999). 
     
Publications by Bapela have also documented the discovery of compounds, called 
naphthoquinones from the roots of the same plant, as well as content variation of these 
compounds in its seed and seedlings.  It was discovered that the roots contain much high 
concentrations of compounds than any other part of the plant (Bapela
(a)
 et al., 2008). 
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1.3 THE LINK BETWEEN DRUG DEVELOPMENT AND TRADITIONAL 
MEDICINE IN   SOUTH AFRICA 
Research is underway in South Africa in the hope of discovering new drugs for drug-resistant 
TB, malaria, obesity and diabetes mellitus. The Medical Research Council of South Africa 
released a briefing document in 2005 to shed light on the work done by organisations that 
include scientific councils as well as institutes of higher learning. The National Research and 
Development Platform (NRDP) for novel drug development from indigenous medical plants 
are bringing together a multidisciplinary research and development team in a consortium.  
The aim is to combine technical skills, research facilities and strategies in order to structure 
and develop novel drugs from medicinal plants. This novel drug development platform 
(NDDP) project has a unique feature in that it is conducted on indigenous plants by 
researchers in the country in collaboration with other researchers from the developing 
countries. The candidate plants are being processed, extracted and screened for in-vitro 
activity under good laboratory practice (GLP) conditions.   
 
The medicinal plants under investigation are indigenous to South Africa which provides 
opportunities for discovery specifically for the country. The following are some of the 
project’s aims for the period of 5 years (2005-2010) since its inception.  
 
 To develop effective and safe novel drugs for TB, malaria and diabetes. 
 To make sure that researchers benefit from transfer of technology 
 The creation of agricultural processing opportunities of medicinal plants in rural 
areas 
 To patent novel plant-derived compounds 
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 To place South Africa in forefront of discovery and development of plant-derived 
medicines 
 The document further goes on to state that after the in-vitro screening of the medicinal 
plants, the in-vivo testing will follow using models of disease in animals including testing 
against drug-resistant TB. WHO made arrangements for the consortium to collaborate with 
other countries in the Sub-Saharan Africa (Folb and Bhagwandin, 2004). 
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1.4 Euclea natalensis: A MEDICINAL PLANT WITH PROMISING ANTI-TB 
ACTIVITY 
In view of the above work being carried out in South Africa, Euclea natalensis plant has been 
identified by South African botanists to be a potential plant in the discovery of novel drugs in 
the fight against the drug-sensitive and drug-resistant strains of bacteria.   
 
Cytotoxicity evaluation, particularly of plant extracts which have shown in-vitro activity 
against human pathogens is essential before such plant extracts could be considered for drug 
discovery. In an investigation of the cytotoxic effects of the crude extracts of Euclea 
natalensis, the extract showed no signs of toxicity at a concentration of 100μg/ml against 
primary vervet monkey kidney cells. While this might indicate a promising drug worthy of 
further exploration the question of cytotoxicity remains unresolved. In addition toxicity 
testing using animal cell cultures may not be a reliable tool to evaluate toxicological effects 
for humans because the metabolism of foreign compounds differs from cell to cell (Lall et al., 
2006).  Acute, sub-acute, sub-chronic and chronic toxicity studies on all organs need to be 
carried out in order to validate toxicological effects in humans. Cell cultures are short assays 
done over short periods where cells are exposed to the plants extract for short periods. TB is 
known to be a chronic disease with treatment administration of six months. Consequently 
chronic studies are needed for toxicity evaluation on the potential plants.  
 
1.4.1THE PLANT CLASSIFICATION 
The plant under investigation belongs to the Ebenacaea family (Figure 1.1). There are two 
classes within the Ebenacaea family called Ebony and Persimmon. Ebony has two genera 
namely Diospyros comprising 450-500 species and Euclea comprising 20 species. Euclea 
natalensis falls under the Euclea genera (Notton, 2010). 
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Figure 1.1 The Ebenacaea plant kingdom 
Euclea natalensis has the following sub-species:  
 Augustifolia White 
 Carpensis White 
 Magutensis White 
 Obivata White 
 Rotundifolia White and 
 natalensis 
1.4.2 THE DISTRIBUTION OF THE PLANT IN SOUTH AFRICA 
Euclea natalensis is widely found around Southern Africa. It is found in the Western Cape 
along the south and the east coast through to Eastern Cape, also in Kwazulu-natal, Swaziland, 
Mozambique, Mpumalanga, Limpopo, Gauteng, and in Ethiopia. It grows under many 
different conditions in wide variety of habitats, ranging from rocky scrub to dune bush. The 
name Euclea means of good report or famous. The species epithet natalensis means from 
Natal. The khoisan clan originally named it the guarrie. The Zulu name inKunzane means the 
strong enema and inKunzane the strong black enema. Euclea natalensis is used for tooth 
EBENACAEA : 2 MAJOR 
CLASSES 
1. Ebony 
2. Persimmon 
Ebony : 2 genera 
1. Diospyros: 450-500 
species 
2. Euclea: 20 species 
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brushing. The roots and the bark are used in quite many traditional remedies. It has been used 
in the treatment of stomach disorders, toothache, chest complaints, urinary infections 
(Notton, 2010). 
1.4.3 THE PLANT NOMENCLAUTURE 
The nomenclature of Euclea natalensis is variable depending on the tribe and region in South 
Africa. Table 1.5 is a summary of the most commonly found terms used to describe this plant 
in various tribal/regional areas of South Africa. 
Table 1.3 Tribal and regional variations in plant nomenclature 
 
REGION/TRIBE NAME 
Natal/Khoisan Natal guari or Natal ebony 
English Large-leaved guari/ natal ebony 
Afrikaaners Natalghwarrie, Berggwarrie, Swartbasbom 
Xhosa umTshakisane, umKhasa 
Zulus iDungamizi, iChutamuzi, umZimane, umTshikisane, inKunzane-
emnyama, umHlalanyamazane, umAnyathi 
Tsonga umHlangula 
(Source: Mander, 1998) 
1.4.4 PLANT DESCRIPTION 
Euclea natalensis is a small bushy tree (shrub)(Figure 1.2). It is about 4-10m tall with a dense 
spreading crown. In warm well-watered conditions the plant can grow to be a medium-sized 
tree of about 12-18m tall, with spreading branches. The spread can reach to about 
approximately 50m. The trunk is usually straight with a thin bark that is finely cracked and 
grey in colour. The branches of the tree are covered in fine rusty hairs, which smoothes with 
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age. The leaves are hard and leathery with dark green colour. They are shiny above and pale 
underneath. Occasionally the upper surface is covered with hairs while the lower surface is 
often covered with thick velvety red hairs. The leaves vary in size, shape, and hairiness. 
Often the shape of the leaves is oblong with pointed or bluntly pointed, rounded tips. Leaves 
have prominent veins especially on the upper surface with thickened margins. In spring the 
new growth is very decorative with its pale, gold-tinged velvety hairs. 
 
The plant is dioecious which means the male and the female flowers are borne on separate 
trees. The flowers are quite small, bell shaped and cream to yellow in colour (Figure 1.3). 
They have a heavy sweet scent. Usually male flowers contain sixteen stamens and a very 
small rudimentary ovary with two types. Female flowers do not have the staminodes. The 
fruits are rounded, fleshy berries of about 70-130 mm in diameter borne on hairy stalks. The 
berries are edible and attract birds. Flowering occurs in winter to spring, fruiting during 
summer and ripening in autumn. Euclea natalensis is an adaptable easy to grow tree with a 
very neat, dense rounded crown of dark green foliage, decorated with pale, gold-tinged new 
growth (Kei Herbarium, 2010). 
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Figure 1.2   Digital Photo of Euclea natalensis 
(Source: Own digital Image Location: Xura River Lusikisiki 2011)                                                                                                                                      
 
    
Figure 1.3 Digital Photo of the Flowers of Euclea natalensis 
(Source: Notton, 2010)  
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1.4.5 MEDICINAL USES OF EUCLEA NATALENSIS 
Euclea Natalensis is used for a variety of purposes such as a source of food, as firewood and 
to prepare dyes (Lall and Meyer, 1999; Notton, 2010). Table 1.6 outlines the common uses of 
this plant in rural communities in South Africa. 
Table 1.4 Medicinal Uses of Euclea Natalensis  
  
Food Fruits are eaten, bark used for meat 
preparation, as well as milk soups 
Fuel Branches are used for fire wood 
Dyes Bark extract is used to prepare dyes 
Alcohol Fruits are used for brewing beer 
Medicinal 
Bark is chewed for oral hygiene and 
appetizer, fruits and roots used as purgative, 
root and bark again used for treatment of 
stomach disorders, chest pains, urinary 
infections, worms, headaches, venereal 
diseases as well as leprosy 
(Source: Adapted from Lall and Meyer, 1999; Notton, 2010) 
1.4.6 THE PHARMACOLOGICAL PROPERTIES OF EUCLEA NATALENSIS 
The pharmacological activity of Euclea Natalensis has been demonstrated by the presence of 
naphthoquinones which are the dominant secondary metabolites of Ebenaceae family. 
Naphthoquinines are natural phenols and have been found to have antimicrobial properties 
against a broad spectrum of pathogens i.e gram positive and gram negative bacteria, 
mycobacterium tuberculosis, and fungi (Kishore et al., 2014). Pharmacologically they are 
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classified as cytostatic and cytotoxic agents. It is documented that many novel synthetic 
naphthoquinones derivatives which have anti-carcinogenic properties have been prepared 
(Babula et al., 2009; Kishore et al., 2014). It has been discovered that these metabolites are 
found in high concentrations in roots of Euclea natalensis and they are: Diospyrin, 
Isodiospyrin, Mamegakinone, 7-Methyljuglone, Neodiospyrin and Shinanolone (Bapela
(b)
 et 
al., 2007; Kishore et al., 2014).  
 
The plant has been proven scientifically that in it novel drugs can be identified in the fight 
against drug-resistant TB. All the naphthoquinones of genus Euclea have potent anti-
tuberculosis activity especially 7-Methyljuglone, Diospyrin and Shinanolone (Van der kooy 
et al., 2006; Babula
(a)
 et al., 2008; Kishore et al., 2014).  
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1.5 TRADITIONAL MEDICINE AND ITS DRAWBACK 
 About 60-80% of population use traditional medicines commonly known as muti in South 
Africa, some of which are toxic. A study was conducted on patients admitted to hospitals in 
Johannesburg over a period of one year in 2003. The overall number of cases with a history 
of ‘muti’ administration was seventy with an overall in-hospital mortality of 33%.  It is 
reported that identity of medication was unknown to both the patients and the relatives. Of 
the mentioned population, 66% were less than a year old. According to their report, the route 
of administration was known to only 52% and included oral (54%), rectal (23%) and a 
combination of both oral and rectal routes (23%). In addition side effects noted included 
gastro-intestinal problems (53%), dehydration (59%), symptomatic liver disease (53%), renal 
dysfunction (97%), malnourished (23%) and kwashiorkor (5%) (Steenkamp et al., 2003).  
 
Traditional remedies, especially those involving plant products may be considered to be 
pharmaceutical products. They may also have associated side effects (Krige, n.d.; Seifert et 
al., 2011). According to Krige, toxicity of plants can vary on a seasonal basis. She further 
states that preparation processes have significance for toxicity in that some heating processes 
may eliminate toxicity or alternatively increase toxicity.  Research and knowledge of 
pharmaceutically active compounds in traditional medicines can make a great contribution 
towards making the preparation methods more systematic and reliable (Krige, n.d.). 
 
The above literature demonstrates that the use of medicinal plants does pose a health threat 
(Niggemann and Grüber, 2003). The WHO recommends and encourages the incorporation of 
traditional medicine within the health fraternity as well as proper and safe use of these 
medicinal plants (WHO, 2010). This study therefore intends to offer an insight of any 
21 
 
potential toxic effects of Euclea natalensis by repeatedly exposing living mammalian tissues 
to the plant extract and with subsequent histopathologic investigation.   
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1.6 THE USE OF PLANT EXTRACTS IN TOXICITY TESTING 
Following a literature review search no plants with putative anti TB properties have been 
tested for toxic potential in a mammalian model such as rats or mice. However, literature 
does document toxicity testing on other plants (Mimosaceous, Zingerber zerumbet Smith, and 
Ocimum tenuiflorum) with anti-microbial properties over other strains of bacteria (Ahmet et 
al., 2012, Ju Chang et al., 2012 and Kalaiselvi et al., 2013).   
 
Ahmed in his study investigated the acute systemic toxicity of methanolic extracts of leaves 
of plants belonging to Mimosaceous family in Swiss albino mice (Adenanthera pavonina L, 
Peltophorum roxburghii Deneger, Prosopis cineraria Druce and Prosopis juliflora DC). 
These four plants are found in Pakistan as well as in India, and they possess chemicals 
including triterpenes, flavonoids, fatty acids, sterols, glycosides, alkaloids, amino acids, and 
diketones. The leaf extract was administered intraperitoneally and clinically observed for 48 
hours. Table 1.5 shows the clinical observations of Swiss Albino mice exposed to methanolic 
extracts of leaves of plants belonging to Mimosaceous family. 
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Table 1.5 Clinical observations of Swiss Albino mice exposed to methanolic extracts of 
leaves of plants belonging to Mimosaceous family. 
 
Treatment Doses(mg/kg  
Body 
weight) 
                                     OBSERVATIONS MORTALITY 
        % INJECTION 
IMMEDIATE
LY 
                                           AFTER 
½ hr 1hr 4hrs 24hrs 48hrs 
DMSO (con --------- Normal activity normal normal normal normal normal ---------- 
A. pavonina 100 Normal normal normal normal normal  0 
150 Normal normal normal normal normal  0 
200 Breathing  
Problem 
Breathing  
problem 
Paralysis 
effect 
No 
movement 
Died ------- 100 
P. roxburgii 100 Normal normal normal normal normal normal 0 
150 Loss of sense Paralysis on 
hind limbs 
Paralysis 
Of hind 
limbs 
3 died, 
3 survived 
Died ------ 100 
200 Breathing 
problem 
Breathing 
problem 
Para, hair 
erection  
Died ------ ------ 100 
P.cineraria 100 Normal normal normal normal normal normal 0 
150 Loss of senses Paralysis of 
hind limbs 
Paralysis 
of hind 
limbs 
3 died 
3 survived 
Died ----- 100 
200 Breathing 
problem 
Breathing 
problem 
Para, hair 
erection 
Died ------- ------ 100 
P. juliflora 100 Normal normal normal normal normal normal 0 
150 Normal Paralysis of 
hind limbs 
Paralysis 
of hind 
limbs 
3 died  
3 survived 
Died ------ 100 
200 Breathing 
problem 
Breathing 
problem 
Para, hair 
erection 
Died ----- -------- 100 
(Source: Ahmet et al., 2012) 
Zingiber zerumbet (L.) Smith (ZZEE) is a medicinal plant used widely in the tropics of 
Southeast Asia. It is commonly known as pine cone or shampoo ginger. It is widely used in 
Asia and in Arabic countries as a spice and traditional medicine to cure many ailments 
(Santosh Kumar et al., 2013).  Acute and sub-acute (28 days) toxicity studies were carried out 
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on ethanol extracts of the plant to evaluate the toxicity following the limit test procedure as 
recommended by OECD guidelines. The extract was administered orally in the 
concentrations; 1000mg/kg, 2000mg/kg and 3000mg/kg.b.w to male and female Wistar rats. 
No clinical observations revealed any sign of toxicity on all treated animals. The 
haematological and biochemical parameters, food consumption as well as absolute organ 
weights and relative organ weights did not reveal any evidence of toxicity in all treated 
animals as compared to controls (Ju chang et al., 2012). 
 
The tables below represent summary of the results obtained from this study. Wistar rats (n = 
10 per group) were administered ZZEE by daily gavage for 4 weeks. Data are expressed as 
mean ± SD.  
Table 1.6 Effects of sub-chronic oral administration of the ethanol extract of EEZZ on body 
weight, food and water intakes in Wistar rats. 
Week (W) of 
Treatment 
Female Male 
Vehicle EEZZ (mg/ kg per day) Vehicle EEZZ (mg/ kg per day) 
 G1 G2(1000) G3(2000) G4(3000 G1 G2(1000) G3(2000) G4(3000) 
Body weight (g) G1 G2 G3 G4 G1 G2 G3 G4 
 W1 212.97 ± 
15.97 
214.83 ± 
13.42 
215.32 ± 
16.41 
218.92 ± 
13.56 
223.61 ± 
16.48 
225.58 ± 
14.59 
229.26 ± 
16.41 
228.12 ± 
15.92 
 W2 229.60 ± 
14.75 
224.67 ± 
14.87 
219.83 ± 
19.26 
223.97 ± 
16.92 
241.08 ± 
15.24 
235.90 ± 
16.11 
241.81 ± 
13.88 
246.37 ± 
19.61 
 W3 245.11 ± 
17.36 
249.32 ± 
15.96 
233.51 ± 
13.88 
241.28 ± 
15.86 
257.36 ± 
17.91 
261.78 ± 
17.26 
256.68 ± 
19.26 
265.41 ± 
20.15 
 W4 244.72 ± 
12.63 
245.21 ± 
17.81 
237.72 ± 
14.72 
243.81 ± 
17.41 
256.96 ± 
13.08 
257.47 ± 
18.90 
261.49 ± 
14.72 
268.19 ± 
18.44 
Food intake (g /day 
per rat) 
        
 W1 22.86 ± 
4.04 
25.95 ± 
3.01 
25.29 ± 
2.84 
24.66 ± 
3.12 
24.13 ± 
4.13 
26.23 ± 
3.47 
26.36 ± 
4.15 
26.17 ± 
4.21 
 W2 20.31 ± 
3.69 
22.25 ± 
2.94 
21.62 ± 
3.14 
20.44 ± 
3.68 
23.16 ± 
4.45 
23.32 ± 
4.17 
23.52 ± 
3.69 
23.52 ± 
3.68 
 W3 22.40 ± 
3.87 
20.83 ± 
3.74 
21.11 ± 
3.49 
21.45 ± 
4.95 
23.21 ± 
4.17 
22.39 ± 
3.49 
22.32 ± 
4.18 
23.58 ± 
3.95 
 W4 19.70 ± 
3.94 
20.59 ± 
4.78 
21.70 ± 
4.32 
20.97 ± 
3.34 
20.08 ± 
3.62 
21.74 ± 
3.35 
22.58 ± 
3.93 
23.14 ± 
4.87 
Water intake (ml/ day 
per rat) 
        
 W1 24.12 ± 
5.62 
25.63 ± 
6.25 
24.08 ± 
6.61 
24.37 ± 
5.12 
25.32 ± 
6.18 
26.38 ± 
6.38 
25.28 ± 
7.41 
25.37 ± 
6.12 
 W2 25.09 ± 
8.61 
25.82 ± 
5.61 
24.62 ± 
7.92 
24.19 ± 
6.83 
26.34 ± 
9.47 
26.11 ± 
6.15 
25.85 ± 
6.76 
25.91 ± 
7.38 
 W3 26.17 ± 
5.09 
25.56 ± 
6.52 
26.51 ± 
8.12 
23.82 ± 
7.14 
27.47 ± 
5.59 
26.83 ± 
5.28 
27.83 ± 
7.31 
26.27 ± 
8.01 
 W4 24.41 ± 
4.97 
24.09 ± 
5.18 
25.41 ± 
6.34 
25.43 ± 
7.27 
25.63 ± 
5.47 
25.29 ± 
5.18 
25.41 ± 
8.12 
25.96 ± 
6.98 
 
(Source: Ju chang et al., 2012) 
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Table 1.7 Effects of sub-chronic oral administration of the ethanol extract of EEZZ on 
haematological parameters of Wistar rats. 
 
Parameters Female Male 
Vehicle EEZZ (mg/kg per day) Vehicle EEZZ (mg/ kg per day) 
 G1 G2(1000) G3(2000) G4(3000) G1 G2(1000) G3(2000) G4(3000) 
WBC 
(103 L−1) 
9.09 ± 0.59 8.69 ± 0.62 8.78 ± 0.57 8.61 ± 0.64 9.20 ± 
0.68 
8.90 ± 
0.70 
8.59 ± 
0.73 
8.76 ± 0.64 
Lymphocytes 
(103 L−1) 
6.76 ± 0.40 6.66 ± 0.65 6.58 ± 0.35 7.14 ± 0.65 6.92 ± 
0.75 
7.36 ± 
0.63 
7.52 ± 
0.60 
7.86 ± 0.71 
Erythrocytes 
(106 L−1) 
7.29 ± 0.07 7.69 ± 0.10 7.70 ± 0.08 7.76 ± 0.11 7.43 ± 
0.11 
7.34 ± 
0.09 
7.37 ± 
0.08 
7.46 ± 0.10 
Hemoglobin 
(g dL−1) 
16.28 ± 0.18 16.36 ± 0.17 16.29 ± 
0.14 
16.47 ± 
0.17 
17.97 ± 
0.24 
17.72 ± 
0.18 
17.48 ± 
0.16 
17.59 ± 0.23 
Hematocrit 
(%) 
41.17 ± 0.25 42.93 ± 0.21 43.29 ± 
0.19 
43.14 ± 
0.21 
42.53 ± 
0.26 
40.28 ± 
0.31 
40.51 ± 
0.29 
40.94 ± 0.23 
MCV (fL) 52.14 ± 0.32 52.26 ± 0.28 50.13 ± 
0.29 
51.97 ± 
0.32 
50.35 ± 
0.29 
51.91 ± 
0.25 
52.76 ± 
0.27 
49.55 ± 0.23 
MCH (pg) 18.86 ± 0.13 19.49 ± 0.19 20.56 ± 
0.12 
19.43 ± 
0.12 
19.85 ± 
0.19 
19.81 ± 
0.18 
19.78 ± 
0.16 
19.31 ± 0.17 
MCHC 
(g dL−1) 
35.43 ± 0.31 35.62 ± 0.42 35.57 ± 
0.38 
35.76 ± 
0.29 
35.30 ± 
0.25 
36.07 ± 
0.33 
36.04 ± 
0.27 
36.01 ± 0.27 
RDW (%) 12.12 ± 0.15 12.15± 0.16 12.16 ± 
0.14 
12.15 ± 
0.17 
17.04 ± 
0.13 
17.10 ± 
0.12 
17.55 ± 
0.13 
17.57 ± 0.17 
Platelets 
(103 L−1) 
647.54 ± 
26.98 
626.31 ± 
25.23 
665.08 ± 
28.80 
642.08 ± 
32.44 
679.54 ± 
37.73 
611.85 ± 
39.58 
619.09 
± 25.29 
606.15 ± 28.31 
MPV (fL) 6.08 ± 0.18 5.90 ± 0.08 5.89 ± 0.06 5.88 ± 0.08 5.48 ± 
0.09 
5.21 ± 
0.08 
5.29 ± 
0.10 
5.29 ± 0.07 
(Source: Ju chang et al., 2012) 
Table 1.8 Effects of sub-chronic oral administration of the ethanol extract of EEZZ on 
biochemical parameters of Wistar rats. 
 
Parameter Female Male 
Vehicle EEZZ (mg/ kg per day) Vehicle EEZZ (mg /g per day) 
 G1 G2(1000) G3(2000) G4(3000) G1 G2(1000) G3(2000) G4(3000) 
Glucose (mg dL−1) 81.30 ± 
7.73 
84.51 ± 
5.35 
82.10 ± 
6.19 
85.88 ± 
7.34 
87.62 ± 
5.29 
89.02 ± 
6.14 
92.38 ± 
5.21 
98.62 ± 
4.52 
BUN (mg dL−1) 44.83± 
2.14 
45.76 ± 
2.16 
45.82 ± 
1.98 
43.51 ± 
1.79 
45.24 ± 
1.63 
46.26 ± 
1.93 
46.76 ± 
1.72 
43.52 ± 
2.11 
Creatinine 
(mg dL−1) 
0.56 ± 
0.01 
0.56 ± 
0.02 
0.58 ± 
0.01 
0.55 ± 
0.01 
0.56 ± 
0.01 
0.57 ± 
0.01 
0.58 ± 
0.01 
0.56 ± 
0.01 
AST (U L−1) 149.51 ± 
10.38 
149.81 ± 
11.51 
146.24 ± 
10.94 
147.64 ± 
12.87 
143.54 ± 
12.48 
144.62 ± 
11.29 
145.83 ± 
13.54 
144.85 ± 
10.76 
ALT (U L−1) 71.46 ± 
3.21 
73.85 ± 
3.19 
72.25 ± 
3.62 
74.38 ± 
2.85 
70.77 ± 
2.54 
79.00 ± 
3.47 
75.58 ± 
3.26 
72.54 ± 
2.78 
Total cholesterol 
(mg dL−1) 
96.50 ± 
4.84 
98.28 ± 
5.70 
100.41 ± 
4.66 
98.21 ± 
5.50 
97.77 ± 
4.20 
97.58 ± 
5.28 
93.05 ± 
4.24 
94.12 ± 
5.15 
Triglycerides 
(mg dL−1) 
76.85 ± 
7.65 
74.23 ± 
7.78 
74.31 ± 
8.10 
73.41 ± 
7.53 
80.52 ± 
5.67 
82.45 ± 
6.90 
83.41 ± 
8.41 
82.10 ± 
8.13 
HDL (mg dL−1) 65.59 ± 
3.77 
61.83 ± 
3.65 
63.84 ± 
3.24 
65.72 ± 
3.57 
43.10 ± 
2.51 
40.52 ± 
1.17 
42.03 ± 
1.89 
41.30 ± 
1.68 
Amylase (U L−1) 515.26 ± 
31.56 
485.62 ± 
37.97 
482.50 ± 
38.96 
498.64 ± 
31.67 
702.64 ± 
59.21 
682.43 ± 
29.07 
714.65 ± 
35.41 
664.32 ± 
56.11 
GGT (U L−1) 2.47 ± 
0.02 
2.49 ± 
0.01 
2.48 ± 
0.02 
2.50 ± 
0.01 
2.53 ± 
0.01 
2.54 ± 
0.02 
2.51 ± 
0.03 
2.50 ± 
0.02 
Total bilirubin 
(mg dL−1) 
0.18 ± 
0.01 
0.17± 0.01 0.17 ± 
0.01 
0.18 ± 
0.01 
0.16 ± 
0.01 
0.17 ± 
0.01 
0.17 ± 
0.01 
0.16 ± 
0.01 
Direct bilirubin 
(mg dL−1) 
0.06 ± 
0.01 
0.06 ± 
0.01 
0.05 ± 
0.01 
0.05 ± 
0.01 
0.05 ± 
0.01 
0.05 ± 
0.01 
0.04 ± 
0.01 
0.05 ± 
0.01 
Indirect bilirubin 
(mg dL−1) 
0.12 ± 
0.01 
0.11 ± 
0.01 
0.12 ± 
0.01 
0.13 ± 
0.02 
0.11 ± 
0.01 
0.12 ± 
0.01 
0.13 ± 
0.01 
0.11 ± 
0.01 
 
(Source: Ju chang et al., 2012) 
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Table 1.9 Effects of subchronic oral administration of the ethanol extract of EEZZ on organ 
weights of female Wistar rats. 
 
Organs Organ weight (g) Relative organ weight (g 100 g of body weight) 
Vehicle EEZZ (mg/ kg per day) Vehicle EEZZ (mg/kg per day) 
 G1 G2(1000) G3(2000) G4(3000) G1 G2(1000) G3(2000) G4(3000) 
Spleen 0.445 ± 
0.028 
0.436 ± 
0.031 
0.456 ± 
0.027 
0.454 ± 
0.027 
0.182 ± 
0.011 
0.178 ± 
0.018 
0.184 ± 
0.013 
0.186 ± 
0.012 
Brain 1.111 ± 
0.026 
1.124 ± 
0.030 
1.097 ± 
0.027 
1.116 ± 
0.031 
0.454 ± 
0.019 
0.458 ± 
0.015 
0.443 ± 
0.014 
0.458 ± 
0.016 
Heart 0.853 ± 
0.018 
0.847 ± 
0.023 
0.825 ± 
0.025 
0.860 ± 
0.019 
0.349 ± 
0.014 
0.345 ± 
0.017 
0.333 ± 
0.011 
0.353 ± 
0.009 
Esophagus 0.093 ± 
0.002 
0.088 ± 
0.003 
0.093 ± 
0.003 
0.093 ± 
0.002 
0.038 ± 
0.003 
0.036 ± 
0.002 
0.038 ± 
0.002 
0.039 ± 
0.004 
Stomach 1.385 ± 
0.027 
1.369 ± 
0.026 
1.371 ± 
0.031 
1.379 ± 
0.029 
0.566 ± 
0.013 
0.558 ± 
0.017 
0.553 ± 
0.015 
0.566 ± 
0.016 
Liver 8.631 ± 
0.048 
8.633 ± 
0.052 
8.523 ± 
0.046 
8.651 ± 
0.061 
3.527 ± 
0.017 
3.520 ± 
0.022 
3.441 ± 
0.019 
3.548 ± 
0.021 
Adrenal gland 0.023 ± 
0.002 
0.025 ± 
0.001 
0.026 ± 
0.002 
0.029 ± 
0.002 
0.009 ± 
0.001 
0.010 ± 
0.002 
0.010 ± 
0.003 
0.011 ± 
0.002 
Hypophysis 0.004 ± 
0.002 
0.004 ± 
0.001 
0.004 ± 
0.001 
0.004 ± 
0.001 
0.001 ± 
0.001 
0.001 ± 
0.001 
0.001 ± 
0.001 
0.001 ± 
0.001 
Hypothalamus 0.027 ± 
0.002 
0.028 ± 
0.001 
0.029 ± 
0.001 
0.027 ± 
0.002 
0.011 ± 
0.003 
0.011 ± 
0.002 
0.011 ± 
0.001 
0.012 ± 
0.003 
Small 
intestine 
0.516 ± 
0.021 
0.525 ± 
0.018 
0.515 ± 
0.019 
0.521 ± 
0.022 
0.211 ± 
0.009 
0.214 ± 
0.008 
0.208 ± 
0.007 
0.214 ± 
0.009 
Lungs 1.309 ± 
0.053 
1.278 ± 
0.046 
1.308 ± 
0.055 
1.320 ± 
0.043 
0.535 ± 
0.017 
0.521 ± 
0.014 
0.528 ± 
0.019 
0.541 ± 
0.022 
Kidney 0.859 ± 
0.029 
0.867 ± 
0.034 
0.874 ± 
0.045 
0.864 ± 
0.037 
0.351 ± 
0.018 
0.354 ± 
0.019 
0.353 ± 
0.017 
0.355 ± 
0.020 
Ovary 0.044 ± 
0.003 
0.043 ± 
0.003 
0.042 ± 
0.002 
0.042 ± 
0.002 
0.018 ± 
0.002 
0.017 ± 
0.002 
0.017 ± 
0.003 
0.017 ± 
0.002 
Uterus 0.546 ± 
0.026 
0.566 ± 
0.029 
0.574 ± 
0.031 
0.551 ± 
0.039 
0.223 ± 
0.022 
0.230 ± 
0.026 
0.231 ± 
0.025 
0.226 ± 
0.025 
(Source: Ju chang et al., 2012) 
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Table 1.10 Effect of sub-chronic oral administration of the ethanol extract of EEZZ on 
organ weights of male Wistar rats. 
 
Organs Organ weight (g) Relative organ weight (g 100 g of body weight) 
Vehicle EEZZ (mg /kg per day) Vehicle EEZZ (mg /kg per day) 
 G1 G2(1000) G3(2000) G4(3000) G1 G2(1000) G3(2000) G4(3000) 
Spleen 0.591 ± 
0.038 
0.571 ± 
0.041 
0.599 ± 
0.039 
0.585 ± 
0.043 
0.230 ± 
0.012 
0.222 ± 
0.009 
0.229 ± 
0.011 
0.218 ± 
0.013 
Brain 1.188 ± 
0.015 
1.197 ± 
0.017 
1.198 ± 
0.018 
1.171 ± 
0.021 
0.464 ± 
0.022 
0.466 ± 
0.027 
0.459 ± 
0.019 
0.437 ± 
0.023 
Heart 1.083 ± 
0.048 
1.072 ± 
0.039 
1.074 ± 
0.043 
1.086 ± 
0.047 
0.427 ± 
0.009 
0.330 ± 
0.016 
0.319 ± 
0.013 
0.282 ± 
0.018 
Esophagus 0.133 ± 
0.010 
0.127 ± 
0.009 
0.122 ± 
0.011 
0.130 ± 
0.008 
0.423 ± 
0.008 
0.049 ± 
0.011 
0.046 ± 
0.009 
0.049 ± 
0.013 
Stomach 1.438 ± 
0.038 
1.482 ± 
0.045 
1.453± 
0.047 
1.461 ± 
0.041 
0.561 ± 
0.021 
0.577 ± 
0.019 
0.556 ± 
0.023 
0.546 ± 
0.021 
Liver 9.971 ± 
0.035 
9.952 ± 
0.043 
9.986 ± 
0.048 
9.994 ± 
0.052 
3.894 ± 
0.118 
3.872 ± 
0.153 
3.826 ± 
0.175 
3.729 ± 
0.143 
Adrenal gland 0.024 ± 
0.002 
0.025 ± 
0.001 
0.021 ± 
0.003 
0.023 ± 
0.003 
0.009 ± 
0.003 
0.009 ± 
0.002 
0.008 ± 
0.002 
0.009 ± 
0.003 
Hypophysis 0.004 ± 
0.001 
0.004 ± 
0.001 
0.004 ± 
0.001 
0.004 ± 
0.001 
0.001 ± 
0.001 
0.001 ± 
0.001 
0.001 ± 
0.001 
0.001 ± 
0.001 
Hypothalamus 0.036 ± 
0.001 
0.035 ± 
0.001 
0.035 ± 
0.001 
0.034 ± 
0.001 
0.014 ± 
0.002 
0.014 ± 
0.001 
0.013 ± 
0.001 
0.013 ± 
0.002 
Small 
intestine 
0.572 ± 
0.045 
0.586 ± 
0.057 
0.582 ± 
0.063 
0.597 ± 
0.068 
0.223 ± 
0.021 
0.228 ± 
0.019 
0.223 ± 
0.017 
0.223 ± 
0.025 
Lungs 1.435 ± 
0.066 
1.441 ± 
0.059 
1.463 ± 
0.065 
1.470 ± 
0.078 
0.381 ± 
0.025 
0.561 ± 
0.028 
0.559 ± 
0.031 
0.549 ± 
0.032 
Kidney 0.975 ± 
0.053 
0.967 ± 
0.059 
0.968 ± 
0.062 
0.948 ± 
0.058 
0.336 ± 
0.015 
0.346 ± 
0.017 
0.351 ± 
0.016 
0.313 ± 
0.015 
Epididymis 0.615 ± 
0.056 
0.603 ± 
0.045 
0.625 ± 
0.038 
0.620 ± 
0.047 
0.239 ± 
0.013 
0.235 ± 
0.009 
0.239 ± 
0.010 
0.232 ± 
0.012 
Vas deferens 0.125 ± 
0.011 
0.129 ± 
0.009 
0.131 ± 
0.008 
0.132 ± 
0.009 
0.049 ± 
0.003 
0.050 ± 
0.005 
0.050 ± 
0.004 
0.049 ± 
0.006 
Prostate 0.553 ± 
0.071 
0.547 ± 
0.053 
0.569 ± 
0.064 
0.565 ± 
0.056 
0.215 ± 
0.011 
0.213 ± 
0.009 
0.218 ± 
0.013 
0.211 ± 
0.012 
Testicle 1.618 ± 
0.072 
1.627 ± 
0.068 
1.614 ± 
0.078 
1.637 ± 
0.059 
0.629 ± 
0.032 
0.632 ± 
0.027 
0.617 ± 
0.031 
0.610 ± 
0.025 
Seminal 
vesicle 
0.467 ± 
0.022 
0.471 ± 
0.017 
0.478 ± 
0.021 
0.469 ± 
0.019 
0.182 ± 
0.007 
0.183 ± 
0.010 
0.183 ± 
0.009 
0.175 ± 
0.013 
(Source: Ju chang et al., 2012) 
a b c d 
e f g h 
Figure 1.4 Photo Micrographs of heart and liver of EEZZ-treated rats. Heart of control (a) 
and 1000, 2000, and 3000 mg /kg EEZZ-treated rat (b, c, d),  and liver of control (e) and 
1000, 2000, and 3000 mg/kg EEZZ-treated rat (f, g, h) stained with haematoxylin and eosin 
(100x). (Source: Ju chang et al., 2012) 
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Similarly, another toxicity study was conducted on leave extract of Ocimum tenuiflorum over 
30 days (chronic toxicity study) (Kalaiselvi et al., 2013. The plant is located in Sembakkam, 
Tambaram, TamilNadu India, and its phytochemical analysis revealed the presence of 
chemicals such as phenols, terpenoids, tannins, flavonoids and reducing sugars.  The study 
documented on anti-bacterial properties of the plant including properties such a 
hypoglycemic, anti-inflammatory and wound healing. The aqueous leave extract of the plant 
was administered by oral gavage to wistar albino rats to assess its toxicity for 30 days. Both 
biochemical parameters and the body weight well fell within the normal ranges. 
Histopathological examination of major vital organs (heart, liver, kidney, lung and brain) 
revealed no significant pathological alterations in the treated animals. The table below shows 
the results obtained. 
Table 1.11 Summary of Body weight changes in experimental rats treated with Ocimum 
tennuiflorum extract. 
 
Groupings Initial weight Final weight 
Control Group  1 143±14.75 226±20.10 
Group 2 152±15.97 240±21.19 
Group 3 153±15.43 253±20.97 
Group 4 151±15.38 276±20.50 
(Source: Kalaiselvi et al., 2013) 
Table 1.12 Summary of Biochemical parameters analyzed in serum of controls and Ocimum 
treated rats 
 
parameters Group 1 Group 2 Group 3 Group 4 
Urea 8.87±0.89 8.97±0.77 9.13±0.81 9.33± 
Creatinine 0.40±0.03 0.47±0.05 0.50±0.05 0.53± 
Uric acid 1.35±0.14 1.23±0.16 1.32±0.17 1.54± 
Protein 6.33±0.59 6.38±0.51 6.32±0.72 6.40± 
AST 13.43±1.37 13.53±1.29 13.7±1.3 12.01± 
ALT 8.34±0.83 8.99±0.90 9.52±1.05 9.95± 
Note: Values expressed as Mean ± SD of 6 animals/group G1- control, G2-100mg/kg, G3-500mg/kg, &G4-1000mg/kg b.w.  
(Source: Kalaiselvi et al., 2013) 
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1.7 THE AIM AND OBJECTIVES OF THE STUDY 
Investigate the histopathology that may be induced by the plant extract that has shown in-
vitro inhibition against both drug- resistant and drug-sensitive strains of Mycobacterium 
tuberculosis.  
The central objectives of this study are two-fold: 
1.  Carry out a 7 day pilot repeated oral toxicity study on albino Swiss mice to:  
 establish the dosages to be administered in the 28 day study, 
 standardise methodologies for assessing animal weight, feed 
consumption, clinical observations and histopathology.  
2. Carry out a 28 day repeated oral toxicity study using the dosages obtained from the 7 day 
study on Swiss albino mice. 
30 
 
CHAPTER TWO 
REPEATED DOSE (7 DAY) ORAL TOXICITY STUDY OF EUCLEA NATALENSIS IN 
SWISS ALBINO MICE 
 
2.1 INTRODUCTION 
 
Short-term studies (both acute and sub-acute) are conducted to establish the mechanism of 
action of the test compounds, to give some ideas of the toxicity, also to identify possible target 
organs. The studies utilise standard histopathological and clinical pathology techniques. The 
main goal of toxicological pathology is to establish the exact degree of risk posed to the treated 
animals under controlled conditions. The very similar process is applicable to diagnostic 
pathology in lesion evaluation, but differing in the manner in which data are compiled. In 
toxicological studies the focus is on representative response of the treated group verses 
individual patients in diagnostic pathology. The objective being to quantify the average 
response of the treated groups compared to untreated control group (Haschek,  Rousseaux, and 
Walling, 2002).  
 
The Naphthoquinones have been the subject of interest in this study. These are a group of 
compounds identified in the root material of the Euclea natalensis plant. The compounds have 
shown (in-vitro) microbial activity against both drug-sensitive and drug-resistant strains of 
Mycobacterium tuberculosis (Lall and Meyer, 1999). The recent study has shown that these 
compounds (e.g. diospyrin and 7-methyljuglone) have been shown to have therapeutic 
potential, particularly against Mycobacterium tuberculosis. It is found that these compounds are 
inhibitors of the supercoiling reaction catalyzed by Mycobacterium tuberculosis gyrase and 
other gyrases (Karkare et al., 2013).  
 
 
31 
 
The evaluation and the assessment of chemical substances for their possible toxic 
characteristics are very important. This assessment is very useful in the determination of 
toxicity of substances where such substances are going to be tested in animal studies following 
a repeated dosing regimen. The initial information on toxicity of such substances could be 
obtained by acute toxicity testing prior to conducting repeat toxicity studies enabling selection 
of the right dose (OECD 407, 2008). However, in case the test compound is considered safe 
(e.g., a herbal formulation/extract used traditionally), a sub-acute toxicity study could be 
carried out following a 7 or 14 day dosing regimen with the limit dose (1000 mg/kg) as the high 
dose and at least two graded lower doses with the view of identifying the NOEL/NOAEL or 
Maximum Tolerated Dose (MTD) as well as target organs, if any. 
 
Sub-acute toxicity tests are usually conducted as they provide the information on the relative 
toxicity that is likely to arise from repeated exposure of the test substance. There are basic 
parameters that are taken into consideration in the event of carrying out sub-acute toxicity tests. 
These include the species of animals to be engaged in the study, the age, number of animals, 
randomization of animals, the dosages as well as the in-life and terminal observations 
(Simmons and Gennings, 1996; Lilienblum et al., 2008; Gupta and Bhardwaj, 2012). 
  
A 28 day repeat dose study will be carried out after the dosage levels have been established 
from the outcome of sub-acute toxicity study. The determined dose levels will then be orally 
administered to the study animals in the main study in an attempt to investigate the 
histopathology of the target organs, if any, that may be induced by the crude extract of Euclea 
Natalensis, which has shown anti-microbial activity against the drug sensitive and drug 
resistant strains of Mycobacterium tuberculosis.  
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The primary objective of 7 day study was to evaluate and determine the dose levels that could 
display the gross behavior, NOEL/NOAEL or MTD and target organs in mice given a repeated 
dose of the crude extract by oral administration for seven consecutive days. 
 
2.1.1 EUCLEA NATALENSIS PLANT – A BRIEF REVIEW 
This is a plant that is indigenous to South Africa, which is mostly found along the coast of the 
country. It’s of the Ebenacaeae family, natalensis species. The plant is used traditionally to 
treat many ailments including pre-dominantly pulmonary related diseases.  Prior studies have 
documented the anti-microbial activity of the plant against both drug sensitive and drug 
resistant strains of Mycobacterium tuberculosis (Lall and Meyer, 1999). Furthermore in the 
same study it is documented that the root material of the plant contains high concentration of 
compounds (naphthoquinones), as compared to the rest of other parts of the plant. Hence the 
root material is the substance of interest in this study. 
 
TB is an Infectious disease caused by a microorganism posing a serious and growing problem 
the world over. It is the most deadly infectious disease in the world with approximately a 
billion people infected and over a million deaths every year. Current treatments involve therapy 
over a long period (6 months), and there are serious problems with drug-resistant strains 
(multidrug-resistant TB and extensively drug resistant-TB). One strategy for developing new 
antibacterial agents is to seek new targets (Verrall et al., 2014). Discovery of anti-
mycobacterium properties of naphthoquinones present in Euclea natalensis is of great 
importance towards the development of new TB drugs (Babula et al., 2009). Until this study, 
no previous toxicity studies have been done on these species to rule out the toxicity potential of 
the plant on mammalian tissues.  
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2.1.2 ORCHID CHEMICALS AND PHARMACUETICAL COMPANY LTD. 
RESEARCH LABORATORIES 
 
This study was conducted as part of an experiential training programme at Orchid Chemicals 
and Pharmaceutical Company Ltd Research Laboratories, in TamilNadu State in the city of 
Chennai, (Madras) in India. Orchid Pharmaceutical Company is located in Chennai India. The 
company manufactures both oral and sterile cephalosporin anti-biotic for the world market 
which started in 1999 after being issued with certification for commencement with business in 
1992. As India’s largest cephalosporin manufacturer, the company ranks as Top-5 in the world. 
It has sophisticated manufacturing facilities that are GMP (Good Manufacturing Practice) 
approved by WHO. It received the GMP certification in 1995. Orchid is India’s only 
Pharmaceutical Company with both ISO9001-2000 and ISO14001 Certification for its quality 
and environmental management systems respectively. The company runs 3 research campuses, 
3 formulation manufacturing sites and 3 Application Programming Interface (API) 
manufacturing sites in India. The experiential training programme was initiated and sponsored 
by India Institute of Advanced Scientific Research through the Department of Science and 
Technology in collaboration with Centre for International Co-operation in Science (CICS) 
India. Orchid Pharmaceutical Company collaborates well with other scientific research 
institutions in India. It came to be the centre of my study through the research proposal that was 
submitted which required the research facilities applicable to my field of study (animal house 
facility, histopathology laboratory, personnel supervision- expertise and skill including 
statistical analysis and methodologies required for toxicity studies). The company was 
identified to meet the research field by the Director of Medical Research council (MRC), TB 
unit in Madras (Dr Somiya). 
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2.2 MATERIALS AND METHODS 
 
2.2.1 Animal selection and quantity 
 A total 40 healthy adult Swiss albino mice were selected for the study. The animals used in the 
experiment were obtained from the Breeding Facility, Orchid Chemicals & Pharmaceuticals 
Ltd. The animals were 6-7 weeks old with the average weight of 25-30g at the time of 
treatment. Animals were grouped into four groups of five per sex.  Animals were selected in 
such a way that the mean body weight of all animals in a group fell between +/- 20% of the 
mean body weight range in order to minimize biological variation. Female mice were 
nulliparous and non-pregnant. 
 
2.2.2 Room Sanitation 
Before the animal could occupy the experimental room, the room was decontaminated and 
room sterility was confirmed by performing a surface viable count. The floor of experimental 
room was swept daily. All worktops and floors were mopped daily with a disinfectant 
(Suprasol LC 5%). 
 
2.2.3 Animal Welfare 
All animals were handled similarly and with due regard for their welfare. Humane treatment 
and care of animals were complied with the Regulations of Committee for the Purpose of 
Control and Supervision of Experiments on Animals (CPCSEA), Government of India 
(Protocol N° 14-IAEC:02/TOX/2010). 
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2.2.4 Acclimatization Period 
Acclimatization of animals was not entertained as the animals were taken from within the 
Animal House at Orchid Chemicals & Pharmaceuticals Ltd. And maintained under similar 
conditions. 
 
2.2.5 Grouping  
The animals were randomly allocated and were equally distributed to four groups; vehicle 
control G1 (0 mg/kg body weight), low dose G2 (125 mg/kg body weight), mid dose G3 (250 
mg/kg body weight) and high dose G4 (500 mg/kg body weight). Each group comprised of 5 
males and 5 females. 
 
2.2.6 Animal Identification 
Animals were given temporary numbers as their identity during randomization. After allocation 
of groups, permanent numbers were issued to all animals and each animal was given a tag 
bearing its number on the cage, with unique color for the specific group (white tag for controls, 
pink tag for low dose, yellow tag for mid dose and red color for high dose).  
 
2.2.7 Animal Husbandry 
Animals were housed individually in polypropylene mice cages (290 mm x 220 mm x 140 mm) 
using autoclaved paddy husk as bedding material. Each cage was fitted with a stainless steel top 
grill having provision to keep pellet feed and a polypropylene water bottle with stainless steel 
nozzle. Cages were placed on 5 tier racks. Cages were changed once in three days a week and 
water bottles once a week. 
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The experimental animals were fed ad libitum mice pellet feed (Nutrilab brand, Tetragon 
Chemie Pvt. Ltd, Bangalore) with unlimited supply of clean drinking water in polypropylene 
bottles (capacity 300mL) filtered through Aquaguard® water filtration system. The quality of 
feed was checked and the batch was accompanied with a certificate of analysis of nutrient 
content. The quality of water was monitored for any known chemical and microbial 
contaminants. There were no contaminants in feed and water at the level which can affect the 
results of the experiment. Animals were maintained in a controlled environment with a 
temperature of 21 - 25°C; humidity of 54 - 69 %; light/dark cycle of ~12 hours and 14 fresh air 
changes per hour. 
 
2.2.8 Study Design 
Summary of group designations is given below (Table 2.1) for the repeated dose (7 day) sub-
acute toxicity study. 
 
Table 2.1 Summary of Animal Grouping  
 
Group N° Treatment 
Dose (mg/kg 
b.wt.) 
N° of animals Animal ID. N° 
Male Female Male Female 
G1 Control 0 5 5 1 - 5 6-10 
G2 Low Dose 125 5 5 11-15 16-20 
G3 Mid Dose 250 5 5 21-25 26-30 
G4 High Dose 500 5 5 31-35 36-40 
 
Four groups of Swiss albino mice comprising 5 males and 5 females per group were 
administered the test formulation at the dose levels of 0, 125, 250 and 500 mg/kg body weight 
through oral route for 7 consecutive days. The test substance was formulated in 20% DMSO 
and 80 % of 0.25% Carboxy Methyl Cellulose (CMC). The control groups received the vehicle 
alone. 
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2.2.9 Dose Preparation and Administration 
The crude extract was repeatedly administered orally once daily using graduated syringe and 
stainless steel intubation cannula for the 7 days of the study. The required quantity of the test 
substance was weighed using a calibrated analytical balance and was suspended in DMSO 
followed by CMC in the stipulated ratios. Due to the thickness of the suspension, Dose volume 
was maintained as 20 ml/kg body weight for all animals. The test suspension was prepared 
every day and was administered immediately. Individual dosage volume was calculated based 
on the initial body weight. The crude extract of Euclea natalensis was suspended in 
DMSO/CMC to attain the required concentrations i.e., 6.25, 12.5, 25mg/ml for the low, mid 
and high dose groups respectively. Fresh suspension of Euclea natalensis was prepared every 
morning prior to dosing. The dose volume administered to each mouse was calculated on the 
basis of a constant factor of 20 ml/kg body weight throughout the study.  
 
2.2.10 Repeated Dose Toxicity Evaluations 
2.2.10.1 Mortality 
All the animals were checked at least twice a day for mortality and signs of morbidity, in the 
morning after oral dosing and in the afternoon. 
 
2.2.10.2 Clinical Signs 
Animals were observed for all visible signs of reaction to the treatment such as skin and fur 
changes, eye and mucous membrane changes, respiratory, circulatory, and autonomic and 
central nervous system, somatomotor activity, behaviour pattern and general changes twice 
daily. 
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2.2.10.3 Body weight 
The body weight of individual animal was recorded prior to first dosing, at 4
th
 day, 7
th
 day and 
before scheduled sacrifice. 
 
2.2.10.4 Feed consumption 
Feed consumption was recorded cage wise for all animals at the 4
th
 day of commencement of 
exposure and at day 7. The average daily feed consumption of individual animals was 
calculated as follows: 
Feed Consumption (g/mouse/day) = Feed input – Feed left over 
                                                   ------------------------------------------------------------- 
                                                        Number of mice in the cage X No. of days 
 
2.2.10.5 Clinical pathology observation 
At the end of the 7-day period, the animals were fasted overnight. The following morning 
(prior to sacrifice), blood was collected from all the animals by puncturing the orbital sinus 
with a heparinised capillary under mild isoflourane anaesthesia. Blood was collected into a 7.5 
cm (length) capillary tube and the clotting time was recorded manually. Approximately 0.1 ml 
of blood was collected in vials containing Ethyl-Diamine Tetra Acetic Acid (EDTA) for 
haematology analysis.  
 
The following haematological parameters were measured; total erythrocyte count (RBC), 
haemoglobin concentration (Hb), packed cell volume (PCV), mean corpuscular volume 
(MCV), mean corpuscular haemoglobin (MCH), mean corpuscular haemoglobin concentration 
(MCHC), platelet count and total differential leucocyte count (WBC). All parameters were 
determined using haematological analyzer (Sysmex KX 21). The procedure specified in the 
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Sysmex Operation’s Manual (1988) for analysis was followed. Table 2.2 outlines the 
haematology investigations performed. 
 
Table 2.2 Summary of Haematological Investigations 
 
Parameter Method 
White blood count DC Detection Method 
Differential leukocyte count DC Detection Method 
Red blood count DC Detection Method 
Haemoglobin Non-cyanide Haemoglobin Analysis Method 
Packed cell volume RBC Pulse High Detection Method 
Mean Corpuscular Volume  Calculated from Haematocrit and RBC values 
Mean Corpuscular Haemoglobin Calculated from Haemoglobin and RBC values  
Mean Corpuscular Haemoglobin 
Concentration 
Calculated from Haemoglobin and Haematocrit 
values 
Platelet Count DC Detection Method 
Clotting Time Capillary Method-Manual 
 
Zero point five to 0.8 ml of blood was collected from each animal in heparinized centrifuge 
tubes and then centrifuged using cooling centrifuge (Eppendorf Centrifuge 5804 R) at 5000 
RPM for 10 minutes and plasma was separated. Plasma biochemical parameters were analysed 
using a fully automated clinical chemistry analyser (ERBA XL 300, Transasia Biomedicals 
Ltd., Mumbai) (Table 2.3).  Table 2.3 Summarises the biochemical investigations performed. 
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Table 2.3 Summary of Biochemical Investigations 
 
Parameter Method 
Fasting Glucose GOD-POD Method 
Total Bilirubin Diazo Method 
Triglycerides GPO Trinder Method 
 Urea  Urea analysed using GLDH-UREASE Method.  
Creatinine  Jaffe’s Method 
Alanine Aminotransferase 
(ALT)  
IFCC, Kinetic without pyridoxal phosphate 
Alanine Aminotransferase 
(ALT)  
IFCC, Kinetic without pyridoxal phosphate 
Total Protein  Biuret Method 
Phosphorous Ammonium Molybdate Method 
Chloride Ferric Thiocynate Method 
 
2.2.10.6 Gross Examination and Histopathology 
All the animals were euthanized with a dose of isoflurane and subjected to a complete necropsy 
under the direct supervision of a veterinary pathologist at the end of the treatment period. Gross 
pathological examination included examination of the external surface of the body, all orifices, 
thoracic and abdominal cavities and their contents. The appearance of macroscopic 
abnormalities was recorded. The thoracic, abdominal and cranial cavities were then cut open 
and thorough examinations of organs were carried out to detect changes or abnormalities. 
Figure 2.1 below outlines the necropsy procedure used in this study. 
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Figure 2.1 Necropsy procedure.  
Source: (Adapted from Orchid Pharmaceutical SOPs, 2013) 
 
2.2.10.6.1 Tissue Fixation  
 
Tissue fixation preserves and saves (stabilize proteins) the tissues from decaying (autolysis) 
and maintains the texture to accommodate and to set a good platform for other procedures to 
follow. Good tissue sections and staining start with good properly fixed tissues. The minimum 
time for tissue fixation is about 1-4 hours, but the specimens maybe kept for longer times 
(Suvarna et al., 2013).  
The chemical composition of the 10% neutral buffered formalin fixative: 
 Formalin (37-40%)     100ml 
 Distilled water             900ml 
 NaH2PO4                                    4g 
Na2HPO4                        6.5g 
Chemicals were mixed to dissolve. (PH 6.8 was maintained) 
 
 
2.2.10.6.2 Tissue Processing 
 
Tissue processing is the second step in the processing of tissues for histology analysis. In this 
procedure, tissues go through a series of steps to give (them) some structural format that 
prepares the tissues for subsequent sectioning and staining (both for diagnostic and research). 
40 ANIMALS FASTED 
(over night) 
INDIVIDUAL ANIMAL 
BODY WEIGHT TAKEN 
EUTHANIZE ANIMAL 
 
EXTERNAL 
MACROSCOPIC 
EXAMINATION  
(including all orifices )  
ORBITAL SINUS 
PUNCTURE 
(bleed animal) 
CUT OPEN ANIMAL 
(upon death and wet 
with 70% alcohol 
externally) 
INTERNAL 
MACROSCOPIC 
EXAMINATION  
(all cavities)  
 
DISSECT  TO HARVEST 
ORGANS  
(organ weight taken) 
ORGAN FIXATION 
(10% buffered 
formalin)  
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The process primarily functions to remove water in the tissues in a very slow manner through 
ascending grades of alcohol (ethanol as is the most commonly used dehydrant). It is done 
slowly to avoid rapid harsh removal of water which could result in tissue shrinkages. On 
completion of the process, the alcohol is removed (clearing). Xylene is the chemical used to 
clear tissues off the dehydrating solvent. It is the transitional step between dehydration and 
infiltration with the embedding medium. Infiltration (interpenetration) process of tissues is the 
actual filling of tissue cavities and cells created by water removed with supporting substance, 
which in this step will be filled with the medium to be used for embedding (molten wax) 
(Suvarna et al., 2013).    
The table below illustrates the stages and chemicals useful in the automatic processing of 
tissues with time frames (Leica, TP1020 operational manual 2009; Histology Lab, Walter 
Sisulu University). 
 
Table 2.4 The stages and chemicals used in the automatic processing of tissues 
Process Reagents Action  Time frames 
Fixation  
(2 stations) 
10% neutral BF Stabilize proteins 1hr 
10% neutral BF 1hr 
Dehydration: ascending 
grades of alcohol 
 
(5 stations) 
70% ethanol  
 
Removal of water 
1:30hr 
80% ethanol 1:30hr 
95% ethanol 1:30hr 
100% ethanol 1:30hr 
100% ethanol 1:30hr 
Clearing 
(3 stations) 
Xylene  
Removal of alcohol 
1:30hr 
Xylene 1:30hr 
Xylene 1:30hr 
Infiltration 
(2 stations) 
Molten wax  
Interpenetration 
2hr 
Molten wax 2hr 
Source:  Leica TP20 Histology laboratory operational manual 
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2.2.10.6.3 Tissue Embedding 
Tissue embedding is one of the techniques used in histology laboratory that primarily prepares 
wax infiltrated tissues for section cutting (microtomy). It is the immediate step after tissue 
processing. The processed and infiltrated tissues are at this stage supported in a medium which 
allows the tissues to be cut without crushing and damaging. This is the outlined embedding 
procedure: 
 Place the paraffin infiltrated tissue cassettes in the tissue embedding centre’s tank, that 
has been heated to the temperature of about 60-65°C 
 Warm the metal block containers in the warm storage area of the machine 
 Place the empty metal container over the hot plate of the embedder 
 Dispense a little hot paraffin wax from the tank into the metal container 
 Take the paraffin infiltrated tissue from the tissue cassette using a forceps  and place it 
in the metal container 
 Using heated forceps orientate the tissue specimen as desired and pore small volume 
hot wax 
 Put back the labeled empty plastic tissue cassette on top of the wax pore more hot 
paraffin wax to cover the plastic cassette 
 Now shift the metal container from the hot plate to the cold plate (-15°C) of the tissue 
embedder 
 When the wax is hard, take out the paraffin block from the metal case; the paraffin 
block is now ready for section cutting (Suvarna et al., 2013).  
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2.2.10.6.4 Tissue/Section Cutting (Microtomy) 
 
Figure 2.2 Rotary Microtome HM 355 S. Histology Laboratory, Walter Sisulu University 
 
 
After the long processes of tissue dehydration, infiltration, clearing and embedding all tissues 
are subjected to cutting using either a bench microtome or a rotary microtome. Section cutting 
involves a number of steps before getting the sections on the glass slide ready for staining. A 
rotary microtome (figure 2.2) is a heavy duty microtome especially for paraffin and hard 
sectioning techniques in biology, medicine, industry and research. The machine cuts sections in 
the range of 0.5μm -100μm. This piece of equipment will normally have both trimming (30μm) 
and cutting (5μm) function modes. Tissue trimming permits fine adjustments up to first cuts 
and this result in larger section thickness during trimming. When trimming is complete the fine 
mode cutting is selected to produce ribbons of sections that are floated in a 60°C water bath to 
align sections properly on the slide (Micron International GmbH, 2007). 
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Procedure for Sectioning (HM 355 S Instruments Instructional Manual no 387841, WSU): 
 Make sure that the clamping screws and clamping levers on the blade holder and 
specimen holder are well tightened.  
 Make sure that the specimen and specimen holder are well oriented 
 Always use sharp blades to produce neat thin sections (avoid compressions) 
 Sectioning should always be carried out in ambient temperatures (excluding frozen 
sections) 
 Cutting speed must be programmed in accordance with texture of the material 
 Trimming thickness must be set at 30μm and cutting thickness at 5μm to produce good 
sections 
 Upon production of tissue ribbons, the sections are flooded in a water bath (58-60°C) 
to flatten and iron out any folds 
 Good, neat sections are picked from the ribbon in the water bath using a labeled slide 
for the exact tissue just cut  
 Sections are left to dry before staining 
 
2.2.10.6.5 Tissue Staining/ Staining Mechanism 
Tissues that are examined microscopically immediately after sectioning without staining appear 
very dull and uninteresting. They lack contrast of all fixed tissue materials and all have a 
similar refractive index and colour. In order to bring out the microscopic structure of these 
tissues, it is essential to stain the cells and connective tissue to expose the different parts in 
contrasting colours. Staining is therefore not simply colouring the sections but relies on using 
differences in chemistry of the tissues to show the different components in different colours. 
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These are achieved by using dyes that can bind to tissues selectively. The most common stain 
in use in histology staining is haematoxylin and eosin (H & E) stain (Suvarna et al., 2013). 
The binding of dyes to tissues is similar to other chemical bonding and the mechanisms is the 
same in that they all rely on the same binding forces occurring in all other organic compounds? 
Eosin is a negatively charged stain (anionic dye) and will stain positively charged (cations) 
tissue ions (cytosol of the cell and connective tissue).  Haematoxylin is a versatile stain and is 
used in combination with mordants (alum salts) that alters the specificity and colour of the 
stain. It will stain the acidic environment of the cell (nucleus) dark blue of purple (Suvarna et 
al., 2013). 
 
After drying the slides are ready to stain, but paraffin sections are still impregnated with 
paraffin wax which forms a water proofing coat that can prevent the stain to access proteins 
within the tissues. Therefore the wax must melt in the oven (60°C) and then be removed before 
sections could be rehydrated (Orchid histopathology staining protocol, 2013). Below is a point-
form summary of the histopathology staining procedure used in this study: 
 
 Xylene                                          5 minutes (2-3 changes) 
 Absolute alcohol                            5 minutes     
 95% alcohol                                   5 minutes 
 70% alcohol                                   5 minutes 
 Distilled water                                3 minutes 
 Harris Haematoxylin                       5 minutes 
 Differentiate in running tap water     2 minutes 
 Eosin-Phloxin                                 1 minute 
 80% alcohol                                     Dips 
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 95% alcohol                                     Dips 
 Absolute alcohol                              Dips ( 2 changes) 
 Xylene                                            5 minutes  (3 changes) 
 Mount in DPX 
 
2.2.10.6.6 Section Mounting 
Staining is subsequently followed by mounting procedure. Normally the mounting medium 
must have a high refractive index (RI). Tissues mostly have an RI of 1.5-1.55 and the mounting 
medium of the same index will offer maximum clarity. The common mountant in histology 
procedures is DPX. It’s a synthetic polystyrene resin that has been dissolved in xylene with 
some plasticizer added to it. It is a clear waterless solution that hardens in about 24 hours. (D= 
Distrene 80, that is a commercial polystyrene; P=Plasticizer, dibutyl phthalate and X=Xylene) 
(Suvarna et al., 2013). Mounting is done under a cover slip and it gives best and clear view of 
the specimen. The cover slip should have the thickness of about 0.17mm to give best results.  
 Mounting is done with slides immersed in xylene. 
 General safety rules must always be adhered to (GLP) 
 Align cover slipper on a flat surface 
 Dispense a small drop of DPX over the cover slip 
  Remove the slide from the xylene bath and right face the slide over the slip 
 Press very gently tapping at the same time to release the bubbles 
 Leave flat on the surface to dry 
 Sort and file in slide boxes ready for microscopy (Orchid histopathology Research 
Laboratory mounting procedure, 2012). 
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2.2.10.7 Organ Weight 
Absolute wet weights of adrenals, brain, uterus, ovaries, testes, epididymides, heart, kidneys, 
liver, spleen and thymus were recorded immediately after dissection for all animals. Relative 
weights of these organs were calculated later. Organs were harvested and cleared from the 
adhering fat and blotted free from blood (Orchid Histopathology Research Laboratory, 2013). 
The absolute weight was recorded to the nearest milligram using a calibrated balance. 
Relative organ weight = organ weight        x 100 
                                  ----------------------------------- 
                                       Animal weight                          
                                   
The following organs of all the animals were collected at necropsy and preserved in 10% 
buffered neutral formalin for processing and microscopic examination; stomach, duodenum, 
jejunum, ileum, caecum, colon, rectum, liver, brain (representative regions including forebrain, 
cerebrum, cerebellum), adrenals, lungs, heart, aorta, spleen, thymus, kidneys, testes, 
epididymides, ovaries, cervix and the uterus. 
 
All the preserved organs from control and high dose groups (G1 and G4) of the animals were 
processed following suitable techniques of washing by tap water, dehydration in ascending 
grades of ethyl alcohol, clearing in xylene, embedding and blocking in paraffin wax. Paraffin 
sections (5μm) were cut, stained with hematoxylin and eosin (H&E), and mounted on slides as 
outline previously.  Veterinary pathologist assisted histopathology screening was carried out on 
all preserved organs and tissues of all the animals in control and high dose groups.  
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2.2.10.8 Statistical Analysis of Results 
 
Raw data were processed statistically. The means and standard deviations were calculated with 
significance between the control and treated groups and all data were summarized in tabular 
form. All the parameters characterized by continuous data such as body weight, feed 
consumption, organ weight, relative organ weight, haematology, clinical chemistry were 
subjected to Bartlett’s test to meet the homogeneity of variance.  All homogenous data were 
analyzed using ANOVA and data showing significance in their variances were subjected to 
Dunnett’s t-test. 
Significance was calculated at 1% as well as 5% level, and indicated in the summary table as 
follows: 
↑ -Significantly higher than control (p˃ 0.05), ↑↑ -Significantly higher than control (p˃ 0.01), 
↓- Significantly lower than control (p<0.05), ↓↓- significantly lower than control (p< 0.01) 
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2.3 RESULTS 
2.3.1 Mortalities  
No mortalities were observed in the control group (G1) as well as any of the treated group 
animals (G2, G3 and G4) exposed to crude extract of Euclea natalensis.  
 
2.3.2 Clinical Observations  
No treatment related visible signs of toxicity were observed in animals in all treated groups. 
Table 2.5 is an outline of the clinical observations noted in the 7 day repeat oral toxicity study. 
 
Table 2.5 Summary of Clinical Observations for Repeated Dose Toxicity Study 
Group N° & Dose 
(mg/kg b.wt.) 
Gender Clinical sign 
N° of Animals Showing Clinical Signs* 
Experiment Day 
1 2 3 4 5 6 7 8 
G1 
(0) 
Male Normal 5 5 5 5 5 5 5 5 
Female Normal 5 5 5 5 5 5 5 5 
G2 
(125) 
Male Normal 5 5 5 5 5 5 5 5 
Female Normal 5 5 5 5 5 5 5 5 
G3 
(250) 
Male Normal 5 5 5 5 5 5 5 5 
Female Normal 5 5 5 5 5 5 5 5 
G4 
(500) 
Male 
Normal 
 
5 5 5 5 5 5 5 5 
Female Normal 5 5 5 5 5 5 5 5 
Key: * = Animals which exhibited clinical signs at least once during the week 
 
2.3.3 Effect of Body Weight   
No significant deviation of weights in mean of all the treated groups was observed as compared 
to the control group, both at day 4, day 7, and at terminal point.  
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Table 2.6 Summary of Body Weight (g) 
Gender: Male 
Day N° 
G1 
(0 mg/kg /Bwt.) 
G2  
(125mg/kg Bwt.) 
G3  
(250mg/kg/Bwt)) 
G4  
(500mg/kg/Bwt.) 
Mean Mean Mean Mean 
# 27.240 ± 3.06 26.620 ± 1.731 27.160±3.244 26.6408±2.438 
Day 4 25.940± 2.092 25.600± 1.672 28.140±4.166 24.040± 1.726 
Day 7 24.000± 1.625 25.180± 2.105 28.460±5.879 22.720±2.523 
Ter. B.wt 24.080± 1.639 24.980± 1.424 28.460±5.748 22.680±2.326 
          #-pre exposure 
 
Gender: Female 
Week N° 
G1 
(0 mg/kg 
B.wt.) 
G2  
(125mg/kg B.wt.) 
G3 
250mg/kgB.wt.) 
G4  
(500 mg/kg B.wt.) 
Mean Mean Mean Mean 
# 25.920±1.279 24.960± 1.686 25.280± 1.318 25.860± 1.777 
Day 4 26.160±1.607 25.500± 2.373 25.040± 1.410 25.320± 2.069 
Day 7 26.060±1.702 26.260±2.324 25.760±1.736 26.140±1.244 
Ter. B.wt 26.020±1.163 25.920±2.331 25.440±1.641 25.500±1.751 
# - Pre exposure 
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2.3.4 Feed Consumption  
No significant changes were observed in the feed consumption of the treated groups of animals 
as compared to the control group. 
 
Table 2.7 Summary of Average Daily Feed Consumption (g/mice/day) 
Gender: Male 
Day 
N° 
G1 
(0 mg/kg Bwt.) 
G2  
(125 mg/kg Bwt.) 
G3  
(250 mg/kg Bwt.) 
G4  
(500 mg/kg Bwt.) 
Mean Mean Mean Mean 
Day4 1.520± 0.614 1.200±  0.689 1.100± 0.951 1.006± 0.922  
Day 7 0.140±  0.055  0.132± 0.064  0.508± 0.428  0.530± 1.101 
 
Gender: Female 
Day N° 
G1 
(0 mg/kg Bwt.) 
G2  
(125 mg/kg Bwt.) 
G3  
(250 mg/kg Bwt.) 
G4  
(500 mg/kg Bwt.) 
Mean Mean Mean Mean 
Day4 1.740± 1.062 
 
1.062± 0.907 0.960± 0.684 1.620±1.203 
Day 7 1.060±0.089 1.320±0.792 0.800±0.721 0.680±0.349 
Key: # = Pre-exposure 
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2.3.5 Haematology 
No statistically significant changes were noticed in all animals (in all sexes) treated with Euclea 
natalensis as compared to non-treated control group.  
Table 2.8 Summary of Haematology Values  
Gender: Male 
Parameter 
G1 
(0 mg/kg b.wt.) 
G2 
(125 mg/kg b.wt.) 
G3 
(250 mg/kg b.wt.) 
G4 
(500 mg/kg b.wt.) 
Mean Mean Mean Mean 
RBC (106/L) 9.050± 0.970 10.018± 0.710 9.378± 0.888 9.958± 0.670 
HGB (g/dL) 14.760± 0.385  15.140± 0.737 14.700± 0.752 15.260± 0.929 
HCT (%) 49.700± 4.836 54.100± 2.791 51.780± 4.225 53.920± 4.428 
MCV (fL) 54.980± 1.363 54.100± 2.747 55.300± 1.612 54.120± 1.566 
MCH (pg) 16.520± 2.229 15.160± 0.902 15.720± 1.028 15.320± 0.522 
MCHC (g/dL) 30.000± 3.924 27.980± 0.277 28.420± 1.165 28.340± 0.826 
PLT (103/L) 1359.600± 441.726 1333.200± 130.051 1067.800± 374.905 1401.600± 249.077 
CL.Time (Sec) 138.000± 12.550 135.000± 15.000 135.000± 15.000 129.000± 13.416 
WBC (103/L) 5.340±0.945 5.180±1.28 6.280±1.499 5.840±2.442 
LYM (%) 67.000± 11.363 69.520± 12.983 67.840± 8.871 63.580± 17.320 
NEU (%) 28.380± 9.949 26.880± 11.954 28.300± 7.703 31.960± 15.820 
MIX (%) 4.620± 1.992 3.600± 1.170 3.860± 1.316 4.460± 1.581 
 
Gender: Female 
Parameter 
G1 
(0 mg/kg b.wt.) 
G2 
(125mg/kg b.wt.) 
G3 
(250 mg/kg b.wt.) 
G4 
(500 mg/kg b.wt.) 
Mean Mean Mean Mean 
RBC (106/L) 9.220± 0.647 9.372±0.284 9.502±0.328 9.586±0.483 
HGB (g/dL) 14.600± 0.453 14.580±0.606 14.900±0.596 15.020±0.396 
HCT (%) 50.960±2.092 51.640±1.877 52.500±3.145 52.360±1.250 
MCV (fL) 55.400±2.661 55.100±1.531 55.220±2.032 54.680±1.908 
MCH (pg) 15.880±0.811 15.560±0.623 15.680±0.259 15.700±0.797 
MCHC (g/dL) 28.640± 0.321 28.260±0.467 28.400±0.570 28.720±0.522 
PLT (103/L) 1109.800±131.089 1015.600±122.692 1197.200±172.967 1131.800±159.588 
CL.Time (Sec) 138.000±12.550 135.000±10.607 
 
147.00±22.24 
139.000±10.840 
WBC (103/L) 4.640±1.527 4.700±1.965 6.425±2.326 5.340±1.278 
LYM (%) 80.840± 5.801 
              
      77.32 ±8.255 
68.450±11.794 76.100±14.015 
NEU (%) 16.480± 4.927 19.920±7.425 27.625±9.981 20.280±11.681 
MIX(%) 2.680± 1.161 2.760±0.974 3.925±1.916 3.620±2.347 
Key: ↓ = significantly low at P  0.05, ↑ = significantly high at P ≥ 0.05, ↓↓ = significantly low at P ≤ 0.01 
↑↑ - Significantly higher than control (p≥ 0.01) 
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2.3.6 Clinical Chemistry  
No statistical significance was observed in all parameters in the male treated animals, except 
for G3 group (250mg/kg b.wt.) which showed a decrease in total protein as compared to the 
untreated animals at 1% significance level (p˂0.01).  In females, all treated animals showed a 
decrease in total cholesterol as compared to control animals although statistically not 
significant. G3 (500mg/kg.b.wt.) showed an increase in phosphorus at 5% (p˂0.05) as 
compared to control group. G2 (125mg/kg b.wt) showed a statistical significance in triglyceride 
level at 5% (p˂0.05). 
 
Table 2.9 Summary of Clinical Biochemistry Values  
Gender: Male 
Parameter 
G1 
(0 mg/kg b.wt.) 
G2 
(125mg/kg b.wt.) 
G3 
(250 mg/kg b.wt.) 
G4 
(500 mg/kg b.wt.) 
Mean Mean Mean Mean 
GLU (mg/dL) 128.780± 34.866 126.660± 26.750 147.520± 67.368 111.680± 21.881 
URE(mg/dL) 27.800± 8.044 26.400± 7.369 29.200± 1.304 31.000± 5.568 
CRE (mg/dL) 0.400± 0.024 0.432± 0.049 0.468± 0.110 0.400±0.060 
T.PRO (g/dL) 7.034± 1.116 6.842±0.829 ↓5.726±0.578 6.450±0.648 
ALB (g/dL) 3.768± 1.451 3.906±1.110 2.282±0.641 4.450±1.255 
CLO (mEq/L) 98.020± 4.110 101.100±2.064 102.840±2.341 96.940±5.505 
PHO (mg/dL) 12.250±4.153 12.662±0.608 11.936±2.873 7.348±1.298 
CHOL (mg/dL) 143.800± 42.204 154.600±24.358 118.600±14.381 182.200±25.352 
TGL (mg/dL) 173.200± 41.294 181.600±51.786 168.400±61.211 194.000±41.851 
T.BIL (mg/dL) 2.286± 1.244 2.876±0.560 2.374±0.998 1.832±0.850 
GOT (IU/L) 149.660± 41.219 162.820±49.563 133.120±44.371 169.900±17.476 
GPT (IU/L) 103.960± 39.435 83.560±14.933 97.440±30.156 99.100±19.047 
ALP (IU/L) 118.200±41.590  145.000±32.381 135.800±42.056 84.000±20.893 
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Table 2.9 (Continued) 
Gender: Female 
Parameter 
G1 (0 mg/kg b.wt.) G2 (125 mg/kg b.wt.) G3 (250 mg/kg b.wt.) G4 (500 mg/kg b.wt.) 
Mean Mean Mean Mean 
GLU (mg/dL) 145.140±12.885 127.320±11.253 140.680±11.989 138.780±21.176 
URE(mg/dL) 20.000± 2.121 18.200±2.387 20.000±1.414 21.800±2.387 
CRE (mg/dL) 0.384± 0.028 0.388±0.027 0.396±0.021 0.380±0.034 
T.PRO (g/dL) 5.948±1.610  5.598±0.412 6.240±0.608 5.592±0.537 
ALB (g/dL) 3.404± 0.940 2.392±0.337 3.188±1.089 2.282±0.213 
CLO (mEq/L) 98.280±1.455 98.860±3.449 101.180±3.507 100.480±2.406 
PHO (mg/dL) 8.876±1.984 8.876±1.984 ↑12.046±1.544 10.596±1.383 
CHOL (mg/dL) 146.600± 42.495 110.600±9.290 121.400±34.595 120.000±14.124 
TGL mg/dL) 162.400±21.916  ↓131.200±17.079 156.400±68.755 169.200±69.694 
T.BIL (mg/dL) 1.530± 0.584 1.606±0.598 1.486±0.514 2.332±1.240 
GOT (IU/L) 146.880± 44.743 107.720±33.345 163.620±56.303 142.780±85.821 
GPT (IU/L) 60.360±24.822 53.640±16.822 64.960±21.036 43.840±6.738 
ALP (IU/L) 166.600± 23.480 189.400±34.290 146.800±44.110 148.800±31.412 
 
Key: ↓ = significantly low at P  0.05, ↓↓ = significantly low at P  0.01  
↑ = significantly high at P ≥ 0.05, ↑↑ = significantly high at P ≥0.01 
 
2.3.7 Absolute Organ Weight  
No significant change in males was seen in all organ weights when compared to the control 
group, except for the weight of the testes in G2 group (250mg/kg.b.wt.) which was significantly 
higher than the control at 1% level. (p˃0.01). In female animals, no deviation of weights is 
observed in all organs. However, the heart weight in both G3 and G4 showed a reduction with 
no statistical significance. This observed change in the absolute and relative heart weight could 
be of biological concern. Table 2.9 is a summary of the absolute organ weights recorded. 
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Table 2.10 Summary of Absolute Organ Weight (g) 
Gender: Male 
Parameter 
Group N° & Dose (mg/kg b.wt.) 
G1 (0) G2 (125) G3 (250) G4 (500) 
Mean Mean Mean Mean 
Terminal Body 
Weight 
24.080±1.639 24.980±1.639 28.460±5.748 22.680±2.326 
Adrenals 0.012±0.003 0.010±0.003 0.012±0.002 0.009±0.004 
Testes 0.183±0.012 ↑↑0.211±0.007 0.178±0.012 0.201±0.021 
Thymus 0.048±0.017 0.045±0.008 0.054±0.015 0.040±0.016 
Epididymis 0.071±0.009 0.075±0.008 0.079±0.011 0.071±0.012 
Spleen 0.115±0.024 0.119±0.027 0.127±0.016 0.115±0.026 
Heart 0.158±0.011 0.163±0.016 0.178±0.034 0.152±0.029 
Brain 0.446±0.022 0.468±0.032 0.469±0.025 0.450±0.021 
Kidneys 0.436±0.061 0.452±0.084 0.554±0.171 0.394±0.072 
Liver 1.546±0.245 1.537±0.093 1.678±0.285 1.386±0.113 
 
Gender: Female 
Parameter 
Group N° & Dose (mg/kg b.wt.) 
G1 (0) G2 (125) G3 (250) G4 (500) 
Mean Mean Mean Mean 
Terminal Body 
Weight 
26.020±1.163 25.920±2.331 25.440±1.641 25.500±1.751 
Adrenals 0.021±0.004 0.017±0.003 0.017±0.002 0.022±0.005 
ovaries 0.389±0.041 0.369±0.035 0.363±0.019 0.379±0.034 
Thymus 0.017±0.005 0.014±0.002 0.016±0.005 0.018±0.002 
uterus 0.102±0.022 0.115±0.034 0.098±0.013 0.098±0.036 
Spleen 0.175±0.087 0.193±0.080 0.160±0.031 0.189±0.056 
Heart 0.142±0.032 0.143±0.034 0.136±0.026 0.131±0.016 
Brain 0.165±0.019 0.165±0.023 0.158±0.009 0.164±0.016 
Kidneys 0.485±0.013 0.482±0.021 0.483±0.012 0.472±0.027 
Liver 1.447±0.160 1.398±0.223 1.413±0.200 1.418±0.120 
Key: ↑↑ = significantly high at P ≥ 0.01.↓↓ = significantly low at P  0.01 
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2.3.8 Relative Organ Weight  
No treatment related changes were observed in relative organ weights of animals treated with 
Euclea natalensis, except for changes seen in female animals in both G3 and G4. Table 2.10 
summarises the relative organ weights recorded. 
 
Table 2.11 Summary of Relative Organ Weight (g) 
Gender: Male 
Parameter 
Group N° & Dose (mg/kg b.wt.) 
G1 (0) G2 (125) G3 (250) G4 (500) 
Mean Mean Mean Mean 
Adrenals 0.048±0.012 0.042±0.014 0.045±0.015 0.041±0.012 
Testes 0.765±0.077 0.845±0.060 0.644±0.127 0.894±0.146 
Thymus 0.202±0.072 0.178±0.029 0.197±0.059 0.174±0.058 
Epididymis 0.293±0.027 0.301±0.017 0.283±0.052 0.314±0.051 
Spleen 0.478±0.099 0.481±0.137 0.458±0.092 0.512±0.141 
Heart 0.658±0.022 0.651±0.047 0.628±0.050 0.668±0.094 
Brain 1.858±0.137 1.874±0.086 1.692±0.274 1.996±0.162 
Kidneys 1.808±0.176 1.801±0.260 1.909±0.247 1.732±0.223 
Liver 6.406±0.825 6.160±0.337 5.943±0.584 6.132±0.483 
 
Gender: Female 
Parameter 
Group N° & Dose (mg/kg b.wt.) 
G1 (0) G2 (125) G3 (250) G4 (500) 
Mean Mean Mean Mean 
Adrenals 0.081±0.016 0.065±0.014 0.066±0.011 0.086±0.020 
ovary 1.491±0.097 1.424±0.110 1.429±0.058 1.489±0.130 
thymus 0.065±0.024 0.055±0.011 0.063±0.025 0.070±0.011 
uterus 0.394±0.092 0.336±0.170 0.389±0.063 0.379±0.129 
Spleen 0.679±0.356 0.737±0.256 0.634±0.155 0.734±0.186 
Heart 0.549±0.133 0.574±0.087 0.534±0.092 0.516±0.057 
Brain 0.635±0.057 0.636±0.038 0.622±0.042 0.646±0.063 
Kidneys 1.867±0.062 1.872±0.185 1.905±0.147 1.857±0.161 
Liver 5.555±0.485 5.373±0.400 5.548±0.655 5.564±0.302 
Key: ↑↑ = significantly high at P  0.01.↓↓ = significantly low at P  0.01 
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2.3.9 Gross Pathological Findings 
2.3.9.1 External Findings 
Gross pathological observations did not reveal any abnormality externally in any of the animals 
belonging to both the control and treated group animals.  
 
2.3.9.2 Internal Findings 
No treatment related gross lesions were observed in any of the animals belonging to either sex 
treated with Euclea natalensis at the dose levels of 500, 250, and 125 mg/kg body weight as 
compared to the control. 
 
Table 2.12 Summary of Gross Pathological Findings 
Gender: Male 
Group and Dose 
(mg/kg b. wt) 
Gross Pathological Findings 
External Internal 
G1(0 mg/kg b. wt) No abnormalities detected in 5/5 No abnormalities detected in 5/5 
G2 (125 mg/kg b. wt.) No abnormalities detected in 5/5 No abnormalities detected in 5/5 
G3 (250 mg/kg b. wt) No abnormalities detected in 5/5 No abnormalities detected in 5/5 
G4 (500 mg/kg b. wt)  No abnormalities detected in 5/5 No abnormalities detected in 5/5 
 
Gender: Female 
Group and Dose 
(mg/kg b. wt) 
Gross Pathological Findings 
External Internal 
G1(0 mg/kg b. wt) No abnormalities detected in 5/5 No abnormalities detected in 5/5 
G2 (125 mg/kg b. wt.) No abnormalities detected in 5/5 No abnormalities detected in 5/5 
G3 (250 mg/kg b. wt) No abnormalities detected in 5/5 No abnormalities detected in 5/5 
G4 (500 mg/kg b. wt)  No abnormalities detected in 5/5 No abnormalities detected in 5/5 
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2.3.10 Histopathological Observations 
Table 2.13 Summary of Histopathological Findings 
Group Animal N° Sex Histopathological Observation 
Control  
(0 mg/kg) 
SA45/1/2 Male Heart: Degenerative cardiac myocytes 
SA/45/6/2 Female Heart: Degenerative cardiac myocytes 
SA45/7/2 Female Adrenal: Involution of the X-Zone  
Treated  
(500 mg/kg) 
SA45/31/1 
SA45/34/1 
Male 
Male 
Lung: Inflammation 
Lung: Inflammation 
SA45/39/2 Female Heart: Degenerative cardiac myocytes 
SA45/37/2 
SA45/40/2 
Female 
Female 
Adrenal: Involution of the X-Zone 
Adrenal: Involution of the X-Zone 
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Figure 2.3 Histopathology Found in the 7 day Repeat Dose Oral Toxicity Study. [A] 
Degenerated cardiac myocytes (H&E, 100x, scale bar = 50µm, Control Mouse, Male). [B] 
Degenerated cardiac myocytes, H&E, 200x, scale bar = 50µm, Control Mouse, Male. [C] 
Adrenal- involution of X-xone, H&E, 100x, scale bar = 50µm, Mouse treated with Euclea 
natalensis at 500mg/kg. [D] Adrenal, Involution of X-zone, H&E, 200x, scale bar = 50µm, 
Mouse treated with Euclea natalensis at 500mg/kg. [E] Airway of Lungs, Inflammation, 
Mononuclear cell Infiltration, H&E, 100x, scale bar = 50µm Mouse treated with Euclea 
natalensis at 500mg/kg. [F] Lungs, Inflammation, dilatation of alveoli, H&E, 100x, scale bar 
= 50µm, Mouse treated with Euclea natalensis at 500mg/kg. 
A B 
C D 
E F 
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CHAPTER THREE 
 REPEATED DOSE (28 DAY) ORAL TOXICITY STUDY OF EUCLEA NATALENSIS 
IN SWISS ALBINO MICE 
A 28-Day toxicity study was carried out to assess the toxicological profile of the crude 
extract of Euclea natalensis following a repeated dose regime. The study provided 
information on major toxicological effects to target organs and estimated a No Observed 
Adverse Effects Level or No Observed Effects Level (NOAEL/NOEL) (OECD, 407).  
Based on the findings from the 7 day repeat dose toxicity study the 28 day repeat dose 
toxicity study was optimised. The following section outlines the methodology used in 
conducting this investigation. 
3.1 MATERIAL AND METHODS 
3.1.1 Production of the Extracts 
3.1.1.1 Plant Collection   
Effort was made to locate the places where the medicinal plant could be collected in the 
country. National Biodiversity Institute of South Africa (NBISA) was contacted and it 
released a guide with various places where the medicinal plant could be found. Research 
proposal of the study was requested and sent to the institution.  Furthermore application form 
was sent to the institute through the authorization of the office of the Head of Department in 
the School of Biomedical technology, Nelson Mandela Metropolitan University (NMMU), 
Professor N Smith. Among the places listed was Lusikisiki which is much nearer to Walter 
Sisulu University where the research work was run. The exact location of the medicinal plant 
in Lusikisiki was obtained in the Kei Herbarium of Walter Sisulu University (WSU). The 
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medicinal plant was collected along Xura River which is about one kilometre from the main 
road.          
 
                                              Figure 3.1   Roots of Euclea natalensis 
 
3.1.1.2 Plant Authentication 
The sourcing of the medicinal plant was achieved with the assistance of the Botany 
technician (Mr Wopula). The specimen was authenticated by Dr Kathy in the Department of 
Botany Walter Sisulu University, and voucher specimen number one was preserved in the 
Kei Herbarium. Roots were obtained as illustrated by the figure above. A week later they 
were chopped into smaller pieces and dried at 40°c overnight. (Kambezi, 2011, Oral 
Communication). After drying the roots were ground using a grinding apparatus. 
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3.1.1.3 The Extract Production 
The extraction procedure was carried out according to the procedure recommended by Draper 
(Draper, 1976). In this procedure 100g of milled root was dissolved in 1000ml of acetone. 
The mixture was left on the shaker for three days to allow for maximum extraction of 
compounds at 25°c at 180r/min. The mixture was then sieved and filtered. The residue was 
washed twice with acetone to complete the extraction. The filtrate was then dried on a rota 
vapour machine at medium speed temperature ranging 40- 56°c to obtain the crystallized 
black crude extract. The crude extract was then stored in capped sterile plastic bottle at room 
temperature.     
 
                                             Figure 3.2 Dry Crude Extract 
 
3.1.2 Albino Mice 
3.1.2.1 Animal Selection and Quantity 
A total of 40 healthy adult albino mice were selected for the study. The animals used in the 
experiment were obtained from Bloemfontein through Shalom Laboratories Suppliers.  The 
animals were 6-7 weeks old with the average weight of 25-30g at the time of treatment. 
Animals were grouped into four groups of five per sex.  In order to minimize biological 
variation, individual body weight of all animals in a group was recorded and the range of all 
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weights fell between +/- 20% of the mean body weight range. Female mice were nulliparous 
and non-pregnant. 
3.1.2.2 Room Sanitation and Animal Welfare  
Before the animals could occupy the experimental room, the room was decontaminated. The 
floor of the experimental room was swept daily and all worktops and floors were mopped 
daily with a disinfectant (5% Bleach). All animals were handled similarly and with due 
regard for their welfare.  
3.1.2.3 Acclimatization Period 
All animals were allowed to acclimatize for at least five days before treatment. 
3.1.2.4 Grouping 
The animals were randomly allocated to different groups. The animals were equally 
distributed to four groups; vehicle control G1 (0 mg/kg body weight), low dose G2 (125 
mg/kg body weight), mid dose G3 (250 mg/kg body weight) and high dose G4 (500 mg/kg 
body weight). Each group comprised of 5 males and 5 females. 
3.1.2.5 Animal Identification 
Animals were given temporary numbers as their identity during randomization. After 
allocation of groups, permanent numbers were issued to all animals and each animal was 
given a tag bearing its number on the cage, with a unique colour for the specific group. (white 
tag for controls, pink tag for low dose, yellow tag for mid dose and purple colour for high 
dose).  
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3.1.2.6 Animal Husbandry 
Animals were housed individually in polypropylene mice cages (410 mm x 282 mm x 180 
mm) using soar dust as bedding material. Each cage was fitted with a stainless steel top grill 
having provision to keep pellet feed and a polypropylene water bottle with stainless steel 
nozzle. Cages were placed on 5 tier racks. The bedding in cages was changed once a week 
and water bottles once a week. 
The experimental animals were fed ad libitum mice pellet feed (Nutrilab brand, shalom 
laboratories Durban) with unlimited supply of clean and boiled drinking water in 
polypropylene bottles (capacity 300mL). The quality of feed was checked and the batch was 
accompanied with a certificate of analysis of nutrient content. The quality of water was 
monitored for any known chemical and microbial contaminants. There were no contaminants 
in feed and water at the level, which can affect the results of the experiment. Animals were 
maintained in a controlled environment with a temperature of 21 - 25°C; light/dark cycle of 
~12 hours. 
3.1.3 Study Design 
Summary of group designations is given below for the repeated dose sub acute toxicity study 
Table 3.1 Summary of Animal Grouping 
Group N° Treatment 
Dose 
(mg/kg 
b.wt.) 
N° of animals Animal ID. N° 
Male Female Male Female 
G1 Control 0 5 5 1 – 5 6-10 
G2 Low Dose 125 5 5 11-15 16-20 
G3 Mid Dose 250 5 5 21-25 26-30 
G4 High Dose 500 5 5 31-35 36-40 
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Four groups of Swiss albino mice comprising 5 males and 5 females per group were 
administered the test formulation at the dose levels of 0, 125, 250 and 500 mg/kg body 
weight through oral route for 28 consecutive days. The control groups received Dimethyl 
Sulfur Oxide (DMSO) and Carboxyl Methyl Cellulose (CMC) in the ratio of 20%; 80% of 
0.25% respectively. 
3.1.3.1 Dose Preparation and Administration 
The crude extract was repeatedly administered orally once daily using graduated syringe and 
stainless steel intubation cannula for 28 days of study. Required quantity of the test substance 
was weighed using a calibrated analytical balance and was suspended in DMSO and CMC in 
the stipulated ratios. Due to the thickness of the suspension, dose volume was maintained as 
20 ml/kg body weight for all animals. The test suspension was prepared every day and was 
administered immediately. Individual dosage volume was calculated based on the initial body 
weight. The crude extract of Euclea natalensis was suspended in DMSO/CMC to attain the 
required concentrations i.e., 6.25, 12.5, 25mg/ml for the low, mid and high dose groups 
respectively. Fresh suspension of Euclea natalensis was prepared every morning prior to 
dosing. The dose volume administered to each mouse was calculated on the basis of a 
constant factor of 20 ml/kg body weight throughout the study.  
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3.1.4 Repeated Dose Toxicity Evaluation 
3.1.4.1 Mortality 
All the animals were checked at least twice a day for mortality and signs of morbidity, in the 
morning after oral dosing and in the afternoon. 
3.1.4.2 Clinical Signs/Observations 
Animals were observed for all visible signs of reaction to the treatment such as skin and fur 
changes, eye and mucous membrane changes, respiratory, circulatory, and autonomic and 
central nervous system, somatomotor activity, behaviour pattern and general changes twice 
daily 
3.1.4.3 Body Weight 
The body weight of individual animals was recorded prior to first dosing, at 7
th
 day, 14th
th
 
21
st
 day and at necropsy (28
th 
day).  
3.1.4.4 Feed Consumption 
Feed consumption was recorded cage wise for all animals at every 7
th
 day of commencement 
of exposure and at 28
th 
day. The average daily feed consumption of individual animal was 
calculated as follows: 
Feed Consumption (g/mouse/day) = Feed input – Feed left over 
                                                   ------------------------------------------------------------- 
                                                        Number of mice in the cage X No. of days 
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 3.1.4.5 Gross Examination  
All the animals were euthanized with a dose of ether and subjected to a complete necropsy. 
Gross pathological examination included examination of the external surface of the body, all 
orifices, thoracic and abdominal cavities and their contents. The appearance of macroscopic 
abnormalities was recorded, if any. The thoracic, abdominal and cranial cavities were then 
cut open and thorough examinations of organs were carried out to detect changes or 
abnormalities, if any. The necropsy procedure is outlined in figure 3.3 below.  
                 
Figure 3.3 Necropsy procedure  
Source: (Adapted from Orchid Pharmaceutical SOPs, 2013) 
 
3.1.4.6 Organ Weight 
Absolute wet weights of adrenals, brain, uterus, ovaries, testes, epididymides, heart, kidneys, 
liver, spleen and thymus were recorded immediately after dissection for all animals. Relative 
weights of these organs were calculated later. Organs were harvested and cleared from the 
40 ANIMALS FASTED 
(over night) 
INDIVIDUAL ANIMAL 
BODY WEIGHT TAKEN 
EUTHANIZE ANIMAL 
 
EXTERNAL 
MACROSCOPIC 
EXAMINATION  
(including all orifices )  
ORBITAL SINUS 
PUNCTURE 
(bleed animal) 
CUT OPEN ANIMAL 
(upon death and wet 
with 70% alcohol 
externally) 
INTERNAL 
MACROSCOPIC 
EXAMINATION  
(all cavities)  
 
DISSECT  TO HARVEST 
ORGANS  
(organ weight taken) 
ORGAN FIXATION 
(10% buffered 
formalin)  
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adhering fat and blotted free from blood (Raghul, 2013). The absolute weight was recorded to 
the nearest milligram using a calibrated balance. The relative organ weigh was determined 
using this formular: 
          
                                               Absolute organ weight (g) 
Relative organ weight (%) = ------------------------------------- x 100 
             Body weight (g) 
 
 
The following organs of all the animals were collected at necropsy and preserved in 10% 
buffered neutral formalin for processing and microscopic examination; stomach, duodenum, 
jejunum, ileum, caecum, colon, rectum, liver, brain (representative regions including 
forebrain, cerebrum, cerebellum), adrenals, lungs, heart, aorta, spleen, thymus, kidneys, 
testes, epididymides, ovaries, cervix and the uterus.  
3.1.4.7 Histopathology 
All the preserved organs from control and high dose groups (G1 and G4) of the animals were 
processed following suitable techniques of washing by tap water, dehydration in ascending 
grades of ethyl alcohol, clearing in xylene, embedding and blocking in paraffin wax. Paraffin 
sections (5μm) were cut, stained with hematoxylin and eosin, and mounted on slides (Stevens 
and Bancroft, 1996).   
Histopathology screening was carried out on all preserved organs and tissues of all the 
animals in control and high dose groups. Complete histopathology was carried out on all 
gross lesions, the preserved organs and tissues of all the animals in the control and high dose 
group. If treatment related effects were noted in any of the tissues, the tissues of animals from 
the next lower dose level were be examined. Successive examination of the next lower dose 
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level continued until no effects were noted. In addition, all tissues from animals, which died 
during the course of the study, were examined microscopically to assess any potential toxic 
effects. The preparatory steps for histopathology evaluation are outlined in sections 3.1.4.7.1 
– 3.1.4.7.6. 
3.1.4.7.1 Tissue Fixation  
Tissue fixation preserves and saves (stabilize proteins) the tissues from decaying (autolysis) 
and maintains the texture to accommodate and to set a good platform for other procedures to 
follow. Good tissue sections and staining start with good properly fixed tissues. The 
minimum time for tissue fixation is about 1-4 hours, but the specimens may be kept for 
longer times (Survana et al., 2013).  
In this study a Formalin solution of 10% buffered neutral buffered formaldehyde was used. 
The chemical composition of the fixative was: 
 Formalin (37-40%)     100ml 
 Distilled water             900ml 
 NaH2PO4                                    4g 
Na2HPO4                        6.5g 
All solid chemicals were adequately dissolved and a pH of 6.8 was maintained and monitored 
with a pH meter. 
 
3.1.4.7.2 Tissue Processing 
Tissue processing is the second step in the processing of tissues for histology analysis. In this 
procedure, tissues go through a series of steps to give (them) some structural format that 
prepares the tissues for subsequent sectioning and staining (both for diagnostic and research) 
(David Carson, nd.) The process primarily functions to remove water in the tissues in a very 
slow manner through ascending grades of ethanol (ethanol as is the most commonly used 
dehydrant). It is done so slowly to avoid rapid harsh removal of water which could result in 
tissue shrinkages. On completion of the process, the alcohol is removed (clearing). Xylene is 
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the chemical used to clear tissues of the dehydrating solvent. It is the transitional step 
between dehydration and infiltration with the embedding medium. Infiltration 
(interpenetration) process of tissues is the actual filling of tissue cavities and cells created by 
water removed with supporting substance, which in this step will be filled with the medium to 
be used for embedding (molten wax) (Suvarna et al., 2013).    
The table below illustrates the stages and chemicals useful in the automatic processing of 
tissues and appropriate time frames.  
Table 3.2 Chemical Constituents of the Automated Tissue Processor Leica, TP1020 Used in 
this Study 
Process Reagents Action  Time frames 
Fixation  
(2 stations) 
10% neutral BF Stabilize proteins 1hr 
10% neutral BF 1hr 
Dehydration: ascending 
grades of alcohol 
 
(5 stations) 
70% ethanol  
 
Removal of water 
1:30hr 
80% ethanol 1:30hr 
95% ethanol 1:30hr 
100% ethanol 1:30hr 
100% ethanol 1:30hr 
Clearing 
(3 stations) 
Xylene  
Removal of alcohol 
1:30hr 
Xylene 1:30hr 
Xylene 1:30hr 
Infiltration 
(2 stations) 
Molten wax  
Interpenetration 
2hr 
Molten wax 2hr 
 
Source: (Adapted from (Leica, TP1020 operational manual 2009; Histology Lab, Walter 
Sisulu University). 
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3.1.4.7.3 Tissue Embedding 
Tissue embedding is one of the techniques used in histology laboratory that primarily 
prepares wax infiltrated tissues for section cutting (microtomy). It is the immediate step after 
tissue processing. The processed and infiltrated tissues are at this stage supported in a 
medium which allows the tissues to be cut without crushing and damaging. This is the 
outlined embedding procedure: 
 Place the paraffin infiltrated tissue cassettes in the tissue embedding centre’s tank, 
that has been heated to the temperature of about 60-65°C 
 Warm the metal block containers in the warm storage area of the machine 
 Place the empty metal container over the hot plate of the embedder 
 Dispense a little hot paraffin wax from the tank into the metal container 
 Take the paraffin infiltrated tissue from the tissue cassette using a forceps  and place 
it in the metal container 
 Using heated forceps orientate the tissue specimen as desired and pore small volume 
of  hot wax 
 Put back the labelled empty plastic tissue cassette on top of the wax pore more hot 
paraffin wax to cover the plastic cassette 
 Now shift the metal container from the hot plate to the cold plate (-15°C) of the 
tissue embedder 
 When the wax is hard, take out the paraffin block from the metal case. The paraffin 
block is now ready for section cutting (Suvarna et al., 2013).  
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3.1.4.7.4 Tissue/Section Cutting (Microtomy) 
 
Figure 3.4 Rotary Microtome HM 355 S. Histology Laboratory, Walter Sisulu University. 
 
After the long processes of tissue dehydration, infiltration, clearing and embedding all tissues 
are subjected to cutting using either a bench microtome or a rotary microtome. Section 
cutting involves a number of steps before getting the sections on the glass slide ready for 
staining. A rotary microtome (figure 3.4) is a heavy duty microtome especially for paraffin 
and hard sectioning techniques in biology, medicine, industry and research. The machine cuts 
sections in the range of 0.5μm -100μm. This piece of equipment will normally have both 
trimming (30μm) and cutting (5μm) function modes. Tissue trimming permits fine 
adjustments up to first cuts and this result in larger section thickness during trimming. When 
trimming is complete the fine mode cutting is selected to produce ribbons of sections that are 
floated in a 60°C water bath to align sections properly on the slide (Micron International 
GmbH, 2007). 
74 
 
Below is a point-form summary of the histopathology microtome procedure used in the this 
study (Procedure for Sectioning (HM 355 S Instruments Instructional Manual no 387841, 
WSU): 
 Make sure that the clamping screws and clamping levers on the blade holder and 
specimen holder are well tightened.  
 Make sure that the specimen and specimen holder are well oriented 
 Always use sharp blades to produce neat thin sections (avoid compressions) 
 Sectioning should always be carried out in ambient temperatures (excluding frozen 
sections) 
 Cutting speed must be programmed in accordance with texture of the material 
 Trimming thickness must be set at 30μm and cutting thickness at 5μm to produce 
good sections 
 Upon production of tissue ribbons, the sections are flooded in a water bath (58-60°C) 
to flatten and iron out any folds 
 Good, neat sections are picked from the ribbon in the water bath using a labeled slide 
for the exact tissue just cut  
 Sections are left to dry before staining 
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3.1.4.7.5 Tissue Staining and the Staining Mechanism 
Tissues that are examined microscopically immediately after sectioning without staining 
appear very dull and uninteresting. They lack contrast of all fixed tissue materials and all 
have a similar refractive index and colour. In order to bring out the microscopic structure of 
these tissues, it is essential to stain the cells and connective tissue to expose the different parts 
in contrasting colours. Staining is therefore not simply colouring the sections but relies on 
using differences in chemistry of the tissues to show the different components in different 
colours. This is achieved by using dyes that can bind to tissues selectively. The most common 
stain in use in histology staining is haematoxylin and eosin (H & E) stain (Suvarna et al., 
2013). 
The binding of dyes to tissues are similar to other chemical bonding and the mechanisms is 
the same in that they all rely on the same binding forces occurring in all other organic 
compounds? Eosin is a negatively charged stain (anionic dye) and will stain positively 
charged (cations) tissue ions (cytosol of the cell and connective tissue).  Haematoxylin is a 
versatile stain and is used in combination with mordants (alum salts) that alters the specificity 
and colour of the stain. It will stain the acidic environment of the cell (nucleus) dark blue or 
purple  (Suvarna et al., 2013). 
After drying, the slides are ready to stain, but paraffin sections are still impregnated with 
paraffin wax which forms a water proofing coat that can prevent the stain to access proteins 
within the tissues. Therefore the wax must melt in the oven (60°C) and then be removed 
before sections could be rehydrated (Orchid histopathology staining protocol, 2013). Below 
is a point-form summary of the histopathology staining procedure used in this study: 
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 Xylene                                           5 minutes (2-3 changes) 
 Absolute alcohol                             5 minutes     
 95% alcohol                                    5 minutes 
 70% alcohol                                    5 minutes 
 Distilled water                                  3 minutes 
 Harris Haematoxylin                       5 minutes 
 Differentiate in running tap water     2 minutes 
 Eosin-Phloxin                                    1minute 
 80% alcohol                                      Dips 
 95% alcohol                                      Dips 
 Absolute alcohol                               Dips ( 2 changes) 
 Xylene                                               5 minutes  (3 changes) 
 Mount in DPX 
3.1.4.7.6 Section Mounting 
Staining is subsequently followed by mounting procedure. Normally the mounting medium 
must have a high RI. Tissues mostly have an RI of 1.5-1.55 and the mounting medium of the 
same index will offer maximum clarity. The common mountant in histology procedures is 
DPX. It’s a synthetic polystyrene resin that has been dissolved in xylene with some 
plasticizer added to it. It is a clear waterless solution that hardens in about 24 hours. (D= 
Distrene 80, that is a commercial polystyrene; P=Plasticizer, dibutyl phthalate and 
X=Xylene) (Suvarna et al., 2013). Mounting is done under a cover slip and it gives best and 
clear view of the specimen. The cover slip should have the thickness of about 0.17mm to give 
best results.  
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 Mounting is done with slides immersed in xylene. 
 General safety rules must always be adhered to (GLP) 
 Align cover slip on a flat surface 
 Dispense a small drop of DPX onto the cover slip 
  Remove the slide from the xylene bath and right face the slide over the slip 
 Press very gently tapping at the same time to release any bubbles 
 Leave flat on the surface to dry 
 Sort and file in slide boxes ready for microscopy (Orchid histopathology Research 
Laboratory mounting procedure, 2012). 
3.1.5 Statistical Analysis of Results 
Raw data were processed statistically. The means and standard deviations were calculated 
with significance between the control and treated groups and all data were summarized in 
tabular form. All the parameters characterized by continuous data such as body weight, feed 
consumption, organ weight, relative organ weight, haematology, clinical chemistry were 
subjected to Bartlett’s test to meet the homogeneity of variance.  All homogenous data were 
analyzed using ANOVA and data showing significance in their variances were subjected to 
Dunnett’s t-test. 
Significance was calculated at 1% as well as 5% level, and indicated in the summary table as 
follows: 
↑ -Significantly higher than control (p˃ 0.05), ↑↑ -Significantly higher than control (p˃ 0.01), 
↓- Significantly lower than control (p<0.05), ↓↓- significantly lower than control (p< 0.01) 
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3.2 RESULTS 
3.2.1 Mortalities  
Seven animals died in all. In the control group (G1), female animal #6 died on the 11
th
 day of 
treatment. On the 10
th
 day the animal looked a bit weak showing sluggish movement on 
examination and the faecal material was soft and mucoid. Animal #14 (male) and Animal #19 
(female) both belonging to low dose group (G2) died on 5
th
 and 8
th 
days of treatment 
respectively. There were no signs of illness during earlier observations.  Female animal #27 
in the mid dose group (G3) died on the 10
th
 day of treatment after a short period of 
deteriorating health which was observed by clinical examination. In addition, animal #28, a 
female in mid dose group (G3) also died on the 10
th
 day. For the two previous days the 
animal’s stomach was empty, due to poor feeding. In high dose (G4) two male animals (#33 
and #35) and one female animal (#37) also died in the third week of treatment. Table 3.2 
summarises the mortalities found in this study.    
Table 3.2 Survival of Mice and Clinical Observations for 28 days Repeated Dose Toxicity Study 
 
Group Number Group 1 / 
Control 
Group 2 Group 3 Group 4 
Dose  0 mg/kg 125 mg/kg 250 mg/kg 500 mg/kg 
Clinical Observations Normal Normal  Normal Normal 
Animals Initially in 
Study 
Male (M) 5 5 5 5 
Female (F) 5 5 5 5 
Natural Deaths Number 1 (F) 1 (M) 2 (F) 2 (M) & 1 (F) 
Day of 
Experiment 
11 8 10 7 & 15 (M) 
17 (F) 
Total Deaths per 
Group 
7 1 1 2 3 
Animals Surviving 
to Study 
Termination 
Male 5 4  5 3 
Female 4  5 3 4 
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3.2.2 Body Weight Changes 
No significant deviation of weights from the mean of all the treated groups was observed as compared 
to the control group at week 1, week 2, week 3,week 4 and at termination of the study. Table 3.3 
summarises the changes in body for the duration of the study. 
Table 3.3 Summary of Body Weight (g)/week 
Gender: Male 
Week N° 
G1 
(0 mg/kg /Bwt.) 
G2  
(125mg/kg Bwt.) 
G3  
(250mg/kg/Bwt)) 
G4  
(500mg/kg/Bwt.) 
Mean 
Mean Mean 
Mean 
        Pre-   exp 25.240±2.059 24.940±2.564 24.940±2.224 24.960±2.526 
Week 1 
26.020±2.640 27.460±1.399 25.280±2.247 25.125±0.818 
Week 2 25.240±3.009 26.625±1.952 24.880±3.093 25.167±1.124 
Week 3 27.340±2.390 27.375±1.850 26.880±2.860 25.667±1.002 
Week 4 28.180±2.607 28.675±1.841 27.360±3.044 24.667±2.281 
Terminal point 25.960±2.626 26.350±0.785 25.240±2.535 22.533±1.172 
 
Gender: Female 
Week N° 
G1 
(0 mg/kg /Bwt.) 
G2  
(125mg/kg Bwt.) 
G3  
(250mg/kg/Bwt)) 
G4  
(500mg/kg/Bwt.) 
Mean 
Mean Mean 
Mean 
        Pre-   exp 23.440±1.609 23.700±2.269 23.420±2.044 23.780±2.264 
Week 1 
24.420±2.262 22.725±3.694 23.340±2.548 23.720±2.401 
Week 2 23.025±1.477 22.625±3.357 22.933±2.303 21.960±4.230 
Week 3 23.875±1.021 22.175±3.106 25.033±2.871 23.350±1.453 
Week 4 24.250±0.933 24.025±4.088 25.333±2.676 24.475±1.808 
Terminal B.Wt 22.600±0.983 22.525±3.87 23.633±2.303 23.300±1.643 
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3.2.3 Feed Consumption 
No significant changes were observed in the feed consumption of the treated groups of 
animals as compared to the control group in four weeks of treatment.  
 
3.2.4 Absolute Organ Weight  
No significant change in females was seen in all organ weights when compared to the control 
group, except for the weight of the adrenal gland in all doses (125, 250, 500mg/kg.b.wt.) 
which was significantly higher than the control (p≥0.05). Absolute weight of the heart in 
female animals was significantly high in the low dose group (p≥0.01).  No significant 
changes were observed in weights in all organs (125, 250, 500 mg/kg.b/wt). Table 3.4 is a 
summary of the absolute mice organ weights at the time of necropsy. 
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Table 3.4 Summary of Absolute Organ Weight (g) 
Gender: Male 
Parameter 
Group N° & Dose (mg/kg b.wt.) 
G1 (0) G2 (125) G3 (250) G4 (500) 
Mean Mean Mean Mean 
Terminal Body 
Weight 
25.240±2.059            24.940±2.564 24.940±2.224 24.960±2.526 
Adrenals 0.011±0.005 0.036±0.024 0.027±0.021 0.042±0.025 
Thymus 0.072±0.044 0.064±0.035 0.068±0.043 0.057±0.036 
Epididymis 
0.027±0.057 0.027±0.029 0.119±0.030 0.093±0.017 
Spleen 0.155±0.055 0.240±0.130 0.148±0.036 0.149±0.018 
Heart 0.135±0.016 0.156±0.033 0.171±0.054 0.129±0.010 
Brain 0.385±0.016 0.454±0.047 0.437±0.086 0.441±0.042 
Kidneys 0.436±0.055 0.460±0.027 0.522±0.238 0.359±0.033 
Testes 0.265±0.079 0.227±0.042 0.331±0.129 0.145±0.077 
Liver 1.532±0.170 1.670±0.085 1.541±0.233 1.346±0.136 
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Table 3.4 Cont. Summary of Absolute Organ Weight (g) 
Gender: Female 
Parameter 
Group N° & Dose (mg/kg b.wt.) 
G1 (0) G2 (125) G3 (250) G4 (500) 
Mean Mean Mean Mean 
Terminal Body 
Weight 
22.600±0.983 22.525±3.87 23.633±2.303 23.300±1.643 
Adrenals 0.006±0.002 0.013±0.006 0.072±0.062 0.013±0.004 
Thymus 0.084±0.054 0.065±0.004 0.062±0.023 0.069±0.011 
Uterus 
0.198± 0.102±0.081 0.954±1.146 0.133±0.034 
Spleen 0.191±0.112 0.146±0.052 0.102±0.041 0.160±0.028 
Heart 0.117±0.006 0.131±0.006 0.153±0.040 0.118±0.017 
Brain 0.394±0.082 0.449±0.057 0.428±0.049 0.458±0.059 
Kidneys 0.297±0.050 0.393±0.034 0.331±0.062 0.327±0.034 
Ovaries 0.115±0.131 0.024±0.014 0.084±0.026 0.049±0.036 
Liver 1.383±0.137 1.409±0.186 1.387±0.078 1.358±0.223 
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3.2.5 Relative Organ Weight  
No treatment related changes were observed in relative organ weights of animals treated with 
Euclea natalensis, except for changes seen in the testes in males of a relative weight that is 
significantly low in the high dose group (500mg/kg.b.wt) (p≤0.01).  Table 3.5 summarises the 
relative organ weights for the animals treated with Euclea natalensis. 
Table 3.5 Summary of Relative Organ Weight (g) 
Gender: Male  
Parameter 
Group N° & Dose (mg/kg b.wt.) 
G1 (0) G2 (125) G3 (250) G4 (500) 
Mean Mean Mean Mean 
Adrenals 0.034±0.027 0.081±0.098 0.087±0.096 0.076±0.121 
Thymus 0.284±0.204 0.145±0.161 0.260±0.143 0.155±0.187 
Epididymis 
0.107±0.240 0.062±0.099 0.301±0.290 0.246±0.229 
Spleen 0.587±0.178 0.730±0.596 0.582±0.097 0.395±0.363 
Heart 0.524±0.074 0.472±0.279 0.669±0.151 0.344±0.319 
Brain 1.500±0.231 1.375±0.779 1.727±0.271 0.885±0.987 
Kidneys 1.680±0.134 1.397±0.783 2.061±0.906 0.957±0.878 
Testes 1.022±0.274 0.691±0.412 1.301±0.460 0.226±0.327 
Liver 5.900±0.224 5.075±2.863 6.095±0.641 3.591±3.314 
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Table 3.5 Cont. Summary of Relative Organ Weight (g) 
Gender: Female  
Parameter 
Group N° & Dose (mg/kg b.wt.) 
G1 (0) G2 (125) G3 (250) G4 (500) 
Mean Mean Mean Mean 
Adrenals 0.019±0.013 0.045±0.033 0.130±0.235 0.044±0.029 
Thymus 0.290±0.248 0.239±0.145 0.102±0.143 0.239±0.144 
Uterus 
0.165±0.369 0.203±0.363 1.479±2.978 0.460±0.294 
Spleen 0.672±0.542 0.545±0.417 0.283±0.265 0.548±0.320 
Heart 0.414±0.233 0.476±0.280 0.396±0.398 0.409±0.246 
Brain 1.395±0.838 1.625±0.971 1.094±1.022 1.579±0.925 
Kidneys 1.048±0.609 1.414±0.812 0.836±0.769 1.123±0.636 
Ovaries 0.293±0.465 0.046±0.076 0.134±0.188 0.164±0.154 
Liver 4.890±2.756 5.038±2.845 3.536±3.244 4.641±2.646 
 
3.2.6 Gross Pathological Findings 
3.2.6.1 External Findings 
Gross pathological observations did not reveal any abnormality externally in any of the 
animals belonging to both the control and treated group animals. Figure 3.3 depicts the 
necropsy process undertaken during the 28 day repeated oral toxicity study. 
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Figure 3.5 Digital Images of the Necropsy on Albino mice 
3.2.6.2 Internal Findings 
No treatment related gross lesions were observed in any of the animals belonging to either 
sex treated with Euclea natalensis at the dose levels of 125, 250, 500mg/kg body weight as 
compared to the control. Below (Table 3.6) is a summary of the gross pathological 
investigation done at necropsy after 28 days exposure to Euclea natalensis. 
Table 3.6 Summary of Gross Pathological Findings 
 
Group Number Group 1 / 
Control 
Group 2 Group 3 Group 4 
Dose  0 mg/kg 125 mg/kg 250 mg/kg 500 mg/kg 
Animals Initially in 
Study 
Male  5 5 5 5 
Female  5 5 5 5 
Gross Pathology 
(External) 
Male 0 0 0 0 
Female 0 0 0 0 
Gross Pathology 
(Internal) 
Male 0 0 0 0 
Female 0 0 0 0 
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3.2.7 Histopathological Observations 
The histopathology is outlined in table 3.7 below. 
Table 3.7 Summary of Histopathological Findings 
 
Group Animal N° Sex Histopathological Observation 
Control  
(0 mg/kg) 
 
SA45/9/3 Female Brain: Medial  mineralization 
SA/45/5/1 Male Liver: Granulopoetic hyperplasia  
SA45/5/1 Male Liver: Hepatocellular basophilic cell focus 
SA45/5/1 Male Lung: Perivascular and Peribronchial lymphoid aggregates 
Treated  
(500 mg/kg) 
SA45/39/1 Female Liver: Hepatocellular basophilic cell focus 
SA45/39/1 Female Lung: Perivascular and Peribronchial lymphoid aggregates 
SA45/31/1 Female Lung: Lymphoid aggregates 
 
Medial mineralization of the brain was found in a female control mouse (Figure 3.6[A]). In 
addition granulopoetic hyperplasia of the liver from a male mouse in the control group was 
noted (Figure 3.6[B]). Hepatocellular basophilic cell foci were recorded in the liver of a male 
control mouse (Figure 3.6[C]) and a female mouse (Figure 3.6[D]) treated with Euclea 
natalensis (500mg/kg). Perivascular and peribronchial lymphoid aggregates of the lung of a 
male control mouse (Figure 3.6[E]) and female mouse (Figure3.6 [F]) treated with Euclea 
natalensis (500mg/kg) was also noted.  
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Figure 3.6 Photomicrographs of Histopathology Found in the 28 day Repeat Dose Oral 
Toxicity Study.   [A] Medial mineralization of the brain found in a female control mouse 
(H&E, x10 magnification, scale bar = 120µm). [B] Granulopoetic hyperplasia of the liver 
from a male mouse in the control group (H&E, x10 magnification, scale bar = 120µm) [C] 
and [D] Hepatocellular basophilic cell focus in the liver of a male control mouse and female 
mouse [D] treated with Euclea natalensis (500mg/kg) (H&E, x10 magnification, scale bar = 
120µm). [E] and [F] Perivascular and peribronchial lymphoid aggregates of the lung of a 
male control mouse and female mouse [F] treated with Euclea natalensis (500mg/kg) (H&E, 
x10 magnification, scale bar = 120µm). 
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CHAPTER 4 
 
DISCUSSION, CONCLUSION AND RECOMMENDATIONS 
 
4.1 INTRODUCTION 
The primary objective of the this study was to conduct a 7 Day  Repeat Oral Toxicty Study 
(ROTS) on Swiss albino mice as a pilot study to prepare for the 28 Day ROTS on the same 
species of animals, in an effort to achieve the main aim of the study which remains a 
histopathological investigation. In order to meet this objective, methodologies were put in 
place to assess and evaluate the possible toxicity of compounds of interest that have been 
extracted from the root material of the medicinal plant (Euclea natalensis). These compounds 
have been identified and tested against the drug resistant and drug sensitive strains of the 
Mycobacterium tuberculosis. The parameters of interest in the two studies were; the body 
weight, the organ weight, the relative organ weight, feed consumption, clinical observations, 
both external and internal gross examinations including the cavities and orifices of all 
animals and lastly the histopathological screening of processed tissues (Lall and Meyer, 
1999).  
 
The overall welfare of all animals, the quantity, the in house allocation and housekeeping, the 
dose levels, and gender distribution were addressed in a similar manner in the two studies. 
The only difference is that the pilot was conducted in India at Orchid Chemicals and 
Pharmaceuticals Ltd, in the biology Laboratories, Toxicology Department. The main study 
was conducted at Walter Sisulu University, Anatomy, Histology and Embryology 
Department.  Effort was made in order to adhere to and maintain good laboratory standards 
and protocols mandated by the toxicology studies guidelines (OECD 407, 2008).  
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4.2 REPEATED DOSE (7 DAY) ORAL TOXICITY STUDY OF EUCLEA 
NATALENSIS IN SWISS ALBINO MICE 
In this dose range finding study forty (twenty per sex) Swiss albino mice were grouped and 
treated with Euclea natalensis crude extract dissolved in 20% DMSO, which was then 
suspended in 80% of 0.25% CMC. The dosages were administered as stipulated in the 
methodology in chapters two and three. Food consumption as well as the clinical 
observations was recorded during the period of dosing. The treated animals did not show any 
change when compared to the control animals. Both externally and internally, gross 
pathological observations in treated animals did not show any abnormality when compared to 
control animals. Animal absolute body weight in treated animals showed no deviation from 
untreated animals. This is expectedly so since the animals consumed food quite well, and 
were healthy which is reflected by weight records. Although absolute weight was maintained, 
treated female animals (G3 & G4) in mid dose (250mg/kg b.wt) and high dose (500mg/kg 
b.wt) showed a decrease in weight of the heart when compared to control animals. This was 
not a significant change statistically but it called for biological concern. As a result the 
relative weight of the heart was decreased. The decreased weight in these animals could be 
attributed to the cardiac mass loss due to degenerative changes noticed in high dose animal, 
although controls did not lose any weight while having a similar histopathological picture as 
that seen in high dose group. 
 
The absolute weight of the testes in treated male animals, G2 (125mg/kg b.wt) was 
statistically elevated at 1% significance level when compared with control animals (p ≥0.01). 
Slegtenhorst and colleagues (1998) found that normal developmental increases in testes size 
in growing mice was the result of increased Sertoli cell proliferation. It is plausible that the 
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testicular weight gain can be attributed to increased Sertoli cell stimulation in the G2 animals 
but remains dubious given the absence of similar changes in the higher dosage groups.  
Haematology results of all treated animals in both the sexes did not show any abnormality 
when compared to their untreated counterparts. In clinical pathology, G3 animals (250mg/kg 
b.wt) showed a significant decline in total protein at 5% level (p≤0.05). Protein levels in 
females did not decrease when compared with control animal. 
 
Total cholesterol level in all treated female groups (G2; 125mg/kg b.wt, G3; 250mg/kg b.wt, 
G4; 500mg/kg b.wt) was decreased when compared with control animals. This is not a 
statistically significant change, but since all treated groups show the same declining picture, 
further investigation might be warranted.  
 
Triglycerides level was significantly low at 5% in female G2 (250mg/kg b.wt) as compared 
to controls group (p ≤0.05). It cannot be concluded that mice in this group suffered 
malabsorption of fats, as the fecal material did not show any signs of undigested fats during 
the period of study. The outstanding fact could be that mice have a very high metabolic rate 
(Speakerman et al., 2004). 
 
Phosphorus level was also significantly higher at 5% level in G3 (250mg/kg b.wt). (p≥0.05). 
High levels are correlated with atherosclerosis in both animals and humans especially in 
kidney diseases (Foley et al., 2008). This is not the case with mice in this group since renal 
histopathology was absent. A treatment related phenomenon isn’t likely given the absence of 
this clinical finding in the remaining treatment groups.  
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Histopathological observations revealed degenerative changes in two control animals 
(SA45/1, SA45/6) and one high dose (500mg/kg b.wt) male animal (SA45/39) in the right 
ventricular wall of the heart. The degenerative lesions in mice carry a spectrum of 
spontaneous and progressive age-related changes in the heart. These various changes have 
been reported with a variety of species of laboratory mice (Maronpot et al., 1999). The 
morphologic changes include myocyte degeneration, as seen in the three animals. As these 
degenerative changes develop, the interstitial tissue in affected areas become fibrotic. There 
may be myocyte atrophy and inflammatory cell infiltration. In these animals the affected 
areas are infiltrated with fibrocytes, implying that there could be laying down of collagen. 
But since the stain used cannot demonstrate collagen, at this stage it cannot be concluded that 
fibrosis did take place. However, this degeneration of muscle tissue could lead to 
cardiomyopathy. Since the two control animals show similar changes seen in treated animals, 
it cannot be concluded that these lesions observed in treated animal are dose dependent. 
 
The X-zone of the adrenal gland is a band of basophilic cells seen just around the medulla of 
the adrenal gland. In female animals, this zone grows until animals are nine weeks old. It 
starts regressing gradually in virgin animals and rapidly upon first pregnancy (Maronpot et 
al., 1999). Initial evidence of regression in females is the lipid vacuolization as seen in the 
three animals, and this should not be taken as a pathological process. The adrenal gland in 
one control animal (SA45/7) and two high dose animals (SA45/37 and SA45/40) exhibited 
the involution of the X-zone with extensive lipid vacuolization and is consequently not 
considered a dose dependent change. 
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The lung tissue of treated male animals SA45/31 and SA45/34 (500mg/kg b.wt) showed 
massive infiltration of mononuclear cells within the lung parenchyma and peri-bronchiolar 
when compared with controls. The alveolar, alveolar sacs, alveolar ducts and the alveolar 
septum have completely lost the normal morphology. There is dilatation of the alveoli. 
Inflammation suggests lung infection, and the dilated alveoli are trying to put in place a 
compensatory mechanism so that the lung is able to continue with normal function. Despite 
the severity of the lung pathology the contextual significance implies a limited extent devoid 
of dose dependence.  
 
In conclusion, all lesions observed in the heart and adrenal glands were spontaneous, age-
related to laboratory animals and are not dose dependent.  Therefore, the 
NOAL/NOAEL/MTD of Euclea natalensis in Swiss albino mice, at termination of the 7 day 
study, was 500mg/kg b.wt . 
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4.3 REPEATED DOSE (28 DAY) ORAL TOXICITY STUDY OF EUCLEA 
NATALENSIS IN SWISS ALBINO MICE 
In this 28 day sub-acute repeated oral toxicity study, forty healthy animals were used, twenty 
males and twenty females. Seven animals died in the 28-Days of treatment in four groups. All 
these deaths are not dose dependent as one control animal also died. The autopsy was 
performed on all animals that died and no abnormalities were found. The internal cavities, 
orifices and gross external and internal examination revealed no abnormality of organs. The 
evidence of poor feed consumption was noted in one animal which showed emptiness of the 
stomach for about three days before dying.  
 
Animals were obtained in Bloemfontein through Shalom Laboratories Suppliers in Durban. 
All parameters (absolute weight, terminal weight, organ weight, feed consumption) did not 
show any statistical significance in all treated groups (500mg/kg, 250mg/kg, and 125mg/kg) 
in both sexes when compared to the control animals. The exception was the relative organ 
weight of testes which is significantly low in high dose (500mg/kg) at 1% level (p≤0.01). In 
females the absolute weight of adrenal gland was significantly high in all treated groups 
(500mg/kg, 250mg/kg, and 125mg/kg) at 5% level (p≥0.05). Low dose (125mg/kg) female 
animals showed significantly high absolute weight of the heart at 1% level (p≥0.01).  
  
The low relative weight of the testes in high dose could be due to poor or compromised 
differentiation and maturation of the sertoli cells of the semineferous tubules. Sertoli cells 
contribute the bulk of mass within the testes. Low relative weight of testes has been observed 
in mice. Mice treated with triidothyronine resulted in low relative weight of testes. This is not 
the case in this study (Auharek et al., 2010). Animals were treated with root extract of Euclea 
natalensis rich in Napthoquinones. The assumption on the observed low relative weight could 
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be that the Napthoquinones have somehow properties and characteristics similar to 
triidothyronine that delays the differentiation and maturation of the sertoli cells which will in 
turn affect the maturation of the germination epithelium in the testes. Further investigation 
might be warranted. 
 
The absolute weight of the adrenal gland was significantly high in all female treated groups 
(500mg/kg, 250mg/kg and 125mg/kg), (p≥0.05). This phenomenon has been observed 
(Bielohuby et al., 2007). Absolute weight of the adrenal gland in female animals has been 
shown to be heavier than in male animals. The increase in absolute weight was observed 
between the age of 3 weeks and 11 weeks. In male animals the weight increased from week 3 
up to week 7 and there was a decline between the age of 9 weeks and 11 weeks. In female 
animals the weight escalated from week 3 up to week 7 and remained at that level until week 
11. All animals in the study were between the age of 6 weeks and 7 weeks at the onset of 
treatment (to include all that showed increase in absolute weight of the adrenal gland). This 
age coincides well with animal age in the Bielohuby study (2007). Female adrenal glands are 
heavier than male adrenal glands in mice. The point being made is that this is normal 
according to his research (Bielohuby et al., 2007). In this study however, the significance 
found was between control animals not gender differences. 
The absolute weight of heart in treated female animals in the low dose (125mg/kg) group was 
significantly high at 1% level (p≥0.01). This might be due to hypertrophied striated myocytes 
of the heart. However, microscopically the heart did not show any signs of hypertrophied 
muscle cells. This weight increase cannot be regarded as dose dependent since animals in 
high dose (500mg/kg) have not shown this picture. In human’s alcohol-induced 
cardiomyopathy, the heart shows areas of hypertrophy with an increase of mass usually of 
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600g or even more in adult heart (Case Files, Pathology, 2008).  This was not seen 
microscopically in the heart of these animals.  
 
In conclusion, all observed lesions are not dose dependent, but are spontaneous lesions 
associated with age in laboratory mice. Therefore, the NOAL/NOAEL/MTD of Euclea 
natalensis in albino mice is 500mg/kg.b.wt for this study 
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4.4 COMPARISON OF REPEATED DOSE (7 DAY) ORAL TOXICITY STUDY OF 
EUCLEA NATALENSIS IN SWISS ALBINO MICE AND REPEATED DOSE (28 
DAY) ORAL TOXICITY STUDY OF EUCLEA NATALENSIS IN SWISS ALBINO 
MICE 
No treatment related changes were observed in relative organ weights of animals treated with 
Euclea natalensis, except for changes seen in the testes in males of a relative weight that is 
significantly low in the high dose group (500mg/kg.b.wt) (p≤0.01). It is interesting to note 
that the weight of the testes in the 7 Day study was increased and decreased in 28 Day study. 
From this finding it can be deliberated that the shorter the animals were exposed to plant 
extract the more the testes developed and the longer they got exposed to the plant extract the 
more the delay in differentiation and maturation of the germination epithelium within the 
tubules. There was no evidence of atrophy of the seminiferous tubules in the organ as seen 
below in both control animal and high dose animal. 
 
  
               Figure 4.1 Photomicrograph of the Control Testes                       Figure 4.2 Photomicrograph of the Testes in the High Dose Group 
                H&E stain. 10x                                                                               H&E stain 20x 
In both studies the same statistical package was employed to analyse all collected data (body 
weights, absolute organ weights, relative organ weights, and feed consumed) (Toxistat 
version, 2005.2). Three tests were followed namely Bartlett’s test, ANOVA and Dunnett’s t-
test. The t-test correlated and compared all mentioned parameters of three treated groups 
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against the non-treated groups (controls) in the two sexes. Analysis of blood for haematology 
and clinical biochemistry was done in 7 Day study and not done in 28 Day study since this 
was beyond the scope of the study. The results that emanated from the blood analysis 
revealed no significant decrease and increases in animals treated with Euclea natalensis as 
compared to the control counterparts in both sexes. The exception was with just a few such as 
a decrease in phosphorus in G4 (500mg/kg.b.wt) (Table 2.3). 
 
The statistical analysis in the two studies reveals mass variations in the absolute weight of the 
heart.  In low dose (125mg/kg/b.wt) animals and in control 1, male at 7 Days the weight 
decreased whereas in the 28 Day study the mass of the same organ increased in 28 Day in the 
same low dose group (125mg/kg.b.wt).  The reduction in mass was supported by loss of 
myocytes in the affected animals where there was evidence of myocyte degeneration in the 
right ventricular wall of the heart. (Figure 3.6 micrograph A). This lesion was not dose 
dependent but regarded as age related alterations associated with laboratory mice since the 
control group also underwent the similar alteration. This has not been the case with neither 
controls nor treated animals in the 28 Day study. Although the weight of the heart increased, 
there was no evidence in the histopathology screening that suggest hypertrophy of the heart 
muscle. This increase might be induced by some unknown factors at present and requires 
further investigation. 
 
There is a common lesion that has been seen in the two studies. The control animals as well 
as the treated animals in 7 Day study exhibited massive white blood cell infiltration within 
the lung parenchyma. In the 28 Day study the lung tissue exhibited aggregates of lymphocyte 
around the blood vessels and the bronchioles (perivascular and peribronchiolar lymphocytic 
aggregations) (Figure 4.3 and Figure 4.4). These lesions were not dose dependent as 
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discussed earlier. The figure bellow shows massive lymphocytic infiltration and perivascular 
and peribronchiolar lymphocytic aggregation in 7 Days and 28 Days respectively. 
 
 
 
  Figure 4.3Photomicrograph of Treatment Lung from 7 Day Study        Figure 4.4   Photomicrograph of Treatment Lung from 28 Day Study 
    H&E statin                                                                                             H&E stain 
No lesions were seen in the liver and brain of animals treated for seven days in the pilot 
study. These lesions were only seen in the 28 days treatment (medial brain mineralization and 
hepatocellular basophilic focus) in both control animals as well as treated animals in both 
sexes. The involution of the X-Zone of the adrenal gland in females control animal was 
observed at 7 Days treatment but was not observed in the 28 Days treatment.  
 
In the 7-Days of treatment, the control and treated animals did not show any age related 
lesions of the liver or the brain.  Histopathological observations in the 28-Days of treatment 
also revealed lesions that are spontaneous and age related in mice. Female control animal 
#45/9 showed medial mineralization of the brain. Control animal #45/4 male showed liver 
basophilic hepatocellular cell focus (due to increased amounts of polyribosomes or rough 
endoplasmic reticulum), as well as liver granulo-poetic hyperplasia.  
 
 
50µm 
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4.5 CONCLUSIONS AND RECOMMENDATIONS 
Medicinal plants have been used by humans as far back as 60 000 years. Ethno medicine is 
broadly defined as the use of plants by humans as medicines. Traditionally this is a non-
Western medicinal practice. According to World Health Organization (WHO), 65% of the 
world’s population has incorporated the traditional medicines into their primary health care 
(Daniel and Norman, 2000).  
 
WHO has documented TB treatment guidelines in effort to control the spread of the disease 
globally (Treatment of Tuberculosis Guidelines, 2009). TB surveillance is ongoing in some 
parts of the world so that the programmes and initiatives instituted by WHO in the fight 
against the disease are met (European Centre for disease prevention, 2008).  
 
Generally, toxicity studies form the basis of many of the standard repeated dose safety 
evaluation studies such as sub-acute, sub-chronic and chronic toxicity studies. These studies 
are designed to characterize the effect of test chemicals over repeated exposure to 
experimental animals. They evaluate health hazards that may result from repeated exposure 
during limited part of test animal’s lifetime, and also evaluate dose related effect on survival, 
body weight, feed consumption, metabolism; gross and microscopic organ changes (Stephen, 
2013). 
 
In South Africa, if we are to reverse the escalating numbers in drug resistance, the list is long 
of questions to be addressed and posed as to the fate of the TB pandemic. But looking at the 
past, present and the future strategies and the state of the disease itself (Edginton, 2000, 
Edginton and Naidoo, 2007), and the enthusiasm exhibited by researchers of the country in 
indigenous plants, there is hope for new inventions of drugs against TB. 
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For South Africa to be able to compete in the global debate on TB prevention and 
eradication, the indigenous plants (Euclea natalensis) available in the country have to be 
considered, appreciated as well as marketed by programmes such as Natural Resources 
Management Programmes together with Department of Environmental Affairs (Mander, 
1998).  Euclea natalensis has been shown to have a wide spectrum on microbial activity not 
only in TB but also as having anti-fungal properties (Lall et al., 2006). It’s a promising 
medicinal plant together with other plants selected that have shown anti-TB properties (Green 
et al., 2010).  
 
Euclea natalensis plant therefore has shown no toxic effects in animals in these two studies 
conducted. Animals that died in the course of treatment in the 28 Days repeated oral toxicity 
study died due to natural courses and was not dose dependent. In conclusion I therefore, 
recommend further exploration of the leading compounds identified in this plant at molecular 
level to completely declare the extracts non toxic. Some compounds that have been 
discovered to be of great importance are 7-Methyl-Juglone and Diospyron (Lall et al., 2006). 
Further research should be done to clarify the underlying mechanisms that account for the 
adrenal and testicular changes noted in this study.  
To elaborate more on future studies on genotoxity profiling of the compounds in this plant, 
studies are underway where the identified active compounds are discovered to inhibit the 
super-coiling reactions of Deoxy-ribose nucleic acid (DNA) in Mycobacterium tuberculosis. 
Enzymes associated with transcription processes of the molecule were inhibited. This new 
chapter in this plant clearly points to a new TB drug that could be produced in the country 
and made available at low cost in the fight against the TB pandemic in South Africa. 
Therefore genotoxicity profiling studies of the leading compounds must be conducted. 
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 APPENDIX 1 
RAW DATA 
  
CAGEWISE FEED INPUT, LEFTOVER AND FEED CONSUMPTION RECORD 
  
G1 0mg/kg 
      A. 
NO 
DAY 
1 FDL AFC   DAY 4 FDL AFC 
   1 100 93 2.3   50 49.7 0.1 
   2 100 96 1.3   50 49.5 0.2 
   3 100 96.5 1.2   50 49.6 0.1 
   4 100 94.2 2   50 49.5 0.2 
   5 100 97.6 0.8   50 49.7 0.1 
   6 100 89.7 3.4   50 46.7 1.1 
   7 100 96.3 1.2   50 46.6 1.1 
   8 100 97.2 0.9   50 47.4 0.9 
   9 100 93.5 2.2   50 46.7 1.1 
   10 100 96.9 1   50 46.6 1.1 
           G2 125mg/kg     
   11 100 95.7 1.4   50 49.7 0.1 
   12 100 99 0.3   50 49.8 0.06 
   13 100 94 2   50 49.6 0.1 
   14 100 97.9 0.7   50 49.5 0.2 
   15 100 95.3 1.6   50 49.3 0.2 
   16 100 96.2 1.3   50 49.1 0.3 
   17 100 90.2 3.3   50 45 1.6 
   18 100 96.7 1.1   50 44.7 1.8 
   19 100 95.1 1.6   50 43.3 2.2 
   20 100 92.8 2.4   50 47.8 0.7 
           G3 250mg/kg     
   21 100 93.3 2.2   50 47.8 0.7 
   22 100 99.8 0.1   50     
   23 100 95.4 1.5   50 49.1 0.3 
   24 100 95.1 1.6   50 47 1 
   25 100 99.8 0.1   50 49.9 0.03 
   26 100 94.9 1.7   50 44.4 1.9 
   27 100 95 1.7   50 48.3 0.6 
   28 100 98.1 0.6   50 46.8 1.1 
   29 100 99 0.3   50 49.7 0.1 
   30 100 98.5 0.5   50 49 0.3 
           G4 500mg/kg     
   31 100 99.7 0.1   50 49.8 0.06 
   32 100 96.8 1.1   50 49.9 0.03 
   33 100 94.6 1.8   50 42.5 2.5 
   34 100 94.1 2   50 49.9 0.03 
   35 100 99.9 0.03   50 49.9 0.03 
   36 100 96.8 1.1   50 46.7 1.1 
   37 100 99.8 0.1   50 47.4 0.9 
   38 100 94.5 1.8   50 49.5 0.2 
   39 100 94.7 1.7   50 48.5 0.5 
   40 100 89.8 3.4   50 47.9 0.7 
    
 Raw data 1; G1-G4 Males 
31.6 27.0 22.2 23.1 0.007 0.023 0.061 0.082 0.144 0.458 0.443 0.191 1.676 0.030 0.100 0.264 0.355 0.623 
27.3 25.8 24.4 24.6 0.010 0.053 0.076 0.113 0.164 0.416 0.419 0.163 1.399 0.041 0.215 0.309 0.459 0.667 
28.5 27.7 24.6 24.6 0.013 0.066 0.065 0.105 0.164 0.440 0.397 0.186 1.743 0.053 0.268 0.264 0.427 0.667 
25.0 26.8 26.2 26.2 0.015 0.042 0.084 0.142 0.171 0.475 0.538 0.190 1.727 0.057 0.160 0.321 0.542 0.653 
23.8 22.4 22.6 21.9 0.013 0.058 0.067 0.133 0.149 0.441 0.384 0.187 1.185 0.059 0.265 0.306 0.607 0.680 
 
28.6 28.0 28.5 26.4 0.011 0.039 0.085 0.085 0.166 0.519 0.567 0.213 1.626 0.042 0.148 0.322 0.322 0.629 
28.3 26.2 24.9 25.2 0.013 0.050 0.077 0.128 0.185 0.455 0.463 0.216 1.600 0.052 0.198 0.306 0.508 0.734 
25.9 24.4 23.5 24.3 0.011 0.051 0.075 0.116 0.157 0.471 0.345 0.201 1.582 0.045 0.210 0.309 0.477 0.646 
25.6 23.7 23.3 22.9 0.012 0.034 0.064 0.158 0.141 0.434 0.402 0.216 1.412 0.052 0.148 0.279 0.690 0.616 
24.7 25.7 25.7 26.1 0.005 0.049 0.076 0.107 0.165 0.461 0.482 0.207 1.466 0.019 0.188 0.291 0.410 0.632 
 
31.9 31.7 31.6 30.9 0.015 0.064 0.081 0.142 0.174 0.496 0.632 0.192 1.685 0.049 0.207 0.262 0.460 0.563 
25.0 31.5 36.0 36.3 0.011 0.036 0.096 0.118 0.224 0.485 0.774 0.187 1.967 0.030 0.099 0.264 0.325 0.617 
28.4 28.0 26.8 27.4 0.010 0.070 0.076 0.146 0.192 0.472 0.513 0.175 1.880 0.036 0.255 0.277 0.533 0.701 
27.0 28.1 27.7 27.1 0.012 0.061 0.065 0.113 0.168 0.460 0.541 0.160 1.624 0.044 0.225 0.240 0.417 0.620 
23.5 21.4 20.2 20.6 0.014 0.041 0.077 0.114 0.132 0.432 0.309 0.176 1.234 0.068 0.199 0.374 0.553 0.641 
 
29.0 24.3 21.8 21.3 0.008 0.034 0.079 0.110 0.153 0.458 0.384 0.216 1.350 0.038 0.160 0.371 0.516 0.718 
28.4 25.3 24.6 24.4 0.015 0.026 0.087 0.121 0.197 0.469 0.473 0.215 1.451 0.061 0.107 0.357 0.496 0.807 
26.9 25.3 26.1 25.9 0.011 0.066 0.068 0.093 0.155 0.461 0.439 0.175 1.473 0.042 0.255 0.263 0.359 0.598 
26.1 24.2 20.9 21.1 0.007 0.030 0.055 0.156 0.123 0.414 0.392 0.181 1.451 0.033 0.142 0.261 0.739 0.583 
22.8 21.1 20.2 20.7 0.006 0.043 0.066 0.093 0.131 0.448 0.283 0.216 1.203 0.029 0.208 0.319 0.449 0.633 
 
   Raw data 1; G1-G4 Females 
 
27.6 28.5 28.2 27.5 0.022 0.014 0.103 0.161 0.163 0.172 0.486 0.446 1.675 0.080 0.051 0.375 0.585 0.593 
26.6 26.8 26.7 26.5 0.016 0.016 0.084 0.081 0.126 0.177 0.496 0.410 1.516 0.060 0.060 0.317 0.306 0.475 
26.1 26.1 26.4 25.9 0.026 0.015 0.078 0.103 0.095 0.154 0.482 0.384 1.400 0.100 0.058 0.301 0.398 0.367 
24.7 25.0 23.6 24.3 0.017 0.026 0.112 0.251 0.174 0.139 0.465 0.347 1.398 0.070 0.107 0.461 1.033 0.716 
24.6 24.4 25.4 25.9 0.024 0.013 0.133 0.278 0.154 0.185 0.498 0.356 1.244 0.093 0.050 0.514 1.073 0.595 
 
  
 25.4 25.2 25.5 25.4 0.014 0.015 0.090 0.111 0.148 0.151 0.514 0.410 1.346 0.055 0.059 0.354 0.437 0.583 
27.3 29.1 29.8 29.4 0.018 0.012 0.167 0.324 0.199 0.198 0.481 0.401 1.782 0.061 0.041 0.057 1.102 0.677 
25.3 26.0 27.3 27.0 0.018 0.013 0.119 0.151 0.126 0.181 0.462 0.361 1.373 0.067 0.048 0.441 0.559 0.467 
24.0 22.6 24.6 24.0 0.013 0.014 0.079 0.196 0.114 0.144 0.488 0.338 1.224 0.054 0.058 0.329 0.817 0.475 
22.8 24.6 24.1 23.8 0.021 0.017 0.119 0.183 0.127 0.153 0.465 0.333 1.266 0.088 0.071 0.500 0.769 0.534 
 
26.8 26.6 28.0 28.0 0.016 0.009 0.079 0.132 0.159 0.159 0.478 0.392 1.538 0.057 0.032 0.282 0.471 0.568 
25.7 25.4 25.4 24.8 0.017 0.020 0.095 0.167 0.149 0.145 0.497 0.371 1.256 0.069 0.081 0.383 0.673 0.601 
26.0 26.0 27.0 25.6 0.018 0.013 0.109 0.171 0.100 0.167 0.484 0.347 1.372 0.070 0.051 0.426 0.668 0.391 
23.5 24.0 23.7 23.5 0.019 0.022 0.098 0.201 0.117 0.154 0.490 0.347 1.209 0.081 0.094 0.417 0.855 0.498 
24.4 23.2 24.7 25.3 0.014 0.014 0.110 0.127 0.155 0.165 0.465 0.358 1.690 0.055 0.055 0.435 0.502 0.613 
 
28.2 28.1 28.1 27.9 0.015 0.018 0.132 0.230 0.146 0.187 0.465 0.406 1.608 0.054 0.065 0.473 0.824 0.523 
27.0 22.6 25.7 24.2 0.024 0.016 0.045 0.124 0.106 0.158 0.511 0.341 1.410 0.099 0.066 0.186 0.512 0.438 
25.6 26.3 26.3 26.4 0.028 0.015 0.093 0.226 0.139 0.156 0.481 0.411 1.440 0.106 0.057 0.352 0.856 0.527 
24.8 25.3 25.9 25.5 0.021 0.020 0.132 0.235 0.126 0.148 0.465 0.344 1.297 0.082 0.078 0.518 0.922 0.494 
23.7 24.3 24.7 23.5 0.021 0.020 0.086 0.131 0.140 0.173 0.437 0.394 1.337 0.089 0.085 0.366 0.557 0.596 
 
 
Raw data 2; Males 
5.3 7.51 15.3 41.3 55 20.4 37 663 49.1 6 44.9 150 2.3 0.1 
5.9 9.3 14.5 51.4 55.3 15.6 28.2 1510 73 3.2 23.8 135 1.3 0.2 
6.5 9.31 14.8 51.8 55.6 15.9 28.6 1819 62.3 7.3 30.4 135 1.2 0.1 
4 8.96 14.3 50.4 56.3 16 28.4 1233 75.6 2.5 21.9 150 2 0.2 
5 10.17 14.9 53.6 52.7 14.7 27.8 1573 75 4.1 20.9 120 0.8 0.1 
 
  
6.7 10.27 16.2 57.7 56.2 15.8 28.1 1333 47.6 5.3 47.1 150 1.4 0.1 
4.5 11.13 15.5 56.2 50.5 13.9 27.6 1213 69.4 3.3 27.3 120 0.3 0.06 
3.8 9.34 15 53 56.7 16.1 28.3 1521 73.9 3.3 22.8 135 2 0.1 
6.4 9.78 14.3 50.8 51.9 14.6 28.1 1388 75.3 4 20.7 150 0.7 0.2 
4.5 9.57 14.7 52.8 55.2 15.4 27.8 1211 81.4 2.1 16.5 120 1.6 0.2 
 
      
 7.8 8.77 15.1 50.6 57.7 17.2 29.8 617 66.4 4.9 28.7 120 2.2 0.7 
7.8 9.26 14.2 49.5 53.5 15.3 28.7 915 79.9 2.4 17.7 150 0.1 
 6.1 9.78 14.9 53.9 55.1 15.2 27.6 1220 57.3 5.3 37.4 120 1.5 0.3 
4.5 8.41 13.7 47 55.9 16.3 29.1 969 73.1 2.6 24.3 135 1.6 1 
5.2 10.67 15.6 57.9 54.3 14.6 26.9 1618 62.5 4.1 33.4 150 0.1 0.03 
 
6.2 9.98 15.5 54.1 54.2 15.5 28.7 1699 34.8 6.8 58.4 120 0.1 0.06 
3.8 10.17 15.2 53.3 52.4 14.9 28.5 1234 65 4.4 30.6 150 1.1 0.03 
2.9 8.94 13.7 47.2 52.8 15.3 29 1288 69.7 4.7 25.6 120 1.8 2.5 
7.8 9.9 15.9 55.6 56.2 16.1 28.6 1637 66.9 4 29.1 120 2 0.03 
8.5 10.8 16 59.4 55 14.8 26.9 1150 81.5 2.4 16.1 135 0.03 0.03 
 
Raw data 2; Females 
3.5 9.18 14.2 48.8 53.2 15.5 29.1 973 77.8 4.1 18.1 135 3.4 1.1 
5.7 9.65 14.7 51.7 53.6 15.2 28.4 1096 90.7 1 8.3 150 1.2 1.1 
2.6 10.01 15.2 53.7 53.6 15.2 28.3 1284 81.4 2.9 15.7 120 0.9 0.9 
5.2 8.92 14.8 51.7 58 16.6 28.6 1196 76.6 3.2 20.2 135 2.2 1.1 
6.2 8.34 14.1 48.9 58.6 16.9 28.8 1000 77.7 2.2 20.1 150 1 1.1 
 
7.2 9.54 14.1 50.4 52.8 14.8 28 1114 85 2.6 12.4 150 1.3 0.3 
2.8 9.02 14.2 49.7 55.1 15.7 28.6 1020 67.2 4.2 28.6 135 3.3 1.6 
6.1 9.17 14.2 50.8 55.4 15.5 28 1129 82.4 1.8 15.8 135 1.1 1.8 
2.8 9.73 14.9 53.6 55.1 15.3 27.8 823 69.6 3.2 27.2 120 1.6 2.2 
4.6 9.4 15.5 53.7 57.1 16.5 28.9 992 82.4 2 15.6 135 2.4 0.7 
 
5.9 9.12 14.5 50.9 55.8 15.9 28.5 1267 57.6 5.9 36.5 180 1.7 1.9 
9 9.77 15 52.2 53.4 15.4 28.7 1240 66.4 3.4 30.2 150 1.7 0.6 
7.3 9.91 15.9 58 58.5 16 27.4 1422 64.6 4.9 30.5 120 0.6 1.1 
3.5 9.32 14.5 50.4 54.1 15.6 28.8 976 85.2 1.5 13.3 150 0.3 0.1 
 
9.39 14.6 51 54.3 15.5 28.6 1081 
   
135 0.5 0.3 
 
  
 4.6 8.92 14.5 50.6 56.7 16.3 28.7 1222 83.7 2.6 13.7 150 1.1 1.1 
5.7 10.24 15 53.8 52.5 14.6 27.9 1292 51.2 7.8 41 150 0.1 0.9 
7.1 9.76 14.9 52 53.3 15.3 28.7 892 83.7 2.5 13.8 125 1.8 0.2 
3.7 9.41 15.6 53.3 56.6 16.6 29.3 1054 82.2 2.3 15.5 135 1.7 0.5 
5.6 9.6 15.1 52.1 54.3 15.7 29 1199 79.7 2.9 17.4 135 3.4 0.7 
 
  
 TOXICSTAT, VERSION 2005.2 
DEPARTMENT OF TOXICOLOGY, OCPL 
STUDY N° SA45 SPECIES MOUSE 
DATA B.WT., ABS. WT., REL.WT. SEX MALE 
T.S.CODE NQ N° OF GROUPS 4 
STUDY TITLE REPEATED DOSE (7 DAYS) TOXICITY STUDY DATE OF ANALYSIS 15-04-2013 
STUDY DIRECTOR MATHLO SHAULI P VALUE 0.05 , 0.01 
PARAMETER 
BARTLETT'S TEST 
CALCULATED 
VALUE 
P = 0.05 P = 0.01 SIGNIFICANCE 
PRE-EXP 1.557 7.815 11.345 N.S 
DAY 4 4.574 7.815 11.345 N.S 
DAY 7 7.559 7.815 11.345 N.S 
TER. B.WT. 9.542 7.815 11.345 S * 
ADR 1.119 7.815 11.345 N.S 
THY 2.251 7.815 11.345 N.S 
EPI 0.991 7.815 11.345 N.S 
SPL 1.061 7.815 11.345 N.S 
HEA 4.874 7.815 11.345 N.S 
BRN 0.715 7.815 11.345 N.S 
KID 5.072 7.815 11.345 N.S 
TES 4.518 7.815 11.345 N.S 
LIV 5.899 7.815 11.345 N.S 
ADR 0.148 7.815 11.345 N.S 
THY 2.709 7.815 11.345 N.S 
EPI 5.405 7.815 11.345 N.S 
SPL 1.010 7.815 11.345 N.S 
HEA 6.755 7.815 11.345 N.S 
BRN 4.829 7.815 11.345 N.S 
KID 0.606 7.815 11.345 N.S 
TES 3.477 7.815 11.345 N.S 
LIV 2.911 7.815 11.345 N.S 
  
 
TOXICSTAT, VERSION 2005.2 
DEPARTMENT OF TOXICOLOGY, OCPL 
STUDY N° SA45 SPECIES MOUSE 
DATA B.WT., ABS. WT., REL.WT. SEX MALE 
T.S.CODE NQ N° OF GROUPS 4 
STUDY TITLE REPEATED DOSE (7 DAYS) TOXICITY STUDY 
DATE OF 
ANALYSIS 
15-04-2013 
STUDY DIRECTOR MATHLO SHAULI P VALUE 0.05 , 0.01 
PARAMETER 
ANOVA DUNNETT'S T-TEST 
CALCULATED 
F-VALUE 
TABLE    
F-
VALUE 
0.05 
TABLE 
F-
VALUE 
0.01 
SIGNIFICANCE 
T-
VALUE 
0.05 
T-
VALUE 
0.01 
G2 SIGNIFICANCE G3 SIGNIFICANCE G4 SIGNIFICANCE 
PRE-EXP 0.076 3.240 5.290 N.S 2.340 3.170 0.365 N.S 0.047 N.S 0.353 N.S 
DAY 4 2.076 3.240 5.290 N.S 2.340 3.170 0.205 N.S 1.327 N.S 1.146 N.S 
DAY 7 2.523 3.240 5.290 N.S 2.340 3.170 0.539 N.S 2.036 N.S 0.584 N.S 
TER. B.WT. 2.809 3.240 5.290 N.S 2.340 3.170 0.433 N.S 2.108 N.S 0.674 N.S 
ADR 0.937 3.240 5.290 N.S 2.340 3.170 0.622 N.S 0.415 N.S 1.141 N.S 
THY 0.935 3.240 5.290 N.S 2.340 3.170 0.421 N.S 0.665 N.S 0.953 N.S 
EPI 0.753 3.240 5.290 N.S 2.340 3.170 0.740 N.S 1.295 N.S 0.062 N.S 
SPL 0.278 3.240 5.290 N.S 2.340 3.170 0.255 N.S 0.778 N.S 0.027 N.S 
HEA 1.054 3.240 5.290 N.S 2.340 3.170 0.287 N.S 1.279 N.S 0.431 N.S 
BRN 1.119 3.240 5.290 N.S 2.340 3.170 1.376 N.S 1.439 N.S 0.250 N.S 
KID 2.036 3.240 5.290 N.S 2.340 3.170 0.232 N.S 1.752 N.S 0.626 N.S 
TES 6.002 3.240 5.290 S ** 2.340 3.170 3.119 S * 0.619 N.S 1.972 N.S 
LIV 1.759 3.240 5.290 N.S 2.340 3.170 0.069 N.S 1.035 N.S 1.258 N.S 
ADR 0.319 3.240 5.290 N.S 2.340 3.170 0.716 N.S 0.310 N.S 0.883 N.S 
THY 0.282 3.240 5.290 N.S 2.340 3.170 0.648 N.S 0.128 N.S 0.760 N.S 
EPI 0.538 3.240 5.290 N.S 2.340 3.170 0.341 N.S 0.372 N.S 0.847 N.S 
SPL 0.176 3.240 5.290 N.S 2.340 3.170 0.045 N.S 0.271 N.S 0.449 N.S 
HEA 0.401 3.240 5.290 N.S 2.340 3.170 0.176 N.S 0.791 N.S 0.262 N.S 
BRN 2.457 3.240 5.290 N.S 2.340 3.170 0.144 N.S 1.476 N.S 1.220 N.S 
 KID 0.505 3.240 5.290 N.S 2.340 3.170 0.047 N.S 0.697 N.S 0.524 N.S 
TES 5.101 3.240 5.290 S * 2.340 3.170 1.173 N.S 1.768 N.S 1.888 N.S 
LIV 0.528 3.240 5.290 N.S 2.340 3.170 0.665 N.S 1.251 N.S 0.740 N.S 
 
DATA B.WT., ABS. WT., REL.WT. SEX MALE 
T.S.CODE NQ N° OF GROUPS 4 
STUDY TITLE REPEATED DOSE (7 DAYS) TOXICITY STUDY DATE OF ANALYSIS 15-04-2013 
STUDY DIRECTOR MATHLO SHAULI P VALUE 0.05 , 0.01 
T TEST 
PARAMETER 
G1 G2 G3 G4 
MEAN SD MEAN SD SIGNIFICANCE MEAN  SD SIGNIFICANCE MEAN SD SIGNIFICANCE 
PRE-EXP 27.240 3.060 26.620 1.731 N.S 27.160 3.244 N.S 26.640 2.438 N.S 
DAY 4 25.940 2.092 25.600 1.672 N.S 28.140 4.166 N.S 24.040 1.726 N.S 
DAY 7 24.000 1.625 25.180 2.105 N.S 28.460 5.879 N.S 22.720 2.523 N.S 
TER. B.WT. 24.080 1.639 24.980 1.424 N.S 28.460 5.748 N.S 22.680 2.326 N.S 
ADR 0.012 0.003 0.010 0.003 N.S 0.012 0.002 N.S 0.009 0.004 N.S 
THY 0.048 0.017 0.045 0.008 N.S 0.054 0.015 N.S 0.040 0.016 N.S 
EPI 0.071 0.009 0.075 0.008 N.S 0.079 0.011 N.S 0.071 0.012 N.S 
SPL 0.115 0.024 0.119 0.027 N.S 0.127 0.016 N.S 0.115 0.026 N.S 
HEA 0.158 0.011 0.163 0.016 N.S 0.178 0.034 N.S 0.152 0.029 N.S 
BRN 0.446 0.022 0.468 0.032 N.S 0.469 0.025 N.S 0.450 0.021 N.S 
KID 0.436 0.061 0.452 0.084 N.S 0.554 0.171 N.S 0.394 0.072 N.S 
TES 0.183 0.012 0.211 0.007 S ** 0.178 0.012 N.S 0.201 0.021 N.S 
LIV 1.546 0.245 1.537 0.093 N.S 1.678 0.285 N.S 1.386 0.113 N.S 
ADR 0.048 0.012 0.042 0.014 N.S 0.045 0.015 N.S 0.041 0.012 N.S 
THY 0.202 0.072 0.178 0.029 N.S 0.197 0.059 N.S 0.174 0.058 N.S 
EPI 0.293 0.027 0.301 0.017 N.S 0.283 0.052 N.S 0.314 0.051 N.S 
SPL 0.478 0.099 0.481 0.137 N.S 0.458 0.092 N.S 0.512 0.141 N.S 
HEA 0.658 0.022 0.651 0.047 N.S 0.628 0.050 N.S 0.668 0.094 N.S 
BRN 1.858 0.137 1.874 0.086 N.S 1.692 0.274 N.S 1.996 0.162 N.S 
KID 1.808 0.176 1.801 0.260 N.S 1.909 0.247 N.S 1.732 0.223 N.S 
TES 0.765 0.077 0.845 0.060 N.S 0.644 0.127 N.S 0.894 0.146 N.S 
LIV 6.406 0.825 6.160 0.337 N.S 5.943 0.584 N.S 6.132 0.483 N.S 
  
CALCULATED 
VALUE
P = 0.05 P = 0.01
PRE-EXP 0.606 7.815 11.345
DAY 4 1.189 7.815 11.345
DAY 7 1.380 7.815 11.345
TER. B.WT. 1.690 7.815 11.345
ADR 2.963 7.815 11.345
THY 5.524 7.815 11.345
EPI 4.158 7.815 11.345
SPL 3.903 7.815 11.345
HEA 2.080 7.815 11.345
BRN 3.008 7.815 11.345
KID 3.063 7.815 11.345
TES 1.978 7.815 11.345
LIV 1.478 7.815 11.345
ADR 1.508 7.815 11.345
THY 3.873 7.815 11.345
EPI 3.676 7.815 11.345
SPL 2.936 7.815 11.345
HEA 2.452 7.815 11.345
BRN 1.282 7.815 11.345
KID 3.789 7.815 11.345
TES 2.212 7.815 11.345
LIV 2.258 7.815 11.345 N.S
N.S
N.S
N.S
N.S
N.S
N.S
N.S
N.S
N.S
N.S
N.S
N.S
N.S
N.S
N.S
N.S
N.S
N.S
N.S
N.S
PARAMETER
BARTLETT'S TEST
SIGNIFICANCE
N.S
STUDY DIRECTOR MATHLO SHAULI P VALUE 0.05 , 0.01
STUDY TITLE REPEATED DOSE (7 DAYS) TOXICITY STUDY DATE OF ANALYSIS 15-04-2013
T.S.CODE NQ N° OF GROUPS 4
DATA B.WT., ABS. WT., REL.WT. SEX FEMALE
TOXICSTAT, VERSION 2005.2
DEPARTMENT OF TOXICOLOGY, OCPL
STUDY N° SA45 SPECIES MOUSE
 
CALCULATED 
F-VALUE
TABLE    
F-VALUE 
0.05
TABLE F-
VALUE 
0.01
SIGNIFICANCE
T-VALUE 
0.05
T-VALUE 
0.01
G2 SIGNIFICANCE G3 SIGNIFICANCE G4 SIGNIFICANCE
PRE-EXP 0.459 3.240 5.290 N.S 2.340 3.170 0.991 N.S 0.661 N.S 0.062 N.S
DAY 4 0.313 3.240 5.290 N.S 2.340 3.170 0.548 N.S 0.931 N.S 0.698 N.S
DAY 7 0.071 3.240 5.290 N.S 2.340 3.170 0.176 N.S 0.265 N.S 0.071 N.S
TER. B.WT. 0.137 3.240 5.290 N.S 2.340 3.170 0.089 N.S 0.518 N.S 0.464 N.S
ADR 2.553 3.240 5.290 N.S 2.340 3.170 1.773 N.S 1.773 N.S 0.338 N.S
THY 0.744 3.240 5.290 N.S 2.340 3.170 1.021 N.S 0.471 N.S 0.393 N.S
EPI 0.409 3.240 5.290 N.S 2.340 3.170 0.723 N.S 0.215 N.S 0.248 N.S
SPL 0.254 3.240 5.290 N.S 2.340 3.170 0.427 N.S 0.356 N.S 0.337 N.S
HEA 0.194 3.240 5.290 N.S 2.340 3.170 0.023 N.S 0.364 N.S 0.626 N.S
BRN 0.212 3.240 5.290 N.S 2.340 3.170 0.000 N.S 0.676 N.S 0.091 N.S
KID 0.479 3.240 5.290 N.S 2.340 3.170 0.278 N.S 0.213 N.S 1.113 N.S
TES 0.584 3.240 5.290 N.S 2.340 3.170 0.951 N.S 1.218 N.S 0.447 N.S
LIV 0.063 3.240 5.290 N.S 2.340 3.170 0.425 N.S 0.295 N.S 0.248 N.S
ADR 2.221 3.240 5.290 N.S 2.340 3.170 1.579 N.S 1.437 N.S 0.546 N.S
THY 0.530 3.240 5.290 N.S 2.340 3.170 0.818 N.S 0.217 N.S 0.418 N.S
EPI 0.236 3.240 5.290 N.S 2.340 3.170 0.754 N.S 0.066 N.S 0.192 N.S
SPL 0.193 3.240 5.290 N.S 2.340 3.170 0.365 N.S 0.285 N.S 0.348 N.S
HEA 0.130 3.240 5.290 N.S 2.340 3.170 0.033 N.S 0.247 N.S 0.554 N.S
BRN 0.179 3.240 5.290 N.S 2.340 3.170 0.037 N.S 0.383 N.S 0.346 N.S
KID 0.101 3.240 5.290 N.S 2.340 3.170 0.045 N.S 0.406 N.S 0.112 N.S
TES 0.652 3.240 5.290 N.S 2.340 3.170 1.033 N.S 0.968 N.S 0.025 N.S
LIV 0.183 3.240 5.290 N.S 2.340 3.170 0.601 N.S 0.020 N.S 0.030 N.S
PARAMETER
ANOVA DUNNETT'S T-TEST
STUDY DIRECTOR MATHLO SHAULI P VALUE 0.05 , 0.01
STUDY TITLE REPEATED DOSE (7 DAYS) TOXICITY STUDY DATE OF ANALYSIS 15-04-2013
T.S.CODE NQ N° OF GROUPS 4
DATA B.WT., ABS. WT., REL.WT. SEX FEMALE
TOXICSTAT, VERSION 2005.2
DEPARTMENT OF TOXICOLOGY, OCPL
STUDY N° SA45 SPECIES MOUSE
 
MOUSE
FEMALE
4
15-04-2013
0.05 , 0.01
MEAN SD MEAN SD SIGNIFICANCE MEAN SD SIGNIFICANCE MEAN SD SIGNIFICANCE
PRE-EXP 25.920 1.279 24.960 1.686 N.S 25.280 1.318 N.S 25.860 1.777 N.S
DAY 4 26.160 1.607 25.500 2.373 N.S 25.040 1.410 N.S 25.320 2.069 N.S
DAY 7 26.060 1.702 26.260 2.324 N.S 25.760 1.736 N.S 26.140 1.244 N.S
TER. B.WT. 26.020 1.163 25.920 2.331 N.S 25.440 1.641 N.S 25.500 1.751 N.S
ADR 0.021 0.004 0.017 0.003 N.S 0.017 0.002 N.S 0.022 0.005 N.S
THY 0.017 0.005 0.014 0.002 N.S 0.016 0.005 N.S 0.018 0.002 N.S
EPI 0.102 0.022 0.115 0.034 N.S 0.098 0.013 N.S 0.098 0.036 N.S
SPL 0.175 0.087 0.193 0.080 N.S 0.160 0.031 N.S 0.189 0.056 N.S
HEA 0.142 0.032 0.143 0.034 N.S 0.136 0.026 N.S 0.131 0.016 N.S
BRN 0.165 0.019 0.165 0.023 N.S 0.158 0.009 N.S 0.164 0.016 N.S
KID 0.485 0.013 0.482 0.021 N.S 0.483 0.012 N.S 0.472 0.027 N.S
TES 0.389 0.041 0.369 0.035 N.S 0.363 0.019 N.S 0.379 0.034 N.S
LIV 1.447 0.160 1.398 0.223 N.S 1.413 0.200 N.S 1.418 0.120 N.S
ADR 0.081 0.016 0.065 0.014 N.S 0.066 0.011 N.S 0.086 0.020 N.S
THY 0.065 0.024 0.055 0.011 N.S 0.063 0.025 N.S 0.070 0.011 N.S
EPI 0.394 0.092 0.336 0.170 N.S 0.389 0.063 N.S 0.379 0.129 N.S
SPL 0.679 0.356 0.737 0.256 N.S 0.634 0.155 N.S 0.734 0.186 N.S
HEA 0.549 0.133 0.547 0.087 N.S 0.534 0.092 N.S 0.516 0.057 N.S
BRN 0.635 0.057 0.636 0.038 N.S 0.622 0.042 N.S 0.646 0.063 N.S
KID 1.867 0.062 1.872 0.185 N.S 1.905 0.147 N.S 1.857 0.161 N.S
TES 1.491 0.097 1.424 0.110 N.S 1.429 0.058 N.S 1.489 0.130 N.S
LIV 5.555 0.485 5.373 0.400 N.S 5.548 0.655 N.S 5.564 0.302 N.S
TOXICSTAT, VERSION 2005.2
DEPARTMENT OF TOXICOLOGY, OCPL
STUDY N° SA45 SPECIES
DATA B.WT., ABS. WT., REL.WT. SEX
T.S.CODE NQ N° OF GROUPS
STUDY TITLE REPEATED DOSE (7 DAYS) TOXICITY STUDY DATE OF ANALYSIS
STUDY DIRECTOR MATHLO SHAULI P VALUE
T TEST
PARAMETER
G1 G2 G3 G4
 
  
CALCULATED 
VALUE
P = 0.05 P = 0.01
GLU 5.696 7.815 11.345
URE 8.743 7.815 11.345
CRE 7.374 7.815 11.345
PRO 1.913 7.815 11.345
ALB 2.265 7.815 11.345
CHO 3.986 7.815 11.345
TRI 0.788 7.815 11.345
PHO 11.725 7.815 11.345
CLO 4.472 7.815 11.345
BIT 2.199 7.815 11.345
GOT 3.545 7.815 11.345
GPT 3.926 7.815 11.345
ALP 1.966 7.815 11.345
N.S
N.S
N.S
N.S
N.S
N.S
S **
N.S
S *
N.S
N.S
N.S
PARAMETER
BARTLETT'S TEST
SIGNIFICANCE
N.S
STUDY DIRECTOR MATHULO SHAULI P VALUE 0.05 , 0.01
STUDY TITLE REPEATED DOSE (7 DAYS) TOXICITY STUDY DATE OF ANALYSIS 16-04-2013
T.S.CODE NQ N° OF GROUPS 4
DATA CLIN. PATH SEX MALE
TOXICSTAT, VERSION 2005.2
DEPARTMENT OF TOXICOLOGY, OCPL
STUDY N° SA45 SPECIES MOUSE
CALCULATED 
F-VALUE
TABLE    
F-VALUE 
0.05
TABLE F-
VALUE 
0.01
SIGNIFICANCE
T-VALUE 
0.05
T-VALUE 
0.01
G2 SIGNIFICANCE G3 SIGNIFICANCE G4 SIGNIFICANCE
GLU 0.622 3.240 5.290 N.S 2.340 3.170 0.080 N.S 0.711 N.S 0.649 N.S
URE 0.510 3.240 5.290 N.S 2.340 3.170 0.359 N.S 0.359 N.S 0.822 N.S
CRE 1.129 3.240 5.290 N.S 2.340 3.170 0.742 N.S 1.577 N.S 0.000 N.S
PRO 2.489 3.240 5.290 N.S 2.340 3.170 0.370 N.S 2.524 S * 1.127 N.S
ALB 3.232 3.240 5.290 N.S 2.340 3.170 0.189 N.S 2.036 N.S 0.935 N.S
CHO 4.306 3.240 5.290 S * 2.340 3.170 0.601 N.S 1.403 N.S 2.139 N.S
TRI 0.255 3.240 5.290 N.S 2.340 3.170 0.267 N.S 0.153 N.S 0.662 N.S
PHO 4.483 3.240 5.290 S * 2.340 3.170 0.248 N.S 0.189 N.S 2.953 S *
CLO 2.606 3.240 5.290 N.S 2.340 3.170 1.291 N.S 2.020 N.S 0.453 N.S
BIT 1.023 3.240 5.290 N.S 2.340 3.170 0.986 N.S 0.147 N.S 0.759 N.S
GOT 0.814 3.240 5.290 N.S 2.340 3.170 0.519 N.S 0.652 N.S 0.798 N.S
GPT 0.502 3.240 5.290 N.S 2.340 3.170 1.168 N.S 0.373 N.S 0.278 N.S
ALP 2.905 3.240 5.290 N.S 2.340 3.170 1.201 N.S 0.788 N.S 1.532 N.S
PARAMETER
ANOVA DUNNETT'S T-TEST
STUDY DIRECTOR MATHULO SHAULI P VALUE 0.05 , 0.01
STUDY TITLE REPEATED DOSE (7 DAYS) TOXICITY STUDY DATE OF ANALYSIS 16-04-2013
T.S.CODE NQ N° OF GROUPS 4
DATA CLIN. PATH SEX MALE
TOXICSTAT, VERSION 2005.2
DEPARTMENT OF TOXICOLOGY, OCPL
STUDY N° SA45 SPECIES MOUSE
 
MOUSE
MALE
4
16-04-2013
0.05 , 0.01
MEAN SD MEAN SD SIGNIFICANCE MEAN SD SIGNIFICANCE MEAN SD SIGNIFICANCE
GLU 128.780 34.866 126.660 26.750 N.S 147.520 67.368 N.S 111.680 21.881 N.S
URE 27.800 8.044 26.400 7.369 N.S 29.200 1.304 N.S 31.000 5.568 N.S
CRE 0.400 0.024 0.432 0.049 N.S 0.468 0.110 N.S 0.400 0.060 N.S
PRO 7.034 1.116 6.842 0.829 N.S 5.726 0.578 S * 6.450 0.648 N.S
ALB 3.768 1.451 3.906 1.110 N.S 2.282 0.641 N.S 4.450 1.255 N.S
CHO 143.800 42.204 154.600 24.358 N.S 118.600 14.381 N.S 182.200 25.352 N.S
TRI 173.200 41.294 181.600 51.786 N.S 168.400 61.211 N.S 194.000 41.851 N.S
PHO 12.250 4.153 12.662 0.608 N.S 11.936 2.873 N.S 7.348 1.298 N.S
CLO 98.020 4.110 101.100 2.064 N.S 102.840 2.341 N.S 96.940 5.505 N.S
BIT 2.286 1.244 2.876 0.560 N.S 2.374 0.998 N.S 1.832 0.850 N.S
GOT 149.660 41.219 162.820 49.563 N.S 133.120 44.371 N.S 169.900 17.476 N.S
GPT 103.960 39.435 83.560 14.933 N.S 97.440 30.156 N.S 99.100 19.047 N.S
ALP 118.200 41.590 145.000 32.381 N.S 135.800 42.056 N.S 84.000 20.893 N.S
TOXICSTAT, VERSION 2005.2
DEPARTMENT OF TOXICOLOGY, OCPL
STUDY N° SA45 SPECIES
DATA CLIN. PATH SEX
T.S.CODE NQ N° OF GROUPS
STUDY TITLE REPEATED DOSE (7 DAYS) TOXICITY STUDY DATE OF ANALYSIS
STUDY DIRECTOR MATHULO SHAULI P VALUE
T TEST
PARAMETER
G1 G2 G3 G4
 
 
CALCULATED 
VALUE
P = 0.05 P = 0.01
GLU 2.062 7.815 11.345
URE 1.144 7.815 11.345
CRE 0.854 7.815 11.345
PRO 8.820 7.815 11.345
ALB 10.430 7.815 11.345
CHO 9.084 7.815 11.345
TRI 9.552 7.815 11.345
PHO 2.484 7.815 11.345
CLO 3.039 7.815 11.345
BIT 4.083 7.815 11.345
GOT 3.474 7.815 11.345
GPT 5.136 7.815 11.345
ALP 1.419 7.815 11.345
N.S
N.S
N.S
N.S
S *
S *
N.S
N.S
N.S
N.S
S *
S *
PARAMETER
BARTLETT'S TEST
SIGNIFICANCE
N.S
STUDY DIRECTOR MATHULO SHAULI P VALUE 0.05 , 0.01
STUDY TITLE REPEATED DOSE (7 DAYS) TOXICITY STUDY DATE OF ANALYSIS 16-04-2013
T.S.CODE NQ N° OF GROUPS 4
DATA CLIN. PATH SEX FEMALE
TOXICSTAT, VERSION 2005.2
DEPARTMENT OF TOXICOLOGY, OCPL
STUDY N° SA45 SPECIES MOUSE
 
CALCULATED 
F-VALUE
TABLE    
F-VALUE 
0.05
TABLE F-
VALUE 
0.01
SIGNIFICANCE
T-VALUE 
0.05
T-VALUE 
0.01
G2 SIGNIFICANCE G3 SIGNIFICANCE G4 SIGNIFICANCE
GLU 1.302 3.240 5.290 N.S 2.340 3.170 1.894 N.S 0.474 N.S 0.676 N.S
URE 2.413 3.240 5.290 N.S 2.340 3.170 1.345 N.S 0.000 N.S 1.345 N.S
CRE 0.303 3.240 5.290 N.S 2.340 3.170 0.228 N.S 0.684 N.S 0.228 N.S
PRO 0.568 3.240 5.290 N.S 2.340 3.170 0.598 N.S 0.499 N.S 0.609 N.S
ALB 2.837 3.240 5.290 N.S 2.340 3.170 2.143 N.S 0.457 N.S 2.376 S *
CHO 1.442 3.240 5.290 N.S 2.340 3.170 1.985 N.S 1.390 N.S 1.467 N.S
TRI 0.531 3.240 5.290 N.S 2.340 3.170 0.970 N.S 0.186 N.S 0.211 N.S
PHO 2.022 3.240 5.290 N.S 2.340 3.170 1.348 N.S 2.458 S * 1.334 N.S
CLO 1.147 3.240 5.290 N.S 2.340 3.170 0.324 N.S 1.619 N.S 1.228 N.S
BIT 1.272 3.240 5.290 N.S 2.340 3.170 0.152 N.S 0.088 N.S 1.604 N.S
GOT 0.808 3.240 5.290 N.S 2.340 3.170 1.060 N.S 0.453 N.S 0.111 N.S
GPT 1.213 3.240 5.290 N.S 2.340 3.170 0.571 N.S 0.391 N.S 1.403 N.S
ALP 1.680 3.240 5.290 N.S 2.340 3.170 1.056 N.S 0.917 N.S 0.825 N.S
PARAMETER
ANOVA DUNNETT'S T-TEST
STUDY DIRECTOR MATHULO SHAULI P VALUE 0.05 , 0.01
STUDY TITLE REPEATED DOSE (7 DAYS) TOXICITY STUDY DATE OF ANALYSIS 16-04-2013
T.S.CODE NQ N° OF GROUPS 4
DATA CLIN. PATH SEX FEMALE
TOXICSTAT, VERSION 2005.2
DEPARTMENT OF TOXICOLOGY, OCPL
STUDY N° SA45 SPECIES MOUSE
 
MOUSE
FEMALE
4
16-04-2013
0.05 , 0.01
MEAN SD MEAN SD SIGNIFICANCE MEAN SD SIGNIFICANCE MEAN SD SIGNIFICANCE
GLU 145.140 12.885 127.320 11.253 S * 140.680 11.989 N.S 138.780 21.176 N.S
URE 20.000 2.121 18.200 2.387 N.S 20.000 1.414 N.S 21.800 2.387 N.S
CRE 0.384 0.028 0.388 0.027 N.S 0.396 0.021 N.S 0.380 0.034 N.S
PRO 5.948 1.610 5.598 0.412 N.S 6.240 0.608 N.S 5.592 0.537 N.S
ALB 3.404 0.940 2.392 0.337 N.S 3.188 1.089 N.S 2.282 0.213 N.S
CHO 146.600 42.495 110.600 9.290 N.S 121.400 34.595 N.S 120.000 14.124 N.S
TRI 162.400 21.916 131.200 17.079 S * 156.400 68.755 N.S 169.200 69.694 N.S
PHO 8.876 1.984 10.614 2.899 N.S 12.046 1.544 S * 10.596 1.383 N.S
CLO 98.280 1.455 98.860 3.449 N.S 101.180 3.507 N.S 100.480 2.406 N.S
BIT 1.530 0.584 1.606 0.598 N.S 1.486 0.514 N.S 2.332 1.240 N.S
GOT 146.880 44.743 107.720 33.345 N.S 163.620 56.303 N.S 142.780 85.821 N.S
GPT 60.360 24.822 53.640 16.822 N.S 64.960 21.036 N.S 43.840 6.738 N.S
ALP 166.600 23.480 189.400 34.290 N.S 146.800 44.110 N.S 148.800 31.412 N.S
STUDY DIRECTOR MATHULO SHAULI P VALUE
T TEST
PARAMETER
G1 G2 G3 G4
T.S.CODE NQ N° OF GROUPS
STUDY TITLE REPEATED DOSE (7 DAYS) TOXICITY STUDY DATE OF ANALYSIS
TOXICSTAT, VERSION 2005.2
DEPARTMENT OF TOXICOLOGY, OCPL
STUDY N° SA45 SPECIES
DATA CLIN. PATH SEX
 
 
CALCULATED 
VALUE
P = 0.05 P = 0.01
WBC 3.518 7.815 11.345
RBC 0.675 7.815 11.345
HGB 2.529 7.815 11.345
HCT 1.113 7.815 11.345
MCV 2.342 7.815 11.345
MCH 7.792 7.815 11.345
MCHC 21.059 7.815 11.345
PLT 5.033 7.815 11.345
LYM 1.682 7.815 11.345
MIX 1.197 7.815 11.345
NEU 1.965 7.815 11.345
CLOT 0.166 7.815 11.345
FC D4 0.978 7.815 11.345
FC D7 30.800 7.815 11.345 S **
N.S
N.S
N.S
N.S
N.S
S **
N.S
N.S
N.S
N.S
N.S
N.S
PARAMETER
BARTLETT'S TEST
SIGNIFICANCE
N.S
STUDY DIRECTOR MATHULO SHAULI P VALUE 0.05 , 0.01
STUDY TITLE REPEATED DOSE (7 DAYS) TOXICITY STUDY DATE OF ANALYSIS 16-04-2013
T.S.CODE NQ N° OF GROUPS 4
DATA HAEMATOLOGY & FC SEX MALE
TOXICSTAT, VERSION 2005.2
DEPARTMENT OF TOXICOLOGY, OCPL
STUDY N° SA45 SPECIES MOUSE
 
 
CALCULATED 
F-VALUE
TABLE    
F-VALUE 
0.05
TABLE F-
VALUE 
0.01
SIGNIFICANCE
T-VALUE 
0.05
T-VALUE 
0.01
G2 SIGNIFICANCE G3 SIGNIFICANCE G4 SIGNIFICANCE
WBC 0.464 3.240 5.290 N.S 2.340 3.170 0.154 N.S 0.906 N.S 0.482 N.S
RBC 1.627 3.240 5.290 N.S 2.340 3.170 1.869 N.S 0.633 N.S 1.753 N.S
HGB 0.723 3.240 5.290 N.S 2.340 3.170 0.826 N.S 0.130 N.S 1.086 N.S
HCT 1.250 3.240 5.290 N.S 2.340 3.170 1.680 N.S 0.794 N.S 1.611 N.S
MCV 0.513 3.240 5.290 N.S 2.340 3.170 0.732 N.S 0.266 N.S 0.715 N.S
MCH 1.038 3.240 5.290 N.S 2.340 3.170 1.613 N.S 0.949 N.S 1.423 N.S
MCHC 0.919 3.240 5.290 N.S 2.340 3.170 1.526 N.S 1.194 N.S 1.254 N.S
PLT 1.102 3.240 5.290 N.S 2.340 3.170 0.130 N.S 1.433 N.S 0.206 N.S
LYM 0.185 3.240 5.290 N.S 2.340 3.170 0.306 N.S 0.102 N.S 0.416 N.S
MIX 0.490 3.240 5.290 N.S 2.340 3.170 1.043 N.S 0.777 N.S 0.164 N.S
NEU 0.170 3.240 5.290 N.S 2.340 3.170 0.202 N.S 0.011 N.S 0.482 N.S
CLOT 0.362 3.240 5.290 N.S 2.340 3.170 0.338 N.S 0.338 N.S 1.014 N.S
FC D4 0.383 3.240 5.290 N.S 2.340 3.170 0.627 N.S 0.823 N.S 1.007 N.S
FC D7 0.644 3.240 5.290 N.S 2.340 3.170 0.021 N.S 0.864 N.S 1.025 N.S
PARAMETER
ANOVA DUNNETT'S T-TEST
STUDY DIRECTOR MATHULO SHAULI P VALUE 0.05 , 0.01
STUDY TITLE REPEATED DOSE (7 DAYS) TOXICITY STUDY DATE OF ANALYSIS 16-04-2013
T.S.CODE NQ N° OF GROUPS 4
DATA HAEMATOLOGY & FC SEX MALE
TOXICSTAT, VERSION 2005.2
DEPARTMENT OF TOXICOLOGY, OCPL
STUDY N° SA45 SPECIES MOUSE
 
 
MOUSE
MALE
4
16-04-2013
0.05 , 0.01
MEAN SD MEAN SD SIGNIFICANCE MEAN SD SIGNIFICANCE MEAN SD SIGNIFICANCE
WBC 5.340 0.945 5.180 1.287 N.S 6.280 1.499 N.S 5.840 2.442 N.S
RBC 9.050 0.970 10.018 0.710 N.S 9.378 0.888 N.S 9.958 0.670 N.S
HGB 14.760 0.385 15.140 0.737 N.S 14.700 0.752 N.S 15.260 0.929 N.S
HCT 49.700 4.836 54.100 2.791 N.S 51.780 4.225 N.S 53.920 4.428 N.S
MCV 54.980 1.363 54.100 2.747 N.S 55.300 1.612 N.S 54.120 1.566 N.S
MCH 16.520 2.229 15.160 0.902 N.S 15.720 1.028 N.S 15.320 0.522 N.S
MCHC 30.000 3.924 27.980 0.277 N.S 28.420 1.165 N.S 28.340 0.826 N.S
PLT 1359.600 441.726 1333.200 130.051 N.S 1067.800 374.905 N.S 1401.600 249.077 N.S
LYM 67.000 11.363 69.520 12.983 N.S 67.840 8.871 N.S 63.580 17.320 N.S
MIX 4.620 1.992 3.600 1.170 N.S 3.860 1.316 N.S 4.460 1.581 N.S
NEU 28.380 9.949 26.880 11.954 N.S 28.300 7.703 N.S 31.960 15.820 N.S
CLOT 138.000 12.550 135.000 15.000 N.S 135.000 15.000 N.S 129.000 13.416 N.S
FC D4 1.520 0.614 1.200 0.689 N.S 1.100 0.951 N.S 1.006 0.922 N.S
FC D7 0.140 0.055 0.132 0.064 N.S 0.508 0.428 N.S 0.530 1.101 N.S
STUDY DIRECTOR MATHULO SHAULI P VALUE
T TEST
PARAMETER
G1 G2 G3 G4
T.S.CODE NQ N° OF GROUPS
STUDY TITLE REPEATED DOSE (7 DAYS) TOXICITY STUDY DATE OF ANALYSIS
TOXICSTAT, VERSION 2005.2
DEPARTMENT OF TOXICOLOGY, OCPL
STUDY N° SA45 SPECIES
DATA HAEMATOLOGY & FC SEX
 
 
CALCULATED 
VALUE
P = 0.05 P = 0.01
WBC 1.332 7.815 11.345
RBC 3.020 7.815 11.345
HGB 0.912 7.815 11.345
HCT 3.015 7.815 11.345
MCV 1.135 7.815 11.345
MCH 4.385 7.815 11.345
MCHC 1.213 7.815 11.345
PLT 0.563 7.815 11.345
LYM 2.932 7.815 11.345
MIX 3.432 7.815 11.345
NEU 2.684 7.815 11.345
CLOT 3.016 7.815 11.345
FC D4 1.188 7.815 11.345
FC D7 12.627 7.815 11.345 S **
N.S
N.S
N.S
N.S
N.S
N.S
N.S
N.S
N.S
N.S
N.S
N.S
PARAMETER
BARTLETT'S TEST
SIGNIFICANCE
N.S
STUDY DIRECTOR MATHULO SHAULI P VALUE 0.05 , 0.01
STUDY TITLE REPEATED DOSE (7 DAYS) TOXICITY STUDY DATE OF ANALYSIS 16-04-2013
T.S.CODE NQ N° OF GROUPS 4
DATA HAEMATOLOGY & FC SEX FEMALE
TOXICSTAT, VERSION 2005.2
DEPARTMENT OF TOXICOLOGY, OCPL
STUDY N° SA45 SPECIES MOUSE
 
 
CALCULATED 
F-VALUE
TABLE    
F-VALUE 
0.05
TABLE F-
VALUE 
0.01
SIGNIFICANCE
T-VALUE 
0.05
T-VALUE 
0.01
G2 SIGNIFICANCE G3 SIGNIFICANCE G4 SIGNIFICANCE
WBC 0.938 3.290 5.420 N.S 2.360 3.200 0.053 N.S 1.418 N.S 0.622 N.S
RBC 0.608 3.290 5.420 N.S 2.360 3.200 0.524 N.S 0.973 N.S 1.263 N.S
HGB 0.887 3.290 5.420 N.S 2.360 3.200 0.061 N.S 0.911 N.S 1.276 N.S
HCT 0.523 3.290 5.420 N.S 2.360 3.200 0.489 N.S 1.107 N.S 1.006 N.S
MCV 0.109 3.290 5.420 N.S 2.360 3.200 0.229 N.S 0.137 N.S 0.549 N.S
MCH 0.200 3.290 5.420 N.S 2.360 3.200 0.766 N.S 0.479 N.S 0.431 N.S
MCHC 0.984 3.290 5.420 N.S 2.360 3.200 1.254 N.S 0.792 N.S 0.264 N.S
PLT 1.289 3.290 5.420 N.S 2.360 3.200 1.006 N.S 0.934 N.S 0.235 N.S
LYM 1.099 3.290 5.420 N.S 2.360 3.200 0.537 N.S 1.691 N.S 0.723 N.S
MIX 0.628 3.290 5.420 N.S 2.360 3.200 0.075 N.S 1.050 N.S 0.886 N.S
NEU 1.225 3.290 5.420 N.S 2.360 3.200 0.618 N.S 1.791 N.S 0.683 N.S
CLOT 0.595 3.290 5.420 N.S 2.360 3.200 0.319 N.S 0.958 N.S 0.106 N.S
FC D4 0.932 3.290 5.420 N.S 2.360 3.200 0.322 N.S 1.254 N.S 0.193 N.S
FC D7 1.271 3.290 5.420 N.S 2.360 3.200 0.728 N.S 0.728 N.S 1.063 N.S
PARAMETER
ANOVA DUNNETT'S T-TEST
STUDY DIRECTOR MATHULO SHAULI P VALUE 0.05 , 0.01
STUDY TITLE REPEATED DOSE (7 DAYS) TOXICITY STUDY DATE OF ANALYSIS 16-04-2013
T.S.CODE NQ N° OF GROUPS 4
DATA HAEMATOLOGY & FC SEX FEMALE
TOXICSTAT, VERSION 2005.2
DEPARTMENT OF TOXICOLOGY, OCPL
STUDY N° SA45 SPECIES MOUSE
 
 
MOUSE
FEMALE
4
16-04-2013
0.05 , 0.01
MEAN SD MEAN SD SIGNIFICANCE MEAN SD SIGNIFICANCE MEAN SD SIGNIFICANCE
WBC 4.640 1.527 4.700 1.965 N.S 6.425 2.326 N.S 5.340 1.278 N.S
RBC 9.220 0.647 9.372 0.284 N.S 9.502 0.328 N.S 9.586 0.483 N.S
HGB 14.600 0.453 14.580 0.606 N.S 14.900 0.596 N.S 15.020 0.396 N.S
HCT 50.960 2.092 51.640 1.877 N.S 52.500 3.145 N.S 52.360 1.250 N.S
MCV 55.400 2.661 55.100 1.531 N.S 55.220 2.032 N.S 54.680 1.908 N.S
MCH 15.880 0.811 15.560 0.623 N.S 15.680 0.259 N.S 15.700 0.797 N.S
MCHC 28.640 0.321 28.260 0.467 N.S 28.400 0.570 N.S 28.720 0.522 N.S
PLT 1109.800 131.089 1015.600 122.692 N.S 1197.200 172.967 N.S 1131.800 159.588 N.S
LYM 80.840 5.801 77.320 8.255 N.S 68.450 11.794 N.S 76.100 14.015 N.S
MIX 2.680 1.161 2.760 0.974 N.S 3.925 1.916 N.S 3.620 2.347 N.S
NEU 16.480 4.927 19.920 7.425 N.S 27.625 9.981 N.S 20.280 11.681 N.S
CLOT 138.000 12.550 135.000 10.607 N.S 147.000 22.249 N.S 139.000 10.840 N.S
FC D4 1.740 1.062 1.940 0.907 N.S 0.960 0.684 N.S 1.620 1.203 N.S
FC D7 1.060 0.089 1.320 0.792 N.S 0.800 0.721 N.S 0.680 0.349 N.S
TOXICSTAT, VERSION 2005.2
DEPARTMENT OF TOXICOLOGY, OCPL
STUDY N° SA45 SPECIES
DATA HAEMATOLOGY & FC SEX
T.S.CODE NQ N° OF GROUPS
STUDY TITLE REPEATED DOSE (7 DAYS) TOXICITY STUDY DATE OF ANALYSIS
STUDY DIRECTOR MATHULO SHAULI P VALUE
T TEST
PARAMETER
G1 G2 G3 G4
 
  
 
CLINICAL PATHOLOGY RESULTS
A.No GLU UREA CRE PRO ALB CHO TRI PHO CLO BIT GOT GPT ALP
1 122.9 15 0.36 5.50 2.37 89 124 9.93 95.6 0.67 136.1 73 151
2 148.5 27 0.40 7.25 4.57 134 165 18.0 104.2 3.11 163.3 122.6 133
3 101.0 37 0.42 7.80 3.71 204 237 14.87 99.4 1.75 139.5 65.7 85
4 178.0 30 0.40 6.35 2.42 160 181 10.8 97.5 3.88 98.7 96.3 158
5 93.5 30 0.42 8.27 5.77 132 159 7.63 93.4 2.02 210.7 162.2 64
6 147.2 23 0.43 8.42 4.69 168 200 6.9 96.2 1.02 122.5 97.9 131
7 123.7 18 0.39 5.87 2.31 101 149 9.18 99.1 1.40 149.3 66.8 159
8 146.3 21 0.37 6.4 3.11 184 160 8.5 97.4 2.47 132.2 48.6 173
9 150.2 18 0.36 4.51 2.91 100 158 12.08 99.8 1.10 222.3 57.6 176
10 158.3 20 0.37 4.54 4.00 180 145 7.72 98.9 1.66 108.1 30.9 194
11 119.5 15 0.41 6.47 3.73 137 108 11.89 99.2 3.11 117.5 67.2 118
12 110.9 32 0.44 8.32 5.48 160 209 13.3 99.6 2.49 242.1 96.9 115
13 109.7 30 0.42 6.40 3.60 190 229 12.95 102.8 3.11 167.1 98.8 153
14 119.4 23 0.38 6.44 4.29 159 215 12.15 103.8 2.13 124.5 69.1 144
15 173.8 32 0.51 6.58 2.43 127 147 13.02 100.1 3.54 162.9 85.8 195
16 132.4 21 0.41 5.98 2.25 123 114 9.71 103.5 2.63 166.7 81.6 148
17 134.4 17 0.37 5.35 2.12 108 158 8.01 94.1 1.15 88.2 54.7 194
18 139.2 18 0.41 5.27 2.20 105 133 8.33 98.2 1.45 87.8 40.2 170
19 115.8 15 0.40 6.11 2.43 100 119 12.09 100.4 1.22 98.1 50.7 240
20 114.8 20 0.35 5.28 2.96 117 132 14.93 98.1 1.58 97.8 41 195
21 139.2 28 0.52 5.23 1.30 110 128 13.20 105.7 2.3 177.6 105.3 129
22 45.9 31 0.63 6.14 2.08 108 270 9.68 100.5 2.45 85.4 67.7 70
23 160.7 28 0.40 6.48 2.46 138 170 11.83 104.5 4.0 112.4 64.1 174
24 234.0 30 0.35 5.64 3.01 107 160 8.9 100.5 1.6 107 119.8 135
25 157.8 29 0.44 5.14 2.56 130 114 16.07 103 1.52 183.2 130.3 171
26 143.8 20 0.38 5.76 2.27 108 103 9.91 96.8 0.79 102.3 49.9 202
27 158.0 18 0.39 6.04 2.40 117 117 11.39 99.8 1.33 172 54.3 121
28 126.4 22 0.43 7.30 4.15 182 166 11.87 105.8 2.22 155.9 61.7 122
29 142.2 20 0.40 6.13 4.58 100 124 13.76 103.5 1.56 252.9 101.8 103
30 133.0 20 0.38 5.97 2.54 100 272 13.30 100.0 1.53 135 57.1 186
31 85.7 27 0.36 5.81 4.73 199 144 5.80 87.6 2.03 193.5 129.9 59
32 118.8 32 0.42 6.89 5.2 153 201 7.62 99.4 1.57 175.7 93.2 104
33 144.6 40 0.32 5.68 2.39 158 172 9.01 100.9 1.08 170.8 77.7 90
34 106.5 26 0.43 6.86 4.30 210 257 6.31 96.4 1.27 164 98.7 102
35 102.8 30 0.47 7.01 5.63 191 196 8.00 100.4 3.21 145.5 96.0 65
36 155.6 22 0.34 4.79 2.05 139 274 10.75 99.5 4.29 86.8 51.3 141
37 106.1 25 0.37 5.60 2.29 112 90 9.67 98.0 0.84 121.7 37.1 124
38 147.8 19 0.36 5.41 2.11 102 194 10.25 103.1 2.08 106.2 36.9 118
39 129.2 20 0.42 6.08 2.58 120 132 12.89 103.0 2.27 104.5 44.4 168
40 155.2 23 0.41 6.08 2.38 127 156 9.42 98.8 2.18 294.7 49.5 193
101 28.3
102 30.1
103 22.8
104 29.5
105 24.6
106 22.9
107 28.4
108 28.1
109 23.4
110 27.1
111 27.0
112 23.7
113 25.9
114 27.8
115 26.2
116 25.6
117 26.7
118 26.3
119 25.3
120 25.6                                                                                                  
T.A. B.W. P.A. T.A. B.W. P.A. T.A. B.W. P.A. T.A. B.W. P.A.
125 26.9 135 25.9 132 26 133 26
130 25.5 131 25.7 126 25.3 123 25.7
134 24.8 124 24.5 129 25.2 127 24.1
122 23.4 139 23.6 128 23.5 140 23.8
121 23.2 137 22.2 138 22.6 136 22.5
Mean 24.8 Mean 24.4 Mean 24.6 Mean 24.4
SD 1.534 SD 1.535 SD 1.413 SD 1.441
Group1 Group2 Group3 Group4
RANDOMIZED BY A. J. ZABIULLAH
STUDY TITLE REP. DOSE(7 DAYS) ORAL TOX. ST. IN MICE
STUDY DIRECTOR MATHULA
SEX Female N° OF GROUPS 4
T.S.CODE NQ SPECIES Mouse
BALANCE ID N° TOX/43 TOTAL N° OF ANIMALS 20
DEPARTMENT OF TOXICOLOGY, OCPL
RANDOMIZATION RESULTS
STUDY N° SA45 DATE OF ANALYSIS 2013/04/01 14:47
 
 121 23.2
122 23.4
123 25.7
124 24.5
125 26.9
126 25.3
127 24.1
128 23.5
129 25.2
130 25.5
131 25.7
132 26.0
133 26.0
134 24.8
135 25.9
136 22.5
137 22.2
138 22.6
139 23.6
140 23.8  
      
T.A. B.W. P.A. T.A. B.W. P.A. T.A. B.W. P.A. T.A. B.W. P.A.
102 30.1 101 28.3 104 29.5 107 28.4
110 27.1 108 28.1 111 27 114 27.8
118 26.3 115 26.2 117 26.7 113 25.9
105 24.6 116 25.6 119 25.3 120 25.6
112 23.7 103 22.8 109 23.4 106 22.9
Mean 26.4 Mean 26.2 Mean 26.4 Mean 26.2
SD 2.486 SD 2.233 SD 2.251 SD 2.163
Group1 Group2 Group3 Group4
RANDOMIZED BY A. J. ZABIULLAH
STUDY TITLE REP. DOSE(7DAYS)ORAL TOX. ST. IN MICE
STUDY DIRECTOR MATHULA
SEX Male N° OF GROUPS 4
T.S.CODE NQ SPECIES Mouse
BALANCE ID N° TOX/43 TOTAL N° OF ANIMALS 20
DEPARTMENT OF TOXICOLOGY, OCPL
RANDOMIZATION RESULTS
STUDY N° SA45 DATE OF ANALYSIS 2013/04/01 14:44
         
 
 
                                   
 
 
 
 
 
 
 
   
CAGEWISE FEED INPUT, LEFTOVER AND FEED CONSUMPTION 
RECORD 
       
 
G1 0mg/kg 
            A. 
NO week 1 FDL AFC   week 2 FDL AFC   WEEK 3 FDL AFC   
WEEK 
4 FDL AFC 
1 285 148 137   285 192 93   285 206.69 78.31   150 111.83 38.17 
2 285 57 114   285 30.2 127.4   285 69.13 107.94   150 44.92 52.54 
3 285 210 75   285 167.3 117.7   285 182.85 102.15   150 103.35 46.65 
4 285 171 114   285 183.8 101.2   285 192.41 92.59   150 89.33 60.67 
5 285 162 123   285 192.9 92.1   285 207.58 77.42   150 111.85 38.15 
6 285 62 111.5   285       285       150     
7 285 150 135   285 177.1 107.9   285 237.42 47.6   150 132.01 17.99 
8 285 230 27.5   285 105.2 89.9   285 124.89 80.05   150 67.55 41.2 
9 285 197 88   285 175.1 109.9   285 181.81 103.19   150 113.14 36.8 
10 285 152 133   285 174.8 110.2   285 177.08 107.92   150 107.95 42.05 
                
 
G2 125mg/kg 
            A. 
NO week 1 FDL AFC   week 2 FDL AFC   WEEK 3 FDL AFC   
WEEK 
4 FDL AFC 
11 285 42 121.5   285 74.9 105.1   285 91.3 96.85   150 56.65 46.73 
12 285 146 139   285 185.7 99.3   285 184.25 100.75   150 90.83 59.17 
13 285 122 163   285 162.2 122.8   285 202.05 82.95   150 107.73 42.27 
14 285 100 185   285 273.8 11.2   285       150     
15 285 24.9 130   285 109.6 87.7   285 90.59 97.2   150 55.28 47.36 
16 285 82 203   285 165 120   285 180.59 104.41   150 95.16 54.84 
17 285 153 132   285 153.5 131.5   285 189.87 95.03   150 92.22 77.22 
18 285 227 58   285 197.4 87.6   285 217.58 67.42   150 103.41 46.59 
19 285       285       285       150     
20 285 137.7 147.3   285 167.5 117.5   285 201.52 83.48   150 90.38 59.62 
                
 
G3 250mg/kg 
             A. 
NO week 1 FDL AFC   week 2 FDL AFC   WEEK 3 FDL AFC   
WEEK 
4 FDL AFC 
21 285 131 154   285 154.8 130.2   285 196.4 88.5   150 110.44 39.5 
22 285 53 232   285 134.3 150.7   285 181.09 103.9   150 98.01 51.99 
23 285 117 168   285 234.5 50.5   285 225.11 59.89   150 106.42 43.58 
24 285 137 148   285 206.8 78.2   285 223.15 61.85   150 129.43 20.57 
25 285 112 173   285 201.8 83.2   285 222.88 62.12   150 117.35 32.65 
23 285 50 235   285 146.1 138.9   285 187.83 100.17   150 96.49 53.57 
27 285 55 115   285       285       150     
28 285 145 140   285 272.7 12.3   285       150     
29 285 217 68   285 207.3 77.7   285 227.78 57.12   150 116.66 33.34 
30 285 200 85   285 167.7 117.3   285 176.71 108.29   150 102.94 47.06 
                
 
G4 500mg/kg 
            A. 
NO week 1 FDL AFC   week 2 FDL AFC   WEEK 3 FDL AFC   
WEEK 
4 FDL AFC 
31 285 173 56   285 152.1 66   285 164.41 60   150 81.11 34.4 
32 285 260 12.5   285 51.1 116.95   285 95.98 94.51   150 55.72 47.1 
33 285 185 100   285 240.1 44.9   285       150     
34 285 197 88   285 208.6 76.4   285 207.77 77.23   150 120.56 29.44 
35 285 217 68   285       285       150     
36 285 219 66   285 237.8 47.2   285 218.33 66.67   150 104.34 45.66 
37 285 247 38   285 242.7 42.3   285       150     
38 285 193 92   285 148.3 136.7   285 209.97 75.03   150 121.45 28.58 
39 285 214 71   285 216.5 68.5   285 222.49 62.5   150 123.67 26.33 
40 285 195 90   285 189.7 95.3   285 218.08 66.92   150 116.77 32.2 
 
 
 
 
 
 
 
  
  
INDIVIDUAL 
ANIMAL 
BODY 
WEIGHT          
    
  
ABSOLUTE 
ORGAN 
WEIGHT                     
RELATIVE 
ORGAN 
WEIGHT             
    G1 0mg/kg                                 G1 0mg/kg               
A. 
No pre-exp 
week 
1 week 2 
week 
3 
week 
4 
term. 
Wt   adrenal ovaries thymus epi/uter spleen heart brain kidney testes liver   adrenal ovaries thymus epi/uter spleen heart brain kidney testes liver 
1 28.3 27.5 26.7 27.5 28.8 27.3       0.08   0.215 0.14 0.352 0.427 0.223 1.634       0.293   0.788 0.513 1.289 1.564 0.817 5.985 
2 25.9 24.5 22 25.2 25.3 22.5   0.015   0.139   0.129 0.116 0.389 0.381 0.261 1.378   0.067   0.618   0.573 0.516 1.729 1.693 1.16 6.124 
3 25.3 27.7 26.8 29.1 29.8 27.4   0.004   0.073   0.183 0.148 0.346 0.521 0.191 1.565   0.015   0.266   0.668 0.54 1.263 1.901 0.697 5.712 
4 23.4 28.3 28.6 30.2 31.3 28.7   0.011   0.045   0.173 0.121 0.423 0.455 0.398 1.741   0.038   0.157   0.603 0.422 1.474 1.585 1.387 6.066 
5 23.3 22.1 22.1 24.7 25.7 23.9   0.012   0.021 0.128 0.073 0.15 0.417 0.396 0.251 1.342   0.05   0.088 0.536 0.305 0.628 1.745 1.657 1.05 5.615 
6 25.7 27.6                                                     
7 24.3 24.9 24.7 23.5 24.1 22.3   0.005   0.074   0.078 0.124 0.272 0.276   1.266   0.022   0.332   0.35 0.556 1.22 1.238   5.677 
8 23 24.5 23.1 23.8 23.8 22.4   0.008 0.03 0.057   0.15 0.112 0.434 0.241   1.324   0.036 0.134 0.254   0.7 0.5 1.938 1.076   5.911 
9 22.7 23.8 23.2 25.3 25.6 24   0.006 0.266 0.162 0.198 0.344 0.118 0.443 0.359   1.58   0.025 1.108 0.675 0.825 1.433 0.492 1.846 1.495   6.583 
10 21.5 21.3 21.1 22.9 23.5 21.7   0.003 0.048 0.041   0.19 0.113 0.428 0.311   1.363   0.014 0.221 0.188   0.876 0.521 1.972 1.433   6.281 
  
G2  125mg/kg 
               
G2  125mg/kg 
      11 27.5 28 25.7 27.3 29.5 25.8   0.013   0.025 0.061 0.284 0.129 0.442 0.439 0.208 1.764   0.05   0.097 0.236 1.101 0.5 1.713 1.702 0.806 6.837 
12 27.2 29 29.5 29.8 30.6 27.5   0.033   0.078 0.01 0.153 0.203 0.5 0.495 0.226 1.602   0.12   0.284 0.036 0.556 0.738 1.818 1.8 0.822 5.825 
13 25.1 28 25.2 27.1 28.3 25.9           0.119 0.138 0.393 0.469 0.286 1.594           0.459 0.533 1.517 1.811 1.104 6.154 
14 23.5 27                                                     
15 21.4 25.3 26.1 25.3 26.3 26.2   0.061   0.09 0.01 0.402 0.154 0.479 0.438 0.189 1.718   0.233   0.344 0.038 1.534 0.588 1.828 1.672 0.721 6.557 
16 27.3 24.8 25 22.9 27.2 25.2   0.02 0.014 0.061 0.045 0.118 0.135 0.5 0.425   1.627   0.079 0.056 0.242 0.179 0.468 0.536 1.984 1.687   6.456 
17 24.2 26.8 26 26.1 27.9 26.5   0.011   0.064   0.116 0.13 0.43 0.408   1.492   0.042   0.242   0.438 0.491 1.623 1.54   5.63 
18 23.4 18.9 20.1 18.8 20.8 19.4   0.006 0.034 0.065   0.223 0.137 0.377 0.347   1.301   0.031 0.175 0.335   1.149 0.706 1.943 1.789   6.706 
19 22                                                       
20 21.6 20.4 19.4 20.9 20.2 19   0.014   0.071 0.159 0.127 0.123 0.489 0.39   1.216   0.074   0.374 0.837 0.668 0.647 2.574 2.053   6.4 
  
G3 250mg/kg 
               
G3 250mg/kg 
      21 28.2 29.1 29.7 30.5 31.7 29.1   0.017   0.131   0.185 0.262 0.512 0.501 0.425 1.767   0.058   0.45   0.636 0.9 1.759 1.722 1.46 6.072 
22 25.4 24 24.4 26.9 27.9 25.7   0.031   0.084   0.174 0.144 0.486 0.44 0.198 1.598   0.121   0.327   0.677 0.56 1.891 1.712 0.77 6.218 
23 25.3 23.5 22.5 22.8 23.3 23.1   0.004   0.06 0.148 0.11 0.17 0.457 0.32 0.308 1.16   0.017   0.26 0.641 0.476 0.736 1.978 1.385 1.333 5.022 
24 23.4 25.4 25.8 28.3 27.7 25.5       0.05 0.122 0.164 0.158 0.441 0.932 0.5 1.67       0.196 0.478 0.643 0.62 1.729 3.655 1.961 6.549 
25 22.4 24.4 22 25.9 26.2 22.8   0.054   0.015 0.088 0.109 0.121 0.291 0.418 0.224 1.508   0.237   0.066 0.386 0.478 0.531 1.276 1.833 0.982 6.614 
26 25.5 24.4 25.3 28.2 28.3 26   0.028 0.102 0.078 1.764 0.147 0.137 0.447 0.4   1.471   0.108 0.392 0.3 6.785 0.565 0.527 1.719 1.538   5.658 
27 25.2 25.4                                                     
28 23.3 19.1                                                     
29 22.6 22.9 20.7 22.6 23.1 21.4   0.116   0.045   0.095 0.199 0.464 0.278   1.374   0.542   0.21   0.444 0.93 2.168 1.299   6.421 
30 20.5 24.9 22.8 24.3 24.6 23.5     0.065   0.143 0.065 0.123 0.372 0.316   1.316     0.277   0.609 0.404 0.523 1.583 1.345   5.6 
  
G4 500mg/kg 
               
G4 500mg/kg 
      
31 27.9 25.1 26.4 25.3 26.7 23.4       0.059 0.112 0.168 0.12 0.472 0.396 0.182 1.461       0.252 0.479 0.718 0.513 2.017 1.692 0.778 6.244 
32 27 25.9 24.2 24.9 25.1 23   0.024   0.02 0.088 0.146 0.127 0.458 0.334 0.196 1.196   0.104   0.087 0.383 0.635 0.552 0.552 1.452 0.085 5.2 
33 24.4 25.5                                                     
34 23.9 24 24.9 26.8 22.2 21.2   0.059   0.092 0.078 0.132 0.139 0.393 0.348 0.057 1.38   0.278   0.434 0.368 0.623 0.656 1.854 1.642 0.269 6.509 
35 21.6                                                       
36 27.3 25.9 26 25.3 25.7 24.5   0.012 0.022 0.065 0.111 0.201 0.119 0.481 0.368   1.598   0.049 0.09 0.265 0.453 0.82 0.486 1.963 1.502   6.522 
37 24 21 14.8                                                   
38 24 24.3 22.3 23.6 22.3 21.6   0.013 0.024 0.063 0.172 0.151 0.136 0.525 0.326   1.205   0.06 0.111 0.292 0.796 0.699 0.63 2.431 1.509   5.579 
39 22.1 26 23.3 22.4 26.2 24.9   0.008 0.1 0.063 0.151 0.139 0.094 0.438 0.33   1.493   0.032 0.402 0.253 0.606 0.558 0.378 1.759 1.325   5.996 
40 21.5 21.4 23.4 22.1 23.7 22.2   0.017 0.048 0.086 0.099 0.147 0.122 0.387 0.284   1.134   0.077 0.216 0.387 0.446 0.662 0.55 1.743 1.279   5.108 
 
 
 
 
 
 
 
 
 
           
ANIMAL 
GROUPING: 
MEAN & SD                 
                               
   group 
1       group 2       
group 
3       
group 
4   
   
TN WT new A.N dose vol TN WT 
new 
A.N 
dose 
vol TN WT new A.N 
dose 
vol TN WT 
new 
A.N 
dose 
vol 
 118 27.5 1 0.28 107 27.30 11 0.27 110 30.5 21 0.31 114 25.3 31 0.25 
 115 25.2 2 0.25 105 29.80 12 0.30 108 26.9 22 0.27 101 24.9 32 0.25 
 112 29.1 3 0.29 104 27.10 13 0.27 117 22.8 23 0.23 103 0 33 0.00 
 109 30.2 4 0.30 119 0.00 14 0.00 113 28.3 24 0.28 116 26.8 34 0.27 week 4 
106 24.7 5 0.25 111 25.30 15 0.25 120 25.9 25 0.26 102 0 35 0.00 
 127 0 6 0.00 121 22.90 16 0.23 139 28.2 26 0.28 126 25.3 36 0.25 
 132 23.5 7 0.24 125 26.10 17 0.26 137 0 27 0.00 133 0 37 0.00 
 138 23.8 8 0.24 130 18.80 18 0.19 131 0 28 0.00 123 23.6 38 0.24 
 122 25.3 9 0.25 140 0.00 19 0.00 135 22.6 29 0.23 136 22.4 39 0.22 
 129 22.9 10 0.23 134 20.90 20 0.21 128 24.3 30 0.24 124 22.1 40 0.22 
 
    tot vol 2.322   
 
tot vol 1.982     tot vol 2.095     
totl 
vol 1.704 
                                 
                                 
                                 
 
                 
  
total vol=6 mL for all 
groups 
3.5ml for all 
groups                   
    
  
    test sub dose mg       test sub 20%dmso 80%cmc t.vol 
    
  
G1 0 0mg 0mg/kg       43.8mg 700ul 2.8ml 3500ul 
    
  
G2 12.5*3.5 43.8mg 125mg/kg low     87.5mg 700ul 2.8ml 3500ul 
    
  
G3 25*3.5 87.5mg 250mg/kg mid     175.0mg 700ul 2.8ml 3500ul 
    
  
G3 50*3.5 175mg 500mg/kg high             
    
           
dmso cmc tot vol 
   
      
due to high viscocity, tot vol was doubled;  700ul 6300ul 7000ul 
   
 APPENDIX 2 
PHOTOMOCROGRAPHS IN MAIN STDY 
 
 
A32 high dose liver x20- male                         A38 high dose adrenal x10-female                       Control A9 adrenal x10-female           A31 high dose lung x10-male 
               
                             
               A36 high dose intestines x4 –female.    A 32 high dose epididymis x20 – male.   A36 high dose brain x4 –female     A38 high dose colon x20-female 
                                   
   
A31 high dose aorta x20- male                         Control 9 brain x4 – female                          A38 high dose liver x10 –female           Control 5 liver x10-male 
 
         A 39 high dose lung x10- female             Animal 39 high dose ovary x4                      Animal 36 high dose smooth muscle x20        Control 4 testes x4-male 
 
 
 
 
